N-Methyl-1-phenylpropan-2-amine (Methamphetamine)

Page 1

Reaxys

PubChem

eMolecules

Reactions (368)

Substances (168)

Structure

Citations (3449)

Structure/Compound Data Chemical Name: methamphetamin Reaxys Registry Number: 1072499

CAS Registry Number: 7632-10-2 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C6H5CH2CH(NHCH3)CH3

Molecular Weight: 149.236

InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N

1

N° of preparations All Preps | All Reactions

Available Data

N° of ref.

60 prep out of 139 reactions.

Identification Physical Data (50) Spectra (31) Bioactivity (108) Other Data (15)

1289

55 prep out of 101 reactions.

Identification Physical Data (46) Spectra (32) Bioactivity (283) Other Data (72)

640

Synthesize | Show Details Find similar Chemical Name: Methamphetamin Reaxys Registry Number: 2207147

CAS Registry Number: 537-46-2 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236

InChI Key: MYWUZJCMWCOHBA-VIFPVBQESA-N

2

Synthesize | Show Details Find similar


Chemical Name: (R)-2-methylamino-1-phenylpropane Reaxys Registry Number: 3081879

CAS Registry Number: 33817-09-3 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236

InChI Key: MYWUZJCMWCOHBA-SECBINFHSA-N

3

40 prep out of 59 reactions.

Identification Physical Data (21) Spectra (13) Bioactivity (47) Other Data (3)

74

1 prep out of 1 reactions.

Identification Physical Data (1) Bioactivity (3)

5

Synthesize | Show Details Find similar Chemical Name: (+)-N-methylamphetamine Reaxys Registry Number: 5248384

CAS Registry Number: 537-46-2, 4846-07-5, 7632-10-2, 33817-09-3 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236

InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N

4

Synthesize | Hide Details Find similar Chemical Names and Synonyms (+)-N-methylamphetamine, (+)-methamphetamine, d-Methamphetamine, (+)-2-methylamino-1-phenyl-propane Identification Substance Label (3) Label

Reference

(+)-13

Malmusi, Luca; Dukat, Malgorzata; Young, Richard; Teitler, Milt; Darmani, Nissar A.; Ahmad, Bashir; Smith, Carol; Glennon, Richard A.

Medicinal Chemistry Research, 1996 , vol. 6, # 6 p. 400 - 411 Title/Abstract Full Text View citing articles Show Details

(+)-II/III

Acs, Maria; Kozma, David; Fogassy, Elemer

ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details

6i

Drabowicz, Jozef; Legedz, Slawomir; Mikolajczik, Marian

Tetrahedron, 1988 , vol. 44, # 16 p. 5243 - 5252 Title/Abstract Full Text View citing articles Show Details

Derivative (1) Comment (Derivative)

Reference

By formation of salt/complex with dilituric acid. Additional data: optical crystallographic properties

Julian; Plein

Journal of Pharmaceutical Sciences, 1981 , vol. 70, # 6 p. 704 - 707 Title/Abstract Full Text View citing articles Show Details

Purification (1) Purification (method)

Reference

via salt with sodium-hydrogen-R,R-tartrate

Acs, Maria; Kozma, David; Fogassy, Elemer

ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details


Physical Data Optical Rotatory Power (1) Type (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

[alpha]

neat (no solvent)

3.32 deg

589 nm

Reference Drabowicz, Jozef; Legedz, Slawomir; Mikolajczik, Marian

Tetrahedron, 1988 , vol. 44, # 16 p. 5243 - 5252 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (3) 1 of 3

2 of 3

3 of 3

Comment (Pharmacological Data)

Bioactivities present

Reference

Drabowicz, Jozef; Legedz, Slawomir; Mikolajczik, Marian

Tetrahedron, 1988 , vol. 44, # 16 p. 5243 - 5252 Title/Abstract Full Text View citing articles Show Details

Kaufmann; Hofmann; Kreiskott

Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 2 p. 335 - 337 Title/Abstract Full Text View citing articles Show Details

Julian; Plein

Journal of Pharmaceutical Sciences, 1981 , vol. 70, # 6 p. 704 - 707 Title/Abstract Full Text View citing articles Show Details

Acs, Maria; Kozma, David; Fogassy, Elemer

ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details

Malmusi, Luca; Dukat, Malgorzata; Young, Richard; Teitler, Milt; Darmani, Nissar A.; Ahmad, Bashir; Smith, Carol; Glennon, Richard A.

Medicinal Chemistry Research, 1996 , vol. 6, # 6 p. 400 - 411 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

locomotor stimulant

Species or TestSystem (Pharmacological Data)

albino ICR mice

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.5 - 2 mg/kg

Kind of Dosing (Pharmacological Data)

0.5, 1.0, and 2.0 mg/kg

Exposure Period (Pharmacological Data)

10 - 40 min

Method (Pharmacological Data)

mouse weight 25-30 g; acclimated for 30 min before treatment; experiments performed between 8.00 and 17.00 h; multiple doses; locomotor activity measured as distance traversed (in cm), recorded by computerized video tracking behavior recognition system

Results

dose-related increase in locomotor stimulation, 2 mg/kg produced 625 percent increase over saline-treated controls

Reference

Malmusi, Luca; Dukat, Malgorzata; Young, Richard; Teitler, Milt; Darmani, Nissar A.; Ahmad, Bashir; Smith, Carol; Glennon, Richard A.

Medicinal Chemistry Research, 1996 , vol. 6, # 6 p. 400 - 411 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

anorexigenic effect; reduces food intake from 9 to 0 g/h (0.5 - 2 mg/kg, rat)

Reference

Kaufmann; Hofmann; Kreiskott

Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 2 p. 335 - 337 Title/Abstract Full Text View citing articles Show Details


Chemical Name: methamphetamine

no reactions.

Reaxys Registry Number: 6269621

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236

InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N

Physical Data (4) Bioactivity (3)

5

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine, Methamphetamin Physical Data Dissociation Exponent (1) Type (Dissociation Exponent)

Reference

b1/apparent

Muller

Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details

Electrochemical Behaviour (1) Description (Electrochemical Behaviour)

Reference

Electrolytic dissociation / protonation equilibrium

Muller

Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details

Liquid/Liquid Systems (MCS) (2) Description (Liquid/Liquid Systems (MCS))

Partner (Liquid/Liquid Systems (MCS))

Reference

Distribution between solvent 1 + 2

1) aqueous buffer solution 2) ether

Muller

Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details

Distribution between solvent 1 + 2

1) aqueous buffer solution 2) CHCl3

Muller

Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (3) 1 of 3

Comment (Pharmacological Data)

Bioactivities present

Reference

Wollweber; Hiltman; Stoepel; Kroneberg

European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 111 - 117 Title/Abstract Full Text View citing articles Show Details

Bekemeier; Wenzel

Pharmazie, 1989 , vol. 44, # 11 p. 781 - 783 Title/Abstract Full Text View citing articles Show Details

Teschendorf; Kretzschmar; Kreiskott; Weifenbach

Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 9 A p. 1580 - 1588 Title/Abstract Full Text View citing articles Show Details

Muller

Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details

Little; Rees

Journal of Pharmacy and Pharmacology, 1980 , vol. 32, # 11 p. 751 - 756 Title/Abstract Full Text View citing articles Show Details

Testa; Salvesen

23


Journal of Pharmaceutical Sciences, 1980 , vol. 69, # 5 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details

Comai; Sullivan

Journal of Pharmaceutical Sciences, 1982 , vol. 71, # 4 p. 418 - 421 Title/Abstract Full Text View citing articles Show Details

Kita, Taizo; Philbert, Martin A.; Wagner, George C.; Huang, Jian; Lowndes, Herbert E.

Pharmacology and Toxicology, 1998 , vol. 83, # 1 p. 36 - 39 Title/Abstract Full Text View citing articles Show Details

Seager

Journal of Pharmacy and Pharmacology, 1998 , vol. 50, # 4 p. 375 - 382 Title/Abstract Full Text View citing articles Show Details

Nakahara, Yuji; Kikura, Ruri

Archives of Toxicology, 1996 , vol. 70, # 12 p. 841 - 849 Title/Abstract Full Text View citing articles Show Details

Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek

Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details

Nakahara, Yuji; Kikura, Ruri

Biological and Pharmaceutical Bulletin, 1997 , vol. 20, # 9 p. 969 - 972 Title/Abstract Full Text View citing articles Show Details

Sekine; Nagao; Nakahara

Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details

Kita, Taizo; Takahashi, Masahiro; Kubo, Kaoru; Wagner, George C.; Nakashima, Toshikatsu

Pharmacology and Toxicology, 1999 , vol. 85, # 3 p. 133 - 137 Title/Abstract Full Text View citing articles Show Details

Fleckenstein, Annette E.; Metzger, Ryan R.; Wilkins, Diana G.; Gibb, James W.; Hanson, Glen R.

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 282, # 2 p. 834 - 838 Title/Abstract Full Text View citing articles Show Details

Jozwiak, Krzysztof; Ravichandran, Sarangan; Collins, Jack R.; Wainer, Irving W.

Journal of Medicinal Chemistry, 2004 , vol. 47, # 16 p. 4008 - 4021 Title/Abstract Full Text View citing articles Show Details

Partilla, John S.; Dempsey, Allison G.; Nagpal, Ameet S.; Blough, Bruce E.; Baumann, Michael H.; Rothman, Richard B.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 237 - 246 Title/Abstract Full Text View citing articles Show Details

Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.

Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details

Banks, Matthew L.; Blough, Bruce E.; Negus, S. Stevens

Behavioural Pharmacology, 2011 , vol. 22, # 8 p. 824 - 836 Title/Abstract Full Text View citing articles Show Details

D'Almeida; Camarini; Azzalis; Mattei; Junqueira; Carlini

Toxicology Letters, 1995 , vol. 81, # 2-3 p. 101 - 105 Title/Abstract Full Text Show Details

2 of 3

Comment (Pharmacological Data)

Bioactivities present

Reference

Roberts; Harbison; Westhouse; James

Toxicology Letters, 1995 , vol. 76, # 1 p. 77 - 83 Title/Abstract Full Text Show Details

Chu; Nordeen; Hardy; Swanson; Giardina; Pernet; Plattner

Journal of Medicinal Chemistry, 1991 , vol. 34, # 1 p. 168 - 174 Title/Abstract Full Text Show Details

PIKULEVA, Irina, A.; MAST, Natalia, V.

Patent: WO2008/153722 A1, 2008 ; Title/Abstract Full Text Show Details

3 of 3

Comment (Pharmacological Data)

mortality after 2h, 4h and 24 h (female NMRI mice, 21.5 mg/kg p.o.): 5/10, 8/10, 9/10 (in groups); 0/10, 0/10, 1/10 (single)

Reference

Teschendorf; Kretzschmar; Kreiskott; Weifenbach

Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 9 A p. 1580 - 1588 Title/Abstract Full Text View citing articles Show Details

Reaxys Registry Number: 7410286

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236

InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N

6

1 prep out of 1 reactions.

Identification

1


Synthesize | Hide Details Find similar

Identification Substance Label (1) Label

Reference

(-)-II/III

Acs, Maria; Kozma, David; Fogassy, Elemer

ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details

Purification (1) Purification (method)

Reference

via salt with sodium-hydrogen-R,R-tartrate

Acs, Maria; Kozma, David; Fogassy, Elemer

ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details

Chemical Name: L-methamphetamine

no reactions.

Reaxys Registry Number: 9387147

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236

InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N 7

Synthesize | Hide Details Find similar Chemical Names and Synonyms L-methamphetamine Identification Substance Label (1) Label

Reference

L-MAMP

Siu, Eric C. K.; Tyndale, Rachel F.

Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (5) 1 of 5

2 of 5

Comment (Pharmacological Data)

Bioactivities present

Reference

Siu, Eric C. K.; Tyndale, Rachel F.

Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

nicotine metabolism, examination of

Species or TestSystem (Pharmacological Data)

CYP2A6 of mouse

Identification Bioactivity (5)

1


3 of 5

4 of 5

5 of 5

Concentration (Pharmacological Data)

10 - 100 μmol/l

Method (Pharmacological Data)

CYP2A6 (20 pM P450/ml plus reductase and cc b5) incubated (15 min, 37 deg C) with mixture, containing title comp., 1 mM NADPH and 100 μM nicotine; reaction stopped with 4percent Na2CO3; samples prepared and analyzed for nicotine and metabolites by HPLC

Further Details (Pharmacological Data)

control: vehicle; internal control: 70 μg 5-methylcotinine; cotinine: product of nicotine oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine; cc: cytochrome

Comment (Pharmacological Data)

No effect

Reference

Siu, Eric C. K.; Tyndale, Rachel F.

Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

nicotine metabolism, inhibition of

Species or TestSystem (Pharmacological Data)

CYP2A5 of mouse

Concentration (Pharmacological Data)

10 - 100 μmol/l

Method (Pharmacological Data)

CYP2A5 (60 pM P450/ml, reductase and cc b5) incubated (15 min, 37 deg C) with mixture, containing title comp., 1 mM NADPH and 60 μM nicotine; reaction stopped with 4percent Na2CO3; samples prepared and analyzed for nicotine and metabolites by HPLC system

Further Details (Pharmacological Data)

control: vehicle; internal control: 70 μg 5-methylcotinine; cotinine: product of nicotine C-oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine; cc: cytochrome

Results

title comp. dose-dep. inhibited nicotine metabolism (formation of cotinine) of CYP2A5; at 100 μM title comp.inhibited nicotine metabolism by ca. 45percent; fig.

Reference

Siu, Eric C. K.; Tyndale, Rachel F.

Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

nicotine metabolism, inhibition of

Species or TestSystem (Pharmacological Data)

liver microsomes of DBA/2 mouse

Concentration (Pharmacological Data)

10 - 100 μmol/l

Method (Pharmacological Data)

MLMs (0.5 mg/ml protein) incubated for 15 min at 37 deg C with mixture, containing title comp., 1 mM NADPH and 10 μM nicotine; reaction stopped with 4percent Na2CO3; then samples prepared and analyzed for nicotine and metabolites by HPLC system

Further Details (Pharmacological Data)

control: vehicle; internal control: 5-methylcotinine; MLMs: mouse liver microsomes; cotinine: product of nicotine C-oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine

Results

title comp. dose-dep. inhibited nicotine metabolism (formation of cotinine); at 100 μM inhibition was ca. 45percent; fig.

Reference

Siu, Eric C. K.; Tyndale, Rachel F.

Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

nicotine metabolism, examination of

Species or TestSystem (Pharmacological Data)

liver microsomes of human

Concentration (Pharmacological Data)

10 - 100 μmol/l


Method (Pharmacological Data)

HLMs (0.5 mg/ml protein) incubated for 20 min at 37 deg C with mixture, containing title comp., 1 mM NADPH and 20 μM nicotine; reaction stopped with 4percent Na2CO3; then samples prepared and analyzed for nicotine and metabolites by HPLC system

Further Details (Pharmacological Data)

control: vehicle; internal control: 5-methylcotinine; HLMs: human liver microsomes; cotinine: product of nicotine C-oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine

Comment (Pharmacological Data)

No effect

Reference

Siu, Eric C. K.; Tyndale, Rachel F.

Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details

Chemical Name: (1R,2S)-2-(Methylamino)-1-deuterio-1-phenylpropane

2 prep out of 2 reactions.

Reaxys Registry Number: 6920257

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H14DN Molecular Weight: 150.228

InChI Key: MYWUZJCMWCOHBA-KENKBMNRSA-N

Identification Physical Data (2) Spectra (6)

1

8

Synthesize | Hide Details Find similar Chemical Names and Synonyms (1R,2S)-2-(Methylamino)-1-deuterio-1-phenylpropane Identification Substance Label (1) Label

Reference

12b

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

Physical Data Boiling Point (1) Boiling Point

Pressure (Boiling Point)

Reference

37 - 41 °C

0.1 Torr

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

Optical Rotatory Power (1) Type (Optical Rotatory Power)

Concentration (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

Temperature (Optical Rotatory Power)

[alpha]

2.07 g/100ml

CH2Cl2

2.61 deg

589 nm

25 °C

Spectra NMR Spectroscopy (4)

Reference Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details


Description (NMR Spectroscopy)

Nucleus (NMR Spectroscopy)

Solvents (NMR Spectroscopy)

Comment (NMR Spectroscopy)

Chemical shifts

1H

CDCl3

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

Chemical shifts

13C

CDCl3

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

Reference

Spin-spin coupling constants

CDCl3

1H-1H

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

Spin-spin coupling constants

CDCl3

2D-13C.

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

IR Spectroscopy (1) Description (IR Spectroscopy)

Solvent (IR Spectroscopy)

Comment (IR Spectroscopy)

Reference

Bands

neat (no solvent)

3300 cm**(-1)

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

Mass Spectrometry (1) Description (Mass Spectrometry)

Reference

spectrum

Almena, Juan; Foubelo, Francisco; Yus, Miguel

Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details

Chemical Name: D, methamphetamine

no reactions.

2

3 prep out of 10 reactions.

1

Reaxys Registry Number: 29823490

Molecular Formula: C10H15N Linear Structure Formula: C10H14(2)HN

Molecular Weight: 150.228

InChI Key: MYWUZJCMWCOHBA-VMNATFBRSA-N

9

Synthesize | Hide Details Find similar Chemical Names and Synonyms D, methamphetamine, methamphetamine-D Reaxys Registry Number: 3943810

Type of Substance: isocyclic Molecular Formula: C10H15N*H Linear Structure Formula: C10H15N*H(1+)

Molecular Weight: 150.244

InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-O

10


Synthesize Find similar Reaxys Registry Number: 26132956

Molecular Formula: C10H15N*H Linear Structure Formula: C10H15N*H(1+)

no reactions.

Bioactivity (1)

1

no reactions.

Bioactivity (1)

1

Molecular Weight: 150.244

InChI Key: MYWUZJCMWCOHBA-SECBINFHSA-O

11

Synthesize | Hide Details Find similar

Bioactivity Pharmacological Data (1) 1 of 1

Comment (Pharmacological Data)

Bioactivities present

Reference

Magyar; Palfi; Tabi; Kalasz; Szende; Szoeko

Current Medicinal Chemistry, 2004 , vol. 11, # 15 p. 2017 - 2031 Title/Abstract Full Text View citing articles Show Details

Reaxys Registry Number: 26132957

CAS Registry Number: 1551249-69-4 Molecular Formula: C10H15N*H Linear Structure Formula: C10H15N*H(1+)

Molecular Weight: 150.244

InChI Key: MYWUZJCMWCOHBA-VIFPVBQESA-O

12

Synthesize | Hide Details Find similar

Bioactivity Pharmacological Data (1) 1 of 1

Comment (Pharmacological Data)

Bioactivities present


Magyar; Palfi; Tabi; Kalasz; Szende; Szoeko

Current Medicinal Chemistry, 2004 , vol. 11, # 15 p. 2017 - 2031 Title/Abstract Full Text View citing articles Show Details

Reference

Chemical Name: (13)C,(15)N-methamphetamine Reaxys Registry Number: 12690028

Molecular Formula: C10H15N Linear Structure Formula: C9(13)CH15(15)N

1 prep out of 1 reactions.

Identification

1

1 prep out of 1 reactions.

1

1 prep out of 1 reactions.

1

Molecular Weight: 151.218

InChI Key: MYWUZJCMWCOHBA-OMUUITEASA-N

13

Synthesize | Hide Details Find similar Chemical Names and Synonyms (13)C,(15)N-methamphetamine Identification Substance Label (1) Label

Reference

a-19

DR PHARMA NOVA, LLC

Patent: WO2006/91885 A2, 2006 ; Title/Abstract Full Text Show Details

Patent-Specific Data (1) Related Markush Structure (RN)

Reference

12690024

DR PHARMA NOVA, LLC

Patent: WO2006/91885 A2, 2006 ; Title/Abstract Full Text Show Details

Chemical Name: S-(+)-[2H2]methamphetamine Reaxys Registry Number: 9758471

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H13D2N Molecular Weight: 151.22

InChI Key: MYWUZJCMWCOHBA-FPCJZCRGSA-N

14

Synthesize | Hide Details Find similar Chemical Names and Synonyms S-(+)-[2H2]methamphetamine Chemical Name: d-methamphetamine-d3

Reaxys Registry Number: 9758470

Type of Substance: isocyclic Molecular Formula: C H N


10 15

Linear Structure Formula: C10H12D3N Molecular Weight: 152.212

InChI Key: MYWUZJCMWCOHBA-XYFUXNRQSA-N

15

Synthesize | Hide Details Find similar Chemical Names and Synonyms d-methamphetamine-d3, S-(+)-[2H3]methamphetamine Chemical Name: (R)-N-d3-methyl-1-phenylpropan-2-amine

1 prep out of 2 reactions.

Reaxys Registry Number: 20920682

CAS Registry Number: 1254494-15-9 Molecular Formula: C10H15N Linear Structure Formula: C10H12(2)H3N

Physical Data (1) Spectra (2)

1

Molecular Weight: 152.212

InChI Key: MYWUZJCMWCOHBA-NNKNZJFPSA-N

16

Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-N-d3-methyl-1-phenylpropan-2-amine Physical Data Crystal Property Description (1) Colour & Other Properties

Location

Reference

colorless

Page/Page column 11

AUSPEX PHARMACEUTICALS, INC.

Patent: US2010/286124 A1, 2010 ; Title/Abstract Full Text Show Details

Spectra NMR Spectroscopy (1) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectroscopy)

1H

chloroform-d1

Original Text (NMR Spectroscopy)

Location

1H-NMR

Page/Page column 11

(CDCl3): δ1.05 (d, J=6.9 Hz, 3H), 1.40 (br s, 1H), 2.61

(m, 1H), 2.70 (m, 1H), 2.78 (m, 1H), 7.10-7.32 (m, 5H)

Comment (NMR Spectroscopy) Signals given

Reference AUSPEX PHARMACEUTICALS, INC.

Patent: US2010/286124 A1, 2010 ; Title/Abstract Full Text Show Details

Mass Spectrometry (1) Location

Reference


AUSPEX PHARMACEUTICALS, INC.

Patent: US2010/286124 A1, 2010 ;

Page/Page column 11

Title/Abstract Full Text Show Details

Chemical Name: (S)-[2',6'-(3)H2]methamphetamine Reaxys Registry Number: 20382968

CAS Registry Number: 1207183-39-8 Molecular Formula: C10H15N Linear Structure Formula: C10H13(3)H2N

1 prep out of 1 reactions.

1

1 prep out of 2 reactions.

Identification Physical Data (1) Spectra (2)

4

Molecular Weight: 153.22

InChI Key: MYWUZJCMWCOHBA-CJTMEMAZSA-N

17

Synthesize | Hide Details Find similar Chemical Names and Synonyms (S)-[2',6'-(3)H2]methamphetamine Chemical Name: 1-phenyl-2-methyl-d3-aminopropane-1,2-d2 Reaxys Registry Number: 2975553

CAS Registry Number: 60124-88-1 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H10D5N Molecular Weight: 154.196

InChI Key: MYWUZJCMWCOHBA-CXVYKYTNSA-N

18

Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-2-methyl-d3-aminopropane-1,2-d2, methamphetamine-D5, Methamphetamine-d5 Identification Substance Label (1) Label

Reference

I

Fentiman; Foltz

Journal of Labelled Compounds and Radiopharmaceuticals, 1976 , vol. 12, p. 69,74 Full Text Show Details

Derivative (1)

Comment (Derivative)

Reference

Hydrochlorid; F: 133-134grad

Fentiman; Foltz

Journal of Labelled Compounds and Radiopharmaceuticals, 1976 , vol. 12, p. 69,74 Full Text Show Details

Physical Data Chromatographic Data (1) Chromatographic data

Reference


Fedorova, Ganna; Randak, Tomas; Lindberg, Richard H.; Grabic, Roman

Rapid Communications in Mass Spectrometry, 2013 , vol. 27, # 15 p. 1751 - 1762 Title/Abstract Full Text View citing articles Show Details

LC (Liquid chromatography)

Spectra Mass Spectrometry (2) Description (Mass Spectrometry)

Reference

tandem mass spectrometry electrospray ionisation (ESI) high resolution mass spectrometry (HRMS) spectrum

Fedorova, Ganna; Randak, Tomas; Lindberg, Richard H.; Grabic, Roman

Rapid Communications in Mass Spectrometry, 2013 , vol. 27, # 15 p. 1751 - 1762 Title/Abstract Full Text View citing articles Show Details

electrospray ionisation (ESI) high resolution mass spectrometry (HRMS) spectrum

Fedorova, Ganna; Randak, Tomas; Lindberg, Richard H.; Grabic, Roman

Rapid Communications in Mass Spectrometry, 2013 , vol. 27, # 15 p. 1751 - 1762 Title/Abstract Full Text View citing articles Show Details

Chemical Name: methamphetamine-d5

no reactions.

Identification Spectra (1)

1

Reaxys Registry Number: 30060469

Molecular Formula: C10H15N Linear Structure Formula: C10H10(2)H5N

Molecular Weight: 154.196

InChI Key: MYWUZJCMWCOHBA-FIJCCKCHSA-N

19

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-d5

Identification Substance Label (1) Label

Reference

MAd5

Earla, Ravinder; Kumar, Santosh; Wang, Lei; Bosinger, Steven; Li, Junhao; Shah, Ankit; Gangwani, Mohitkumar; Nookala, Anantha; Liu, Xun; Cao, Lu; Jackson, Austin; Silverstein, Peter S.; Fox, Howard S.; Li, Weihua; Kumar, Anil

Drug Metabolism and Disposition, 2014 , vol. 42, # 12 p. 2097 - 2108 Title/Abstract Full Text Show Details

Spectra Mass Spectrometry (1) Description (Mass Spectrometry) electrospray ionisation (ESI) liquid chromatography mass spectrometry (LCMS) tandem mass spectrometry spectrum

Location

Reference

supporting information

Earla, Ravinder; Kumar, Santosh; Wang, Lei; Bosinger, Steven; Li, Junhao; Shah, Ankit; Gangwani, Mohitkumar; Nookala, Anantha; Liu, Xun; Cao, Lu; Jackson, Austin; Silverstein, Peter S.; Fox, Howard S.; Li, Weihua; Kumar, Anil

Drug Metabolism and Disposition, 2014 , vol. 42, # 12 p. 2097 - 2108 Title/Abstract Full Text Show Details

Chemical Name: methamphetamine-D5 Reaxys Registry Number: 30195335

Molecular Formula: C10H15N Linear Structure Formula: C10H10(2)H5N

no reactions.

6


Molecular Weight: 154.196

InChI Key: MYWUZJCMWCOHBA-QIYJHHKOSA-N

20

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-D5 Chemical Name: methamphetamine-d5

no reactions.

Spectra (1)

1

Reaxys Registry Number: 30549854

Molecular Formula: C10H15N Linear Structure Formula: C10H10(2)H5N

Molecular Weight: 154.196

InChI Key: MYWUZJCMWCOHBA-DKFMXDSJSA-N

21

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-d5 Spectra Mass Spectrometry (1) Description (Mass Spectrometry) electrospray ionisation (ESI) spectrum

Reference Paíga, Paula; Rodrigues, Manuela J.E.; Correia, Manuela; Amaral, Joana S.; Oliveira, M. Beatriz P.P.; Delerue-Matos, Cristina

European Journal of Pharmaceutical Sciences, 2017 , vol. 99, p. 219 - 227 Title/Abstract Full Text Show Details

Chemical Name: DL-[13C6]-methamphetamine Reaxys Registry Number: 26969029

Molecular Formula: C10H15N Linear Structure Formula: C4(13)C6H15N

Molecular Weight: 155.17

InChI Key: MYWUZJCMWCOHBA-RKQYQYHUSA-N

22

Synthesize | Hide Details Find similar

1 prep out of 2 reactions.

Identification

1


Chemical Names and Synonyms DL-[13C6]-methamphetamine Identification Patent-Specific Data (1) Related Markush Structure (RN)

Reference

30665511

CHIRON AS; Johansen, Jon Eigill; Liu, Huiling; Karlsen, Morten

Patent: US9435816 B2, 2016 ; Title/Abstract Full Text Show Details

Chemical Name: 1-phenyl-2-methylaminopropane-1,1,2,3,3,3-d6 Reaxys Registry Number: 7532918

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H9D6N Molecular Weight: 155.188

InChI Key: MYWUZJCMWCOHBA-KLJQIKPOSA-N

23

0 prep out of 2 reactions.

1

0 prep out of 2 reactions.

1

no reactions.

1

Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-2-methylaminopropane-1,1,2,3,3,3-d6 Chemical Name: 1-phenyl-2-methyl-d3-aminopropane-1,2,3,3,3-d5 Reaxys Registry Number: 7535408

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H7D8N Molecular Weight: 157.172

InChI Key: MYWUZJCMWCOHBA-URFKORASSA-N

24

Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-2-methyl-d3-aminopropane-1,2,3,3,3-d5 Chemical Name: methamphetamine-D9

Reaxys Registry Number: 30638606

Molecular Formula: C10H15N Linear Structure Formula: C10H6(2)H9N

25

Molecular Weight: 158.164

InChI Key: MYWUZJCMWCOHBA-FUUWYYHRSA-N


Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-D9

Chemical Name: 1-phenyl-d5-2-methyl-d3-aminopropane-3,3,3-d3 Reaxys Registry Number: 7539213

Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H4D11N Molecular Weight: 160.148

InChI Key: MYWUZJCMWCOHBA-JFZRXOORSA-N

26

0 prep out of 2 reactions.

1

no reactions.

19

no reactions.

10

Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-d5-2-methyl-d3-aminopropane-3,3,3-d3 Chemical Name: methane ice Reaxys Registry Number: 30156167

Molecular Formula: CH4*C10H15N Linear Structure Formula: CH4*C10H15N Molecular Weight: 165.279

InChI Key: JPKWQXJAZOTHAQ-FVGYRXGTSA-N

27

Synthesize | Hide Details Find similar Chemical Names and Synonyms methane ice Chemical Name: ammonia ice Reaxys Registry Number: 30204741

Molecular Formula: C10H15N*H3N Linear Structure Formula: C10H15N*H3N Molecular Weight: 166.266

InChI Key: YJWVKGVRRKFJIZ-FVGYRXGTSA-N

28

Synthesize | Hide Details Find similar Chemical Names and Synonyms ammonia ice


Chemical Name: (2S)-N-methyl-1-phenylpropan-2-amine hydrate Reaxys Registry Number: 13191660

Molecular Formula: C10H15N*H2O Linear Structure Formula: C10H15N*H2O Molecular Weight: 167.251

InChI Key: JEPOEABJTIMMHD-FVGYRXGTSA-N

29

1 prep out of 8 reactions.

1251

no reactions.

Identification Bioactivity (3)

1

Synthesize | Hide Details Find similar Chemical Names and Synonyms (2S)-N-methyl-1-phenylpropan-2-amine hydrate, ice+water, ice +water, Ice water, Ice H2O Chemical Name: sodium salt of methamphetamine Reaxys Registry Number: 8164135

Type of Substance: isocyclic Molecular Formula: C10H14N*Na Linear Structure Formula: C10H14N(1-)*Na(1+)

Molecular Weight: 171.218

InChI Key: DOEOAPQAINWNIB-UHFFFAOYSA-N

30

Synthesize | Hide Details Find similar Chemical Names and Synonyms sodium salt of methamphetamine Identification Substance Label (1) Label

Reference

MNa

Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek

Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (3) 1 of 3

2 of 3

Comment (Pharmacological Data)

Bioactivities present

Reference

Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek

Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

analgesic, other

Species or TestSystem (Pharmacological Data)

white Wistar rat

Sex

male and female


3 of 3

Route of Application

epicutaneous

Concentration (Pharmacological Data)

18 mg/kg

Kind of Dosing (Pharmacological Data)

test comp. appl. as a paste

Exposure Period (Pharmacological Data)

24 h

Method (Pharmacological Data)

rats weigh. 180-220 g; edema induced by burning of hind paws (60 deg C for 5 sec); decrease in pain sensitivity threshold of inflammed extremities

Further Details (Pharmacological Data)

test comp. applied onto burned surface 2 h after thermal irritation when edema reached 210-215 percent of initial paw volume

Results

23.8-48.1 percent reduction of pain sensitivity threshold

Reference

Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek

Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

antiinflammatory

Species or TestSystem (Pharmacological Data)

white Wistar rat

Sex

male and female

Route of Application

epicutaneous

Concentration (Pharmacological Data)

18 mg/kg

Kind of Dosing (Pharmacological Data)

test comp. appl. as a paste

Exposure Period (Pharmacological Data)

24 h

Method (Pharmacological Data)

rats weigh. 180-220 g; edema induced by burning of hind paws (60 deg C for 5 sec)

Further Details (Pharmacological Data)

test comp. applied onto burned surface 2 h after thermal irritation when edema reached 210-215 percent of initial paw volume

Results

13.5-39.3 percent edema inhibition

Reference

Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek

Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details

Chemical Name: carbon monoxide ice Reaxys Registry Number: 30636987

Molecular Formula: CO*C10H15N Linear Structure Formula: CO*C10H15N Molecular Weight: 177.246

InChI Key: VAQJAOMKVIEPJH-FVGYRXGTSA-N

31

Synthesize | Hide Details

no reactions.

2


Find similar Chemical Names and Synonyms carbon monoxide ice Chemical Name: ethylene ice

no reactions.

no reactions.

1

no reactions.

1

no reactions.

4

Reaxys Registry Number: 30842693

Molecular Formula: C2H4*C10H15N Linear Structure Formula: C2H4*C10H15N Molecular Weight: 177.29

InChI Key: VMFZMCDVULWGCK-FVGYRXGTSA-N

32

Synthesize | Hide Details Find similar Chemical Names and Synonyms ethylene ice Chemical Name: aluminum ice Reaxys Registry Number: 30842761

Molecular Formula: AlH3*C10H15N Linear Structure Formula: AlH3*C10H15N Molecular Weight: 179.241

InChI Key: QZEOTIOXDXGEKT-ZWACTXNCSA-N

33

Synthesize | Hide Details Find similar Chemical Names and Synonyms aluminum ice Chemical Name: formaldehyde ice Reaxys Registry Number: 30786718

Molecular Formula: CH2O*C10H15N Linear Structure Formula: CH2O*C10H15N Molecular Weight: 179.262

InChI Key: SZXXRURPJQVWLY-FVGYRXGTSA-N

34

Synthesize | Hide Details Find similar Chemical Names and Synonyms formaldehyde ice Chemical Name:


ethane ice Reaxys Registry Number: 30159202

Molecular Formula: C2H6*C10H15N Linear Structure Formula: C2H6*C10H15N Molecular Weight: 179.305

InChI Key: RFIMPHSGLJKTCZ-FVGYRXGTSA-N

35

Synthesize | Hide Details Find similar Chemical Names and Synonyms ethane ice Chemical Name: ice methanol

no reactions.

14

no reactions.

Bioactivity (1)

2

Reaxys Registry Number: 29866147

Molecular Formula: CH4O*C10H15N Linear Structure Formula: CH4O*C10H15N Molecular Weight: 181.278

InChI Key: IKIQMUFOYPAWCN-FVGYRXGTSA-N

36

Synthesize | Hide Details Find similar Chemical Names and Synonyms ice methanol, methanol ice Chemical Name: (-)-Metamphetamine phosphate Reaxys Registry Number: 24296479

Molecular Formula: C10H15N*0H3O4P Linear Structure Formula: C10H15N*0.33H3O4P Molecular Weight: 181.574

InChI Key: LERYZJIMAXSLFC-SBSPUUFOSA-N

37

Synthesize | Hide Details Find similar Chemical Names and Synonyms (-)-Metamphetamine phosphate Bioactivity Pharmacological Data (1) 1 of 1

Comment (Pharmacological Data)

Bioactivities present


Reference

Campbell; Patil; LaPidus; Campbell; Tye

Title/Abstract Full Text Show Details

LaPidus; Patil; LaPidus; Tye

Title/Abstract Full Text Show Details

Chemical Name: methamphetamine hydroxylamine

no reactions.

1

no reactions.

1

2 prep out of 6 reactions.

Identification Physical Data (21) Spectra (7) Bioactivity (40) Other Data (2)

60

Reaxys Registry Number: 30249430

Molecular Formula: C10H15N*H3NO Linear Structure Formula: C10H15N*H3NO Molecular Weight: 182.266

InChI Key: QSHWSGSYMIEDMV-UHFFFAOYSA-N

38

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine hydroxylamine Chemical Name: ammonia hydrate ice Reaxys Registry Number: 30428298

Molecular Formula: C10H15N*H2O*H3N Linear Structure Formula: C10H15N*H2O*H3N Molecular Weight: 184.282

InChI Key: XFSDUYCHTDEMIL-WWPIYYJJSA-N

39

Synthesize | Hide Details Find similar Chemical Names and Synonyms ammonia hydrate ice Chemical Name: D-methamphetamine hydrochloride Reaxys Registry Number: 4155698

CAS Registry Number: 300-42-5 Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697

InChI Key: TWXDDNPPQUTEOV-UHFFFAOYSA-N

40

Synthesize | Hide Details Find similar Chemical Names and Synonyms D-methamphetamine hydrochloride, d-Methamphetamine hydrochloride, Amphedroxyn, methamphetamine hydrochloride, (+/-)-methamphetamine hydrochloride, (+)-methamphetamine hydrochloride, (+-)-methyl-(1-methyl-2-phenyl-ethyl)-amine; hydrochloride


Identification Substance Label (4) Label

Reference

METH

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Sandoval, Veronica; RIddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2003 , vol. 304, # 3 p. 1181 - 1187 Title/Abstract Full Text View citing articles Show Details

Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details

Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details

Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon

Pharmacology Biochemistry and Behavior, 2017 , vol. 153, p. 160 - 167 Title/Abstract Full Text Show Details

MPA*HCl

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Meth

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

MAHCl

Sekine; Nagao; Nakahara

Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details

Patent-Specific Data (1) Location in Patent

Reference

Claim

Alza Corporation

Patent: US3968245 A1, 1976 ; Title/Abstract Full Text Show Details

Men, Tewa; Men, Yangyang

Patent: EP1232748 A1, 2002 ; Title/Abstract Full Text Show Details

Nippon Shinyaju Co., Ltd.

Patent: US5811547 A1, 1998 ; Title/Abstract Full Text Show Details

Cascade Development, Inc.

Patent: US6312728 B1, 2001 ; Title/Abstract Full Text Show Details

Cascade Development, Inc. a subsidiary of Cardinal Health, Inc.

Patent: US5968554 A1, 1999 ; Title/Abstract Full Text Show Details

General Mills, Inc.

Patent: US2002/44968 A1, 2002 ; Title/Abstract Full Text Show Details

Alza Corporation

Patent: US5023088 A1, 1991 ; Title/Abstract Full Text Show Details

Physical Data Melting Point (6)


Melting Point

Solvent (Melting Point)

Reference

129 - 134 °C

de Sarlo,F. et al.

Tetrahedron, 1966 , vol. 22, p. 2989 - 2994 Full Text View citing articles Show Details

135 - 136 °C

acetone

Nishimura; Takamatsu

Yakugaku Zasshi, 1964 , vol. 84, p. 938,943 Chem.Abstr., 1965 , vol. 62, # 2731 Full Text Show Details

134 - 135 °C

Shiho

Nippon Kagaku Kaishi, 1944 , vol. 65, p. 237 Chem.Abstr., 1947 , p. 3800 Full Text Show Details

135 - 136 °C

ethanol diethyl ether

Woodruff; Lambooy; Burt

Journal of the American Chemical Society, 1940 , vol. 62, p. 922 Full Text View citing articles Show Details

133 - 135 °C

ethanol diethyl ether

Novelli

Anales de la Asociacion Quimica Argentina (1921-2001), 1939 , vol. 27, p. 162,164 Chem.Abstr., 1940 , p. 1695 Full Text Show Details

134 - 135 °C

ethanol

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Adsorption (MCS) (1) Description (Adsorption (MCS))

Reference

Adsorption isotherm

Sengling; Guth

Journal of Pharmaceutical Sciences, 1961 , vol. 50, p. 929 Full Text View citing articles Show Details

Association (MCS) (11) Partner (Association (MCS))

Solvent (Association (MCS))

Comment (Association (MCS))

Formation constant of a complex

2,4,6-trinitrotoluene

CHCl3

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Formation constant of a complex

2,3-dicyano-5,6-dichloro-pbenzoquinone

CHCl3

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Formation constant of a complex

bromocresol green

CHCl3

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Formation constant of a complex

chlorophenol red

CHCl3

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Formation constant of a complex

bromcresol purple

CHCl3

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

UV/VIS spectrum of the complex

2,4,6-trinitrotoluene

CHCl3

concentration dependence

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular

Description (Association (MCS))

Reference


Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

UV/VIS spectrum of the complex

2,3-dicyano-5,6-dichloro-pbenzoquinone

CHCl3

concentration dependence

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

UV/VIS spectrum of the complex

bromocresol green

CHCl3

concentration dependence

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

UV/VIS spectrum of the complex

chlorophenol red

CHCl3

concentration dependence

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

UV/VIS spectrum of the complex

bromcresol purple

CHCl3

concentration dependence

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Further physical properties of the complex

3,7-dihydro-1,3,7-trimethyl-1H-purine2,6-dione; sodium benzoate

solid

Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty

Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details

Crystal Property Description (2) Colour & Other Properties

Reference

white

Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.

Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details

Tafeln

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Optics (1) Description (Optics)

Reference

Crystal refractive indices

Keenan

Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details

Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)

Nucleus (NMR Spectroscopy)

Solvents (NMR Spectroscopy)

Frequency (NMR Spectroscopy)

Chemical shifts

1H

water-d2

400 MHz

Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.

Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details

Chemical shifts

13C

water-d2

100 MHz

Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.

Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details

IR Spectroscopy (2) Description (IR Spectroscopy)

Solvent (IR Spectroscopy)

Comment (IR Spectroscopy)

Reference

Reference


Bands

potassium bromide

Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.

Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details

Spectrum

3500 - 500 cm**(-1)

Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty

Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details

UV/VIS Spectroscopy (1) Description (UV/VIS Spectroscopy)

Solvent (UV/VIS Spectroscopy)

Spectrum

CHCl3

Reference Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Raman Spectroscopy (2) Description (Raman Spectroscopy)

Comment (Raman Spectroscopy)

Reference

Spectrum

H2O

Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty

Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details

Spectrum

neat (no solvent, solid phase)

Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty

Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (40) 1 of 40

Comment (Pharmacological Data)

Bioactivities present

Reference

Alza Corporation

Patent: US3968245 A1, 1976 ; Title/Abstract Full Text Show Details

Men, Tewa; Men, Yangyang

Patent: EP1232748 A1, 2002 ; Title/Abstract Full Text Show Details

de Sarlo,F. et al.

Tetrahedron, 1966 , vol. 22, p. 2989 - 2994 Full Text View citing articles Show Details

Nippon Shinyaju Co., Ltd.

Patent: US5811547 A1, 1998 ; Title/Abstract Full Text Show Details

Cascade Development, Inc.

Patent: US6312728 B1, 2001 ; Title/Abstract Full Text Show Details

Cascade Development, Inc. a subsidiary of Cardinal Health, Inc.

Patent: US5968554 A1, 1999 ; Title/Abstract Full Text Show Details

General Mills, Inc.

Patent: US2002/44968 A1, 2002 ; Title/Abstract Full Text Show Details

Luk, Andrew Sheung-King; Lam, Stan; Zhang, Yuanpeng

Patent: US2005/118206 A1, 2005 ; Title/Abstract Full Text Show Details

Novelli

Anales de la Asociacion Quimica Argentina (1921-2001), 1939 , vol. 27, p. 162,164 Chem.Abstr., 1940 , p. 1695 Full Text Show Details

Keenan

Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details

Ogata


Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Shiho

Nippon Kagaku Kaishi, 1944 , vol. 65, p. 237 Chem.Abstr., 1947 , p. 3800 Full Text Show Details

Woodruff; Lambooy; Burt

Journal of the American Chemical Society, 1940 , vol. 62, p. 922 Full Text View citing articles Show Details

Nishimura; Takamatsu

Yakugaku Zasshi, 1964 , vol. 84, p. 938,943 Chem.Abstr., 1965 , vol. 62, # 2731 Full Text Show Details

Sengling; Guth

Journal of Pharmaceutical Sciences, 1961 , vol. 50, p. 929 Full Text View citing articles Show Details

Herraez-Hernandez, Rosa; Campins-Falco, Pilar; Sevillano-Cabeza, Adela

Analytical Chemistry, 1996 , vol. 68, # 5 p. 734 - 739 Title/Abstract Full Text View citing articles Show Details

Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty

Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details

Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi

Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details

Ohno; Watanabe

European Journal of Pharmacology, 1995 , vol. 275, # 1 p. 39 - 44 Title/Abstract Full Text View citing articles Show Details

Kuribara, Hisashi

Journal of Pharmacy and Pharmacology, 1998 , vol. 50, # 3 p. 303 - 309 Title/Abstract Full Text View citing articles Show Details

2 of 40

Comment (Pharmacological Data)

Bioactivities present

Reference

Sekine; Nagao; Nakahara

Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Sandoval, Veronica; RIddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2003 , vol. 304, # 3 p. 1181 - 1187 Title/Abstract Full Text View citing articles Show Details

Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details

Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details

Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

Morton-Norwich Products, Inc.

Patent: US4097500 A1, 1978 ; Title/Abstract Full Text Show Details

Alza Corporation

Patent: US5023088 A1, 1991 ; Title/Abstract Full Text Show Details

Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details

Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.

Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details

David, Gabrielle E.; Hibbert, D. Brynn; Frew, Russell D.; Hayman, Alan R.

Australian Journal of Chemistry, 2010 , vol. 63, # 1 p. 22 - 29 Title/Abstract Full Text View citing articles Show Details

Coote, Steven J.; Davies, Stephen G.; Fletcher, Ai M.; Roberts, Paul M.; Thomson, James E.

Chemistry - An Asian Journal, 2010 , vol. 5, # 3 p. 589 - 604 Title/Abstract Full Text View citing articles Show Details

Daly; Creveling; Witkop


Journal of medicinal chemistry, 1966 , vol. 9, # 3 p. 273 - 280 Title/Abstract Full Text Show Details

Zhu, Binling; Meng, Liang; Zheng, Kefang

Forensic Science International, 2014 , vol. 242, p. e44 - e47 Title/Abstract Full Text View citing articles Show Details

Shen, Ying-Ling; Chen, Shao-Tsu; Chan, Tzu-Yi; Hung, Tsai-Wei; Tao, Pao-Luh; Liao, Ruey-Ming; Chan, Ming-Huan; Chen, Hwei-Hsien

Neurobiology of Learning and Memory, 2016 , vol. 128, p. 56 - 64 Title/Abstract Full Text View citing articles Show Details

Nawata, Yoko; Kitaichi, Kiyoyuki; Yamamoto, Tsuneyuki

Drug and Alcohol Dependence, 2016 , vol. 160, p. 76 - 81 Title/Abstract Full Text View citing articles Show Details

Mori, Tomohisa; Iwase, Yoshiyuki; Murata, Asami; Iwata, Noriyuki; Suzuki, Tsutomu

Behavioural Brain Research, 2016 , vol. 306, p. 64 - 70 Title/Abstract Full Text View citing articles Show Details

Irii, Toshiaki; Maebashi, Kyoko; Fukui, Kenji; Sohma, Ryoko; Matsumoto, Sari; Takasu, Shojiro; Iwadate, Kimiharu

Legal Medicine, 2016 , vol. 20, p. 53 - 60 Title/Abstract Full Text View citing articles Show Details

3 of 40

Comment (Pharmacological Data)

Bioactivities present

Reference

Fernandes, Nicole C.; Sriram, Uma; Gofman, Larisa; Cenna, Jonathan M.; Ramirez, Servio H.; Potula, Raghava

Journal of Neuroinflammation, 2016 , vol. 13, # 1 art. no. 91 Title/Abstract Full Text View citing articles Show Details

Marks, Katherine R.; Lile, Joshua A.; Stoops, William W.; Glaser, Paul E. A.; Hays, Lon R.; Rush, Craig R.

Journal of Clinical Psychopharmacology, 2016 , vol. 36, # 3 p. 213 - 221 Title/Abstract Full Text View citing articles Show Details

Manning, Elizabeth E.; Halberstadt, Adam L.; Van Den Buuse, Maarten

International Journal of Neuropsychopharmacology, 2016 , vol. 19, # 4 art. no. PYV116 Title/Abstract Full Text View citing articles Show Details

Hopkins, Adam J.; Cooper, Justin L.; Profeta, Luisa T.M.; Ford, Alan R.

Applied Spectroscopy, 2016 , vol. 70, # 5 p. 861 - 873 Title/Abstract Full Text View citing articles Show Details

Hikichi, Hirohiko; Hiyoshi, Tetsuaki; Marumo, Toshiyuki; Tomishima, Yasumitsu; Kaku, Ayaka; Iida, Izumi; Urabe, Hiroki; Tamita, Tomoko; Yasuhara, Akito; Karasawa, Jun-ichi; Chaki, Shigeyuki

Journal of pharmacological sciences, 2015 , vol. 127, # 3 p. 352 - 361 Title/Abstract Full Text Show Details

Collins, Gregory T.; Abbott, Megan; Galindo, Kayla; Rush, Elise L.; Rice, Kenner C.; France, Charles P.

Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 1 p. 1 - 10 Title/Abstract Full Text Show Details

Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon

Behavioural Brain Research, 2017 , vol. 317, p. 494 - 501 Title/Abstract Full Text Show Details

Murphy, Brian L.

Environmental Forensics, 2016 , vol. 17, # 4 p. 282 - 293 Title/Abstract Full Text Show Details

Murphy, Brian L.

Environmental Forensics, 2016 , vol. 17, # 4 p. 282 - 293 Title/Abstract Full Text Show Details

Zhu, Rui; Yang, Tianjiao; Kobeissy, Firas; Mouhieddine, Tarek H.; Raad, Mohamad; Nokkari, Amaly; Gold, Mark S.; Wang, Kevin K.; Mechref, Yehia

PLoS ONE, 2016 , vol. 11, # 4 art. no. 0151034 Title/Abstract Full Text Show Details

Li, Zhi; Zhang, Shuaihua; Cai, Yi; Wu, Qiuhua; Chen, Hao

Analytical Methods, 2016 , vol. 8, # 43 p. 7800 - 7807 Title/Abstract Full Text Show Details

Gerak, Lisa R.; Collins, Gregory T.; France, Charles P.

Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 3 p. 383 - 391 Title/Abstract Full Text Show Details

Alcamán, Katherinne; Duffau, Boris Ettienne; Morales, Daniela

Journal of Planar Chromatography - Modern TLC, 2016 , vol. 29, # 6 p. 474 - 476 Title/Abstract Full Text Show Details

Bahmanabadi; Akhgari; Jokar; Sadeghi

Human and Experimental Toxicology, 2017 , vol. 36, # 2 p. 195 - 202 Title/Abstract Full Text Show Details

Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon

Pharmacology Biochemistry and Behavior, 2017 , vol. 153, p. 160 - 167 Title/Abstract Full Text Show Details

Jafari Giv, Mahsa

Cardiovascular Toxicology, 2017 , vol. 17, # 1 p. 13 - 24 Title/Abstract Full Text Show Details

Abbasian, Maryam; Balali-Mood, Mahdi; Salar Amoli, Hossein; Masoumi, Akram

Journal of Sol-Gel Science and Technology, 2017 , vol. 81, # 1 p. 247 - 260 Title/Abstract Full Text Show Details

Jalewa, Jaishree; Sharma, Mohit Kumar; Gengler, Simon; Hölscher, Christian

Neuropharmacology, 2017 , vol. 117, p. 238 - 248 Title/Abstract Full Text Show Details

Hassanzadeh, Javad; Khataee, Alireza; Lotfi, Roya

Microchemical Journal, 2017 , vol. 132, p. 371 - 377 Title/Abstract Full Text Show Details

Graniczkowska, Kinga; Pütz, Michael; Hauser, Frank M.; De Saeger, Sarah; Beloglazova, Natalia V.

Biosensors and Bioelectronics, 2017 , vol. 92, p. 741 - 747


Title/Abstract Full Text Show Details

4 of 40

5 of 40

6 of 40

7 of 40

8 of 40

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon

Pharmacology Biochemistry and Behavior, 2017 , vol. 153, p. 160 - 167 Title/Abstract Full Text Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Gerak, Lisa R.; Collins, Gregory T.; France, Charles P.

Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 3 p. 383 - 391 Title/Abstract Full Text Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Collins, Gregory T.; Abbott, Megan; Galindo, Kayla; Rush, Elise L.; Rice, Kenner C.; France, Charles P.

Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 1 p. 1 - 10 Title/Abstract Full Text Show Details

Effect (Pharmacological Data)

tolerance; induction of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 24 h - 31 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval

Method (Pharmacological Data)

pretreatment and challenge with title comp.; 22 h after the last dose dopamine and serotonin (5-HT) concentration in striatum and 5-HT concentration in frontal cortex and hippocampus were determined using high-performance liquid chromatography

Further Details (Pharmacological Data)

controls: pretreatment and/or challenge with saline

Results

title comp. pretreatment induced tolerance against monoamine level reduction by title comp. challenge when given 24 h - 7 d, but not 14 31 d prior to challenge; tolerance was noted for striatum and frontal cortex levels, but not in hippocampus

Reference

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

tolerance; induction of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 24 h - 14 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval

Method (Pharmacological Data)

pretreatment and challenge with title comp.; core body temp. was recorded every 4 h during challenge period (9 time points)

Further Details (Pharmacological Data)

controls: pretreatment and/or challenge with saline


9 of 40

10 of 40

11 of 40

Results

title comp. pretreatment induced tolerance against body temp. increase by title comp. challenge; effect was significant at 6, 1, and 3 time points for pretreatment-challenge interval of 24 h, 7 d, and 14 d, resp.

Reference

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 31 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval

Method (Pharmacological Data)

pretreatment and challenge with title comp.; core body temp. was recorded every 4 h during challenge period (9 time points)

Further Details (Pharmacological Data)

controls: pretreatment and/or challenge with saline

Results

title comp. pretreatment enhanced body temp. increase by title comp. challenge; effect was significant at 3 time points

Reference

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; effect on

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals

Method (Pharmacological Data)

treatment with title comp.; 24 h - 31 d later challenge with saline injections during 16 h; 22 h later dopamine and serotonin (5-HT) concentrations in striatum and 5-HT concentrations in frontal cortex and hippocampus were determined using HPLC

Further Details (Pharmacological Data)

controls: saline; HPLC: high-performance liquid chromatography

Comment (Pharmacological Data)

No effect

Reference

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

body temperature; effect on

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male


12 of 40

13 of 40

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals

Method (Pharmacological Data)

treatment with title comp.; 24 h - 31 d later core body temp. was recorded every 4 h during a period of 16 h

Further Details (Pharmacological Data)

controls: saline

Comment (Pharmacological Data)

No effect

Reference

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 24 h - 31 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval

Method (Pharmacological Data)

pretreatment and challenge with title comp.; 2 h after the last dose title comp. and amphetamine were measured in striatum, hippocampus, frontal cortex, and plasma using liquid chromatography/tandem mass spectrometry

Further Details (Pharmacological Data)

control: pretreatment with saline

Results

title comp. and amphetamine levels in brain had no regional differences; title comp. and amphetamine levels in brain and plasma were not affected by title comp. pretreatment

Metabolite (Pharmacological Data)

2-amino-1-phenylpropane [Reaxys RN: 507867]

Reference

Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline, administered singlely in a volume of 1 ml/kg; dose referred to free base

Method (Pharmacological Data)

rats sacrificed 3 h after treatment; brains separated; number of neurons expressing ppNPY mRNA in rostral, middle and caudal striatum regions determined using in situ hybridization histochemistry ppNPY: prepro-neuropeptide Y


Further Details (Pharmacological Data)

14 of 40

15 of 40

16 of 40

Results

title comp. treatment caused significant increase in number of neurons expressing ppNPY mRNA in all regions of striatum examined compared to control (diagram)

Reference

Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and administered in a volume of 1 ml/kg as five injections at 6-h intervals; dose referred to free base

Method (Pharmacological Data)

rats sacrificed 3 h after last injection; brains separated; number of neurons expressing ppNPY and pSOM mRNA in rostral, middle and caudal striatum regions determined using in situ hybridization histochemistry

Further Details (Pharmacological Data)

ppNPY: prepro-neuropeptide Y; pSOM: prosomatostatin; further investigations on mechanisms of action in presence of dopamine D1 and D2 receptor antagonists SCH22390 and eticlopride, resp.

Results

title comp. treatment caused significant increase in number of neurons expressing ppNPY mRNA in all striatum regions but did not change number of neurons expressing pSOM mRNA; effect was suggested to depend on dopamine D1 but not D2 receptor activation

Reference

Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; decrease of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals

Method (Pharmacological Data)

rats treated with PCA/saline; after 7 days, administered with title comp.; sacrificed after 1 h; synaptic vesicles from hippocampus prepared; <3H>dopamine uptake evaluated by incubating synaptic vesicles at 30 deg C for 3 min in presence of <3H>dopamine

Further Details (Pharmacological Data)

control: saline; PCA: para-chloroamphetamine

Results

title comp. acutely decreased vesicular dopamine uptake; in rats pretreated with PCA, title comp. was devoid of this effect; diagram

Reference

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological

Sprague-Dawley rat


Data)

17 of 40

18 of 40

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals

Method (Pharmacological Data)

rats treated with PCA/saline; after 7 days, administered with title comp.; sacrificed after 1 h; hippocampus dissected; serotonin and norepinephrine content determined by HPLC coupled to electrochemical detector

Further Details (Pharmacological Data)

control: saline; PCA: para-chloroamphetamine

Results

title comp. acutely decreased tissue serotonin content; in rats pretreated with PCA, title comp. was devoid of this effect; table

Reference

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; effect on

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

7.5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was administered 4 times

Method (Pharmacological Data)

rats administered with title comp.; before 15 min, fluoxetine/saline administered; sacrificed after 1 h; hippocampal vesicular dopamine uptake assessed by incubating (30 deg C, 3 min) in presence of <3H>dopamine; hippocampal serotonin content assessed

Further Details (Pharmacological Data)

control: saline

Results

title comp. acutely decreased <3H>dopamine uptake and serotonin content; fluoxetine pretreatment prevented title comp. effect; diagrams

Reference

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

hyperthermic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

7.5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was administered 4 times

Method (Pharmacological Data)

rats administered with title comp.; before 15 min, fluoxetine or saline administered; rectal temperatures taken every hour beginning 30 min before title comp. administration


19 of 40

20 of 40

Further Details (Pharmacological Data)

control: saline

Results

title comp. induced hyperthermia; fluoxetine pretreatment prevented title comp. effect; diagrams

Reference

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; decrease of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals

Method (Pharmacological Data)

rats treated with DSP-4 (50 mg/kg, i.p.)/saline 15 min after fluoxetine (10 mg/kg, i.p.)/saline pretreatment; 7 days later, treated with title comp.; sacrificed after 1 h; hippocampal vesicular dopamine uptake assessed, 30 deg C, 10 min

Further Details (Pharmacological Data)

control: saline; DSP-4: N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine

Results

title comp. acutely decreased dopamine uptake; title comp.-induced decrease in vesicular uptake occurred in rats pretreated with DSP-4; diagram

Reference

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; decrease of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals

Method (Pharmacological Data)

rats treated with DSP-4 (50 mg/kg, i.p.) or saline 15 min after either fluoxetine (10 mg/kg, i.p.) or saline pretreatment; 7 days later, treated with title comp.; sacrificed after 1 h; hippocampal serotonin and norepinephrine content detd. by HPLC-ED

Further Details (Pharmacological Data)

control: saline; HPLC-ED: HPLC coupled to electrochemical detector; DSP-4: N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride

Results

title comp. acutely decreased serotonin and norepinephrine content; title comp.-induced decrease occurred in rats pretreated with DSP-4; table

Reference

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological

Sprague-Dawley rat

Hide facts 21 of 40


Data)

22 of 40

23 of 40

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

7.5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. administered 4 times

Method (Pharmacological Data)

rats treated with title comp.; sacrificed after 1, 48 or 144 h; hippocampal serotonin and norepinephrine content detd. by HPLC coupled to electrochemical detector

Further Details (Pharmacological Data)

control: saline

Results

title comp. reduced levels of serotonin but not norepinephrine, 6 days after last administration; diagram

Reference

Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 - 8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 4-h intervals and with 40-h intervals between each dosing regimen

Method (Pharmacological Data)

2, 4 and 6 mg/kg of title comp. were injected on days 1, 3, and 5, resp.; 66 h after last pretreatment rats challenged with high dose of title comp. (8 mg/kg); 7 d after last injection striatum was dissected, and content of DA determined by HPLC

Further Details (Pharmacological Data)

control: saline pretreatment or/and challenge; DA: dopamine; HPLC: high performance liquid chromotography

Results

high-dose injections of title comp. decreased striatal DA content by 69 percent; pretreatment with increasing doses of title comp. decreased depletion effect of high-dose challenge by 51 percent; treatment with increasing doses caused only 27 percent decrease in DA content

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 - 8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 4-h intervals and 40-h drug-free periods between each dosing regimen


24 of 40

25 of 40

Method (Pharmacological Data)

2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5, resp.; 66 h after last pretreatment rats challenged with high dose of title comp. (8 mg/kg); core body temperature recorded every 1 h after each title comp. injection

Further Details (Pharmacological Data)

control: saline pretreatment and/or challenge

Results

high-dose injections of title comp. induced signficant elevation of core body temperature; pretreatment with increasing doses of title comp. prior high dose injections slightly attenuated elevation of body temperature

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 2-h intervals

Method (Pharmacological Data)

rats were challenged with title comp.; core body temperature were recorded with BAT-12 model thermometer and thermocoupled rectal probe (model RET-2) every 1 h after each title comp. injection at 24 deg C and 6 deg C

Further Details (Pharmacological Data)

control: saline

Results

multiple injections of title comp. elevated core body temperature at room temperature; this effect of title comp. was blocked in rats treated with title comp. at 6 deg C

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter uptake; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 2-h intervals

Method (Pharmacological Data)

rats were challenged with title comp.; <3H>dopamine uptake of synaptic vesicles prepared from striatum was assessed 1 h after last injection at 24 deg C and 6 deg C

Further Details (Pharmacological Data)

control: saline

Results

multiple injections of title comp. at 24 deg C decreased vesicular dopamine uptake by 72 percent compared to saline-treated rats; at 6 deg C title comp. injections decreased vesicular dopamine uptake by 75 percent

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details


26 of 40

27 of 40

28 of 40

Effect (Pharmacological Data)

transmitter uptake; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 - 8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 4-h intervals and 40-h periods between each dosing regimen

Method (Pharmacological Data)

2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5, resp.; 66 h after last injection rats challenged with high dose of title comp. (8 mg/kg); 1 h after last injection <3H>DA uptake via plasmalemmal DAT assessed in striatal synaptosomes

Further Details (Pharmacological Data)

control: saline pretreatment and/or challenge; DAT: dopamine transporter; DA: dopamine

Results

high doses of title comp. decreased plasmalemmal DAT DA uptake by 72 percent; pretreatment with increasing doses of title comp. prior high dose challenge attenuated this effect, DA uptake was decreased only by 58 percent

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter uptake; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 - 8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 4-h intervals; 40-h drug-free intervals between each dosing regimen

Method (Pharmacological Data)

2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5; 66 h after last injection rats challenged with high dose of title comp. (8 mg/kg); 2 h after last injection vesicular <3H>DA uptake was assessed in striatum

Further Details (Pharmacological Data)

control: saline pretreatment and challenge; DA: dopamine

Results

high doses title comp. decreased vesicular DA uptake by 57 percent compared to control; pretreatment with title comp. prior high dose challenge attenuated this effect by 39 percent

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

protein expression; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous


29 of 40

30 of 40

Concentration (Pharmacological Data)

2 - 8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 4 h intervals with 40 h drug-free intervals between each dosing regimen

Method (Pharmacological Data)

2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5; 66 h after last injection rats challenged with high dose of title comp. (8 mg/kg); 2 h after last injection Western blotting performed to determine protein level of VMAT-2

Further Details (Pharmacological Data)

VMAT-2 determined in S3, P3, P2 fractions; control: saline; VMAT-2: vesicular monoamine transporter-2; S3: nonmembrane-associated fraction; P3: membrane-associated fraction; P2: whole synaptosomal fraction pellet

Results

high doses of title comp. decreased VMAT-2 immunoreactivity in S3; pretreatment with title comp. prior high dose challenge significantly attenuated this effect; similar results obtained in P2 and P3

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 - 8 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was injected 4 times a day with 4-h intervals; 40-h drug-free periods between each dosing regimen

Method (Pharmacological Data)

2, 4, and 6 mg/kg of title comp. injected on days 1, 3 and 5, resp.; title comp. and AM conc. measured in striatum with mass spectrometer 66 h after last injection (6 mg/kg) and 0.5, 1 and 2 h after last challenge with high dose of title comp. (8 mg/kg)

Further Details (Pharmacological Data)

control: saline; AM: amphetamine

Results

66 h after pretreatment with title comp. neither title comp. nor amphetamine were detected in striatum; 0.5, 1, 2 h after high-dose challenge of title comp. its conc. elevated similarly in striatum of pretreated and nonpretreated rats

Reference

Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

7.5 mg/kg

Kind of Dosing (Pharmacological Data)

four doses of 7.5 mg/kg at 2-h intervals; dissolved in 0.9 percent saline; doses calculated as free base

Method (Pharmacological Data)

up to 7 days pt synaptic vesicular <3H>DOPA uptake (30 deg C, 3 min) and <3H>DHTB binding (25 deg C, 10 min) measured by liquid scintillation counting, striatal DOPA levels by HPLC-ED and binding of VMAT-2 antibody in S3, P2, P3 by Western blot analysis

Further Details (Pharmacological Data)

pt: posttreatment; DOPA: dopamine; DHTB: dihydrotetrabenazine; S3: vesicular subcellular fraction; P2: whole synaptosomal fraction; P3: plasmalemmal membrane fraction; HPLC-ED: high-performance liquid chromatography with electrochemical detection


31 of 40

32 of 40

33 of 40

Results

title comp. decreased vesicular DOPA uptake and DHTB binding in striatal vesicles and VMAT-2 immunoreactivity in S3 prepared 1 h after last title comp. dose; striatal DOPA levels decreased at 7 days pt

Reference

Sandoval, Veronica; RIddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2003 , vol. 304, # 3 p. 1181 - 1187 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times a day with 2-h interval between doses

Method (Pharmacological Data)

rats pretreated with title comp. or saline on days 1, 3 and 5; 66 h after last pretreatment they were challenged with 4 injections (2-h intervals) of 10 mg/kg title comp.; animals were sacrificed 7 d later; dopamine levels in striatum determined by HPLC

Further Details (Pharmacological Data)

HPLC: high-performance liquid chromatography; HPLC coupled with electrochemical detector was used in the study; control: saline

Results

in saline-pretreated group title comp. induced a significant decrease in striatal dopamine levels; this effect was attenuated in the group pretreated with title comp.

Reference

Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times a day with 2-h interval between doses

Method (Pharmacological Data)

rats pretreated with title comp. or saline on days 1, 3 and 5; 66 h later challenged with 4 injections (2-h intervals) of 10 mg/kg title comp.; after 7 d rats sacrificed; serotonin levels in striatum, hippocampus and frontal cortex determined by HPLC

Further Details (Pharmacological Data)

HPLC: high-performance liquid chromatography; HPLC coupled with electrochemical detector was used in the study; control: saline

Results

in saline-pretreated group title comp. induced a significant decrease of serotonin content in striatum, hippocampus and frontal cortex; this effect was attenuated in the group pretreated with title comp.

Reference

Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing

during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times


34 of 40

35 of 40

(Pharmacological Data)

a day with 2-h interval between doses

Method (Pharmacological Data)

rats were pretreated with title comp. or saline on days 1, 3 and 5; 66 h later challenged with four injections (2-h intervals) of 10 mg/kg title comp.; rectal temperatures were measured

Further Details (Pharmacological Data)

control: saline

Results

title comp. induced an increase in core body temperature both in saline-pretreated and title comp.-pretreated groups on the day of the challenge; a trend for the stronger effect in group pretreated with title comp. was observed

Reference

Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times a day with 2-h interval between doses

Method (Pharmacological Data)

rats were pretreated with title comp. or saline on days 1, 3 and 5; 66 h later challenged with four injections (2-h intervals) 10 mg/kg of title comp.; the levels of title comp. in striatum, hippocampus and frontal cortex measured 7 days later by MS

Further Details (Pharmacological Data)

MS: mass spectrometry; control: saline

Results

the levels of title comp. were similar in three brain regions both in saline-pretreated group (5.7, 4.6 and 6.0 ng/mg tissue for striatum, hippocampus and frontal cortex, resp.) and in group pretreated with title comp. (5.4, 6.5 and 5.8 ng/mg)

Reference

Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.

European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; decrease of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 - 15 mg/kg

Method (Pharmacological Data)

rats admin. with title comp.; decapitated 1 or 24 h later; synaptic vesicles obtained; vesicular pellet prepd.; incubated in presence of <3H>DA at 30 deg C for 3 min in assay buffer; radioactivity counted by LSC; vesicular <3H>DA uptake (VDU) detd.

Further Details (Pharmacological Data)

control: saline; LSC: liquid scintillation counter; DA: dopamine; further studies with SCH23390, quinpirole (QE), cocaine (CE) and core body temperature (CBT) on title comp. effect; LT: little change

Results

title comp. (15 mg/kg) rapidly decreased VDU (25 percent); decreased Vmax with LT in Km of VDU was 607 fmol/μg of protein/min and 187 nmol/l post-dose (15 mg/kg), resp.; effect increased by QE/CE, not prevented by SCH23390, and not affected by CBT; diagrams

Reference

Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details


36 of 40

37 of 40

38 of 40

Effect (Pharmacological Data)

transport; decrease of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

15 mg/kg

Method (Pharmacological Data)

rats admin. with title comp.; decapitated 1 or 24 h later; synaptic vesicles obtained; vesicular pellet prepd.; incubated in presence of <3H>DA at 30 deg C for 3 min in assay buffer; radioactivity counted by LSC; vesicular <3H>DA uptake (VDU) detd.

Further Details (Pharmacological Data)

control: saline; LSC: liquid scintillation counter; DA: dopamine; all rats were maintained in an ambient environment of 24 deg C; further study with SCH23390 (DA D1 receptor antagonist), quinpirole (DA D2 receptor agonist) and cocaine (VDU inhibitor)

Results

decrease in vesicular <3H>DA uptake recovered by 24 h after title comp. admin.; effect of title comp. in decreasing <3H>DA uptake was not prevented by SCH23390; quinpirole and cocaine increased <3H>DA uptake by 1 h after title comp. admin.; diagrams

Reference

Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; decrease of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

15 mg/kg

Method (Pharmacological Data)

rats admin. with title comp.; decapitated 1 h later; synaptic vesicles obtained; vesicular pellet prepd.; incubated in presence of <3H>DA at 30 deg C for 3 min in assay buffer; radioactivity counted by LSC; vesicular <3H>DA uptake (VDU) detd.

Further Details (Pharmacological Data)

control: saline; LSC: liquid scintillation counter; DA: dopamine; rats were maintained in 24 or 6 deg C environment; further study with eticlopride (ET, DA D2 receptor antagonist, rats were placed in 24 or 28.5 deg C environment)

Results

attenuation of hyperthermia by rats exposed to cool environment did not prevent title comp.-induced decrease in VDU; ET attenuating title comp.-induced decrease in VDU was not reversed by restoring hyperthermia in ET + title comp.-treated rats; diagrams

Reference

Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

ddY mice

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 mg/kg

Kind of Dosing (Pharmacological

in physiological saline


Data)

39 of 40

40 of 40

Method (Pharmacological Data)

6-week-old mice; 8 groups of 10 mice: 7 times at three-day intervals treatment; placing in the activity cages for 3 h after each dosing or in the jars; circling measurement for 1 min

Further Details (Pharmacological Data)

food and water ad libitum

Results

ambulatory sensitization at placing in 20-cm diameter activity cages after each dose; inhibition of ambulatory sensitization with circling behaviour concurrently increase at small jars (6-cm diameter)

Reference

Kuribara, Hisashi

Journal of Pharmacy and Pharmacology, 1998 , vol. 50, # 3 p. 303 - 309 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

metabolic

Species or TestSystem (Pharmacological Data)

ICR SPF mice

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 - 10 mg/kg

Exposure Period (Pharmacological Data)

6 - 72 h

Method (Pharmacological Data)

mice 8 weeks old; 34-38 g; metabolic cage; urinary excretion of metabolites; urine samples were collected during 0-6, 6-12, 12-24, 24-48 and 48-72 h after injection

Results

metabolites (total excretion): amphetamine (2.6-9.1 percent), p-hydroxymethamphetamine (0.9-1.5 percent), p-hydroxyamphetamine (0.2-0.6 percent); title comp. excretion: 24.8-30.9 percent (as free base); time-course of excretion

Reference

Sekine; Nagao; Nakahara

Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

metabolic

Species or TestSystem (Pharmacological Data)

Wistar SPF rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 - 10 mg/kg

Exposure Period (Pharmacological Data)

6 - 72 h

Method (Pharmacological Data)

rats 8 weeks old; 190-205 g; metabolic cage; urinary excretion of metabolites; urine samples were collected during 0-6, 6-12, 12-24, 24-48 and 48-72 h after injection

Results

metabolites (total excretion): amphetamine (2.9-3.5 percent), p-hydroxymethamphetamine (18.4-27.2 percent), p-hydroxyamphetamine (4.3-27.2 percent); title comp. excretion: 6.1-9.7 percent (as free base); time-course of excretion

Reference

Sekine; Nagao; Nakahara

Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details

Other Data Use (2) Use Pattern

Reference


sustained delivery of a beneficial agent

Luk, Andrew Sheung-King; Lam, Stan; Zhang, Yuanpeng

Patent: US2005/118206 A1, 2005 ; Title/Abstract Full Text Show Details

Luk, Andrew Sheung-King; Lam, Stan; Zhang, Yuanpeng

Patent: US2005/118206 A1, 2005 ;

beneficial agent

Title/Abstract Full Text Show Details

Chemical Name: S-methamphetamine hydrochloride Reaxys Registry Number: 5125268

CAS Registry Number: 51-57-0 Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697

InChI Key: TWXDDNPPQUTEOV-FVGYRXGTSA-N

41

8 prep out of 31 reactions.

Synthesize | Hide Details Find similar Chemical Names and Synonyms S-methamphetamine hydrochloride, Metamphetamine hydrochloride, Desoxyn, (+)-N-α-dimethylphenethylamine hydrochloride, (S)-metamphetamine hydrochloride, d-desoxyephedrine hydrochloride, metamphetamine*HCl Identification Substance Label (17) Label

Reference

MA

Ohmori, T.; Abekawa, T.; Koyama, T.

Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1230 Title/Abstract Full Text View citing articles Show Details

Tsutsumi, Hiroe; Katagi, Munehiro; Nishikawa, Mayumi; Tsuchihashi, Hitoshi; Kasuya, Fumiyo; Igarashi, Kazuo

Biological and Pharmaceutical Bulletin, 2004 , vol. 27, # 10 p. 1572 - 1575 Title/Abstract Full Text View citing articles Show Details

Czoty, Paul W.; Ramanathan, Chinnasamy R.; Mutschler, Nicole H.; Makriyannis, Alexandros; Bergman, Jack

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 2 p. 720 - 727 Title/Abstract Full Text View citing articles Show Details

Ishiguro, Yoshiki; Morgan, James P.

Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details

Collins, Karen C.; Schlosburg, Joel E.; Bremer, Paul T.; Janda, Kim D.

Journal of Medicinal Chemistry, 2016 , vol. 59, # 8 p. 3878 - 3885 Title/Abstract Full Text View citing articles Show Details

METH

Bronstein; Hong

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details

Albers; Sonsalla

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 275, # 3 p. 1104 - 1114 Title/Abstract Full Text View citing articles Show Details

Itzhak; Gandia; Huang; Ali

The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details

Farfel; Seiden

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details

Rocher; Gardier

Naunyn-Schmiedeberg's Archives of Pharmacology, 2001 , vol. 363, # 4 p. 422 - 428 Title/Abstract Full Text View citing articles Show Details

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.

European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details

Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.

European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details

Identification Physical Data (35) Spectra (11) Bioactivity (173) Other Data (5)

127


Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details

Peltier; Li; Lytle; Taylor; Emmett-Oglesby

Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka

Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details

Jiang, Wenda; Li, Ji; Zhang, Zhuang; Wang, Hongxin; Wang, Zhejian

European Journal of Pharmacology, 2014 , vol. 745, p. 243 - 248 Title/Abstract Full Text View citing articles Show Details

Sanchez, Ana B.; Varano, Giuseppe P.; De Rozieres, Cyrus M.; Maung, Ricky; Catalan, Irene C.; Dowling, Cari C.; Sejbuk, Natalia E.; Hoefer, Melanie M.; Kaul, Marcus

Antimicrobial Agents and Chemotherapy, 2016 , vol. 60, # 1 p. 168 - 179 Title/Abstract Full Text View citing articles Show Details

Mori, Tomohisa; Uzawa, Naoki; Iwase, Yoshiyuki; Masukawa, Daiki; Rahmadi, Mahardian; Hirayama, Shigeto; Hokazono, Mayuna; Higashiyama, Kimio; Shioda, Seiji; Suzuki, Tsutomu

Psychopharmacology, 2016 , vol. 233, # 12 p. 2343 - 2353 Title/Abstract Full Text View citing articles Show Details

Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Rice, Kenner C.; Gannon, Brenda M.; Fantegrossi, William E.; Gonzalez, Carmen; Paule, Merle G.; Ali, Syed F.

Neuroscience Letters, 2016 , vol. 629, p. 125 - 130 Title/Abstract Full Text View citing articles Show Details

4

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

2

Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.

Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details

S-(+)-METH; + METH

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

met; M

Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details

Methamphet

Li, Su-Min; Campbell, Bettye L.; Katz, Jonathan L.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 317, # 3 p. 1088 - 1096 Title/Abstract Full Text View citing articles Show Details

methamph

Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details

MAP

Shibata; Ono; Fukuhara; Watanabe

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 688 - 694 Title/Abstract Full Text View citing articles Show Details

Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji

Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details

Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji

Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details

Merck12 6015

Kuribara, Hisashi

European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 6 Title/Abstract Full Text View citing articles Show Details

Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details


Thomas, David M.; Walker, Paul D.; Benjamins, Joyce A.; Geddes, Timothy J.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 1 p. 1 - 7 Title/Abstract Full Text View citing articles Show Details

Merck 12: 6015

Morrow; Corrigan; Waldren

Planta Medica, 2001 , vol. 67, # 9 p. 843 - 846 Title/Abstract Full Text View citing articles Show Details

Meth

Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa

Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details

Merck Index 6015

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

METH-HCl

Cass, Wayne A.

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 280, # 1 p. 105 - 113 Title/Abstract Full Text View citing articles Show Details

MI 12 6015

Toyoshi, Tohru; Ukai, Makoto; Kameyama, Tsutomu

Biological and Pharmaceutical Bulletin, 1996 , vol. 19, # 3 p. 369 - 374 Title/Abstract Full Text View citing articles Show Details

Negwer 2038

Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton

Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details

MeAmp (Merck 6015)

Melega; Williams; Schmitz; DiStefano; Cho

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 1 p. 90 - 96 Title/Abstract Full Text View citing articles Show Details

Patent-Specific Data (1) Location in Patent

Reference

Claim

Halikas; James A.

Patent: US5102913 A1, 1992 ; Title/Abstract Full Text Show Details

The Regents of the University of Minnesota

Patent: US5028611 A1, 1991 ; Title/Abstract Full Text Show Details

Physical Data Melting Point (14) Melting Point

Solvent (Melting Point)

Location

Reference

170 - 172 °C

supporting information

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

172.4 178.4 °C

MALLINCKRODT INC.

Patent: WO2006/73547 A1, 2006 ;

170 - 175 °C

Title/Abstract Full Text Show Details

MALLINCKRODT INC.

Patent: WO2006/73547 A1, 2006 ; Title/Abstract Full Text Show Details

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

166 - 167 °C

ethanol diethyl ether

Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall

Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details

168 - 171 °C

Fowler

The Journal of organic chemistry, 1977 , vol. 42, # 15 p. 2637 - 2637


Title/Abstract Full Text View citing articles Show Details

171 - 175 °C

SINSHEIMER; SMITH

Journal of pharmaceutical sciences, 1963 , vol. 52, p. 1080 - 1085 Title/Abstract Full Text View citing articles Show Details

171 - 172 °C

ethanol

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

171 - 172 °C

acetone

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

174 - 175 °C

Adamson et al.

Journal of the Chemical Society, 1949 , p. Spl. 144, 152 Full Text Show Details

172 °C

ethanol

Rosenmund; Karg

Chemische Berichte, 1942 , vol. 75, p. 1850,1856 Full Text Show Details

Emde

Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details

Temmler

Patent: DE767186 ; Full Text Show Details

172 °C

CHCl3 ethyl acetate

Rosenmund; Karg

Chemische Berichte, 1942 , vol. 75, p. 1850,1856 Full Text Show Details

Temmler

Patent: DE767186 ; Full Text Show Details

173 °C

Hauschild

Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie, 1938 , vol. 191, p. 465 Full Text View citing articles Show Details

171 - 172 °C

ethanol diethyl ether

Leithe

Chemische Berichte, 1932 , vol. 65, p. 660,665 Full Text Show Details

172 °C

acetone

Schmidt

Archiv der Pharmazie (Weinheim, Germany), 1914 , vol. 252, p. 121 Archiv der Pharmazie (Weinheim, Germany), 1915 , vol. 253, p. 52 Full Text Show Details

Crystal Property Description (3) Colour & Other Properties

Location

Reference

colourless

supporting information

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

white

MALLINCKRODT INC.

Patent: WO2006/73547 A1, 2006 ; Title/Abstract Full Text Show Details

Staebchen

Emde

Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details

Optical Rotatory Dispersion (1) Solvent (Optical Rotatory Dispersion)

Reference

H2O

Emde

Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details


Optical Rotatory Power (16) Type (Optical Rotatory Power)

Concentration (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

Temperature (Optical Rotatory Power)

[alpha]

4 g/100ml

water

17.56 deg

589 nm

[alpha]

1.2 g/100ml

H2O

19.3 deg

[alpha]

16.1 g/100ml

H2O

[alpha]

c=2

[alpha]

Location

Reference

25 °C

supporting information

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

589 nm

23 °C

Buckley, Thomas F.; Rapoport, Henry

Journal of the American Chemical Society, 1981 , vol. 103, # 20 p. 6157 - 6163 Title/Abstract Full Text View citing articles Show Details

-12.6 deg

589 nm

25 °C

Fowler

The Journal of organic chemistry, 1977 , vol. 42, # 15 p. 2637 - 2637 Title/Abstract Full Text View citing articles Show Details

ethanol

-7.9 deg

589 nm

20 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

c=4

ethanol

-6 deg

589 nm

28 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

c=2

H2O

16.8 deg

589 nm

20 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

c=4

H2O

16 deg

589 nm

28 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

c=4

H2O

17.5 deg

589 nm

18 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

c=10

H2O

16 deg

589 nm

21.5 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

c=0.2

acetone

-13.9 deg

589 nm

22 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

c=0.9

methanol

1.62 deg

589 nm

23 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

c=1.8

methanol

0.39 deg

589 nm

24 °C

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

[alpha]

H2O

21.6 deg

589 nm

Freudenberg; Nikolai

Justus Liebigs Annalen der Chemie, 1934 , vol. 510, p. 223,227 Full Text Show Details

[alpha]

c=7

H2O

15.7 deg

589 nm

15 °C

Leithe

Chemische Berichte, 1932 , vol. 65, p. 660,665 Full Text Show Details


[alpha]

c=2.8

H2O

17.9 deg

589 nm

20 °C

Emde

Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details

[alpha]

c=1.1

H2O

17.8 deg

589 nm

17.5 °C

Schmidt

Archiv der Pharmazie (Weinheim, Germany), 1914 , vol. 252, p. 121 Archiv der Pharmazie (Weinheim, Germany), 1915 , vol. 253, p. 52 Full Text Show Details

Optics (1) Description (Optics)

Reference

Crystal refractive indices

Keenan

Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details

Spectra NMR Spectroscopy (5) Description (NMR Spectroscopy)

Nucleus (NMR Spectroscopy)

Solvents (NMR Spectroscopy)

Temperature (NMR Spectroscopy)

Frequency (NMR Spectroscopy)

Chemical shifts Spectrum

1H

water-d2

Chemical shifts Spectrum

13C

water-d2

Chemical shifts Spectrum

1H

Chemical shifts Spectrum

Chemical shifts

Location

Reference

200 MHz

supporting information

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

50 MHz

supporting information

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

chloroform-d1

400 MHz

supporting information

Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.

Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details

13C

chloroform-d1

100.5 MHz

supporting information

Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.

Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details

1H

24.84 °C

Matsumoto, Teruki; Urano, Yasuteru; Makino, Yukiko; Kikura-Hanajiri, Ruri; Kawahara, Nobuo; Goda, Yukihiro; Nagano, Tetsuo

Analytical Chemistry, 2008 , vol. 80, # 4 p. 1176 - 1181 Title/Abstract Full Text View citing articles Show Details

IR Spectroscopy (2) Description (IR Spectroscopy)

Solvent (IR Spectroscopy)

Comment (IR Spectroscopy)

Reference

Bands

Thompson,W.E. et al.

Journal of Pharmaceutical Sciences, 1965 , vol. 54, p. 1819 - 1821 Full Text View citing articles Show Details

Spectrum

KBr

4000 - 650 cm**(-1)

Chatten; Levi

Analytical Chemistry, 1959 , vol. 31, p. 1581,1582,1585 Full Text View citing articles Show Details

Mass Spectrometry (4) Description (Mass Spectrometry)

Location

Reference

time-of-flight mass spectra

Muramoto, Shin; Forbes, Thomas P.; Van Asten, Arian C.; Gillen, Greg


(TOFMS) spectrum

Analytical Chemistry, 2015 , vol. 87, # 10 p. 5444 - 5450 Title/Abstract Full Text View citing articles Show Details

high resolution mass spectrometry (HRMS) electrospray ionisation (ESI) spectrum

supporting information

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

liquid chromatography mass spectrometry (LCMS) spectrum

Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.

Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details

DESI (desorption electrospray ionization) IT (ion trap) LCMS (Liquid chromatography mass spectrometry) Spectrum

Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao

International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (172) 1 of 172

Comment (Pharmacological Data)

Bioactivities present

Reference

E. R. Squibb and Sons, Inc.

Patent: US4602092 A1, 1986 ; Title/Abstract Full Text Show Details

Schmitt,J. et al.

Chimica Therapeutica, 1967 , vol. 2, p. 260 - 267 Full Text View citing articles Show Details

Halikas; James A.

Patent: US5102913 A1, 1992 ; Title/Abstract Full Text Show Details

Fowler

The Journal of organic chemistry, 1977 , vol. 42, # 15 p. 2637 - 2637 Title/Abstract Full Text View citing articles Show Details

SINSHEIMER; SMITH

Journal of pharmaceutical sciences, 1963 , vol. 52, p. 1080 - 1085 Title/Abstract Full Text View citing articles Show Details

Thompson,W.E. et al.

Journal of Pharmaceutical Sciences, 1965 , vol. 54, p. 1819 - 1821 Full Text View citing articles Show Details

HISAMITSU PHARMACEUTICAL CO., INC.

Patent: EP1541177 A1, 2005 ; Title/Abstract Full Text Show Details

CORTEX PHARMACEUTICALS, INC.; The Regents of the University of California

Patent: EP1026950 B1, 2006 ; Title/Abstract Full Text Show Details

MALLINCKRODT INC.

Patent: WO2006/73547 A1, 2006 ; Title/Abstract Full Text Show Details

Adamson et al.

Journal of the Chemical Society, 1949 , p. Spl. 144, 152 Full Text Show Details

Keenan

Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details

Freudenberg; Nikolai

Justus Liebigs Annalen der Chemie, 1934 , vol. 510, p. 223,227 Full Text Show Details

Rosenmund; Karg

Chemische Berichte, 1942 , vol. 75, p. 1850,1856 Full Text Show Details

Schmidt

Archiv der Pharmazie (Weinheim, Germany), 1914 , vol. 252, p. 121 Archiv der Pharmazie (Weinheim, Germany), 1915 , vol. 253, p. 52 Full Text Show Details

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Emde


Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details

Leithe

Chemische Berichte, 1932 , vol. 65, p. 660,665 Full Text Show Details

Temmler

Patent: DE767186 ; Full Text Show Details

Hauschild

Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie, 1938 , vol. 191, p. 465 Full Text View citing articles Show Details

Chatten; Levi

Analytical Chemistry, 1959 , vol. 31, p. 1581,1582,1585 Full Text View citing articles Show Details

2 of 172

3 of 172

Comment (Pharmacological Data)

Bioactivities present

Reference

Chiang

Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details

Buckley, Thomas F.; Rapoport, Henry

Journal of the American Chemical Society, 1981 , vol. 103, # 20 p. 6157 - 6163 Title/Abstract Full Text View citing articles Show Details

Glennon; Ablordeppey; Ismaiel; El-Ashmawy; Fischer; Howie

Journal of Medicinal Chemistry, 1994 , vol. 37, # 8 p. 1214 - 1219 Title/Abstract Full Text View citing articles Show Details

Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall

Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details

Fukuchi, Isao; Asahi, Toshio; Kawashima, Kazutaka; Kawashima, Yumiko; Yamamura, Michio; Matsuoka, Yuzo; Kinoshita, Kiyoshi

Arzneimittel-Forschung/Drug Research, 1998 , vol. 48, # 4 p. 353 - 359 Title/Abstract Full Text View citing articles Show Details

Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton

Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details

Toyoshi, Tohru; Ukai, Makoto; Kameyama, Tsutomu

Biological and Pharmaceutical Bulletin, 1996 , vol. 19, # 3 p. 369 - 374 Title/Abstract Full Text View citing articles Show Details

Ohmori, T.; Abekawa, T.; Koyama, T.

Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1230 Title/Abstract Full Text View citing articles Show Details

Bronstein; Hong

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

Shibata; Ono; Fukuhara; Watanabe

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 688 - 694 Title/Abstract Full Text View citing articles Show Details

Melega; Williams; Schmitz; DiStefano; Cho

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 1 p. 90 - 96 Title/Abstract Full Text View citing articles Show Details

Albers; Sonsalla

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 275, # 3 p. 1104 - 1114 Title/Abstract Full Text View citing articles Show Details

Knoll; Miklya; Marko; Kelemen

Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details

Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji

Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details

Itzhak; Gandia; Huang; Ali

The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details

Farfel; Seiden

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details

Wu, Dafang; Victoria Otton, S.; Inaba, Tadanobu; Kalow, Werner; Sellers, Edward M.

Biochemical Pharmacology, 1997 , vol. 53, # 11 p. 1605 - 1612 Title/Abstract Full Text View citing articles Show Details

Kuribara, Hisashi

European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 6 Title/Abstract Full Text View citing articles Show Details

Cass, Wayne A.

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 280, # 1 p. 105 - 113 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

Bioactivities present


4 of 172

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Rocher; Gardier

Naunyn-Schmiedeberg's Archives of Pharmacology, 2001 , vol. 363, # 4 p. 422 - 428 Title/Abstract Full Text View citing articles Show Details

Tsutsumi, Hiroe; Katagi, Munehiro; Nishikawa, Mayumi; Tsuchihashi, Hitoshi; Kasuya, Fumiyo; Igarashi, Kazuo

Biological and Pharmaceutical Bulletin, 2004 , vol. 27, # 10 p. 1572 - 1575 Title/Abstract Full Text View citing articles Show Details

Morrow; Corrigan; Waldren

Planta Medica, 2001 , vol. 67, # 9 p. 843 - 846 Title/Abstract Full Text View citing articles Show Details

Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details

Sheridan, Robert D.; Turner, Simon R.; Cooper, Graham J.; Tattersall, John E.H.

European Journal of Pharmacology, 2005 , vol. 511, # 2-3 p. 99 - 107 Title/Abstract Full Text View citing articles Show Details

Czoty, Paul W.; Ramanathan, Chinnasamy R.; Mutschler, Nicole H.; Makriyannis, Alexandros; Bergman, Jack

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 2 p. 720 - 727 Title/Abstract Full Text View citing articles Show Details

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.

European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details

Suzuki, Tsutomu; Fukuoka, Yoshie; Mori, Tomohisa; Miyatake, Mayumi; Narita, Minoru

European Journal of Pharmacology, 2004 , vol. 498, # 1-3 p. 157 - 161 Title/Abstract Full Text View citing articles Show Details

Thomas, David M.; Walker, Paul D.; Benjamins, Joyce A.; Geddes, Timothy J.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 1 p. 1 - 7 Title/Abstract Full Text View citing articles Show Details

Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.

European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details

Ishiguro, Yoshiki; Morgan, James P.

Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details

Suzuki, Tsutomu; Kishimoto, Yayoi; Misawa, Miwa

Life Sciences, 1996 , vol. 59, # 19 p. 1667 - 1674 Title/Abstract Full Text View citing articles Show Details

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Li, Su-Min; Campbell, Bettye L.; Katz, Jonathan L.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 317, # 3 p. 1088 - 1096 Title/Abstract Full Text View citing articles Show Details

Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji

Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details

Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa

Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

Bioactivities present

Reference

Peltier; Li; Lytle; Taylor; Emmett-Oglesby

Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details

Munzar, Patrik; Kutkat, Scott W; Miller, Cori R; Goldberg, Steven R

European Journal of Pharmacology, 2000 , vol. 408, # 2 p. 169 - 174 Title/Abstract Full Text View citing articles Show Details

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Schindler, Charles W.; Bross, Joshua G.; Thorndike, Eric B.

European Journal of Pharmacology, 2002 , vol. 442, # 3 p. 231 - 235 Title/Abstract Full Text View citing articles Show Details

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636


Title/Abstract Full Text View citing articles Show Details

Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details

Suzuki, Tsutomu; Shindo, Keiko; Miyatake, Mayumi; Kurokawa, Kazuhiro; Higashiyama, Kimio; Suzuki, Masami; Narita, Minoru

European Journal of Pharmacology, 2007 , vol. 574, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details

Biosite Diagnostics Incorporated

Patent: US5470997 A1, 1995 ; Title/Abstract Full Text Show Details

Syntex (U.S.A.) Inc.

Patent: US5135863 A1, 1992 ; Title/Abstract Full Text Show Details

The Regents of the University of Minnesota

Patent: US5028611 A1, 1991 ; Title/Abstract Full Text Show Details

Matsumoto, Teruki; Urano, Yasuteru; Makino, Yukiko; Kikura-Hanajiri, Ruri; Kawahara, Nobuo; Goda, Yukihiro; Nagano, Tetsuo

Analytical Chemistry, 2008 , vol. 80, # 4 p. 1176 - 1181 Title/Abstract Full Text View citing articles Show Details

Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka

Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details

David, Gabrielle E.; Hibbert, D. Brynn; Frew, Russell D.; Hayman, Alan R.

Australian Journal of Chemistry, 2010 , vol. 63, # 1 p. 22 - 29 Title/Abstract Full Text View citing articles Show Details

Emcure Pharmaceuticals Limited

Patent: US2011/46416 A1, 2011 ; Title/Abstract Full Text Show Details

Moreno, Amira Y.; Mayorov, Alexander V.; Janda, Kim D.

Journal of the American Chemical Society, 2011 , vol. 133, # 17 p. 6587 - 6595 Title/Abstract Full Text View citing articles Show Details

5 of 172

Comment (Pharmacological Data)

Bioactivities present

Reference

Leis, Hans J.; Windischhofer, Werner

Rapid Communications in Mass Spectrometry, 2010 , vol. 24, # 22 p. 3320 - 3324 Title/Abstract Full Text View citing articles Show Details

Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao

International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details

Wood, Matthew R.; Lalancette, Roger A.

Acta Crystallographica Section C: Crystal Structure Communications, 2013 , vol. 69, # 4 p. 388 - 393 Title/Abstract Full Text View citing articles Show Details

Guharoy, Roy; Medicis, Joe; Choi, Se; Stalder, Bruce; Kusiowski, Kim; Allen, Andrea

Veterinary and Human Toxicology, 1999 , vol. 41, # 1 p. 28 - 30 Title/Abstract Full Text View citing articles Show Details

Itzhak, Yossef; Gandia, Carlos; Huang, Paul L.; Ali, Syed F.

Journal of Pharmacology and Experimental Therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details

Kuribara, Hisashi

European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 5 Title/Abstract Full Text View citing articles Show Details

Knoll; Miklya; Marko; Kelemen

Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text Show Details

Ohmori; Abekawa; Koyama

Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1229 Title/Abstract Full Text Show Details

Witkin; Ricaurte; Katz

Journal of Pharmacology and Experimental Therapeutics, 1990 , vol. 253, # 2 p. 466 - 474 Title/Abstract Full Text View citing articles Show Details

Chahl

British journal of pharmacology, 1972 , vol. 45, # 3 p. 510 - 518


Title/Abstract Full Text Show Details

Campbell; Patil; LaPidus; Campbell; Tye

Title/Abstract Full Text Show Details

LaPidus; Patil; LaPidus; Tye

Title/Abstract Full Text Show Details

Type: Review, Lab: EFF_071212, Owner: EFFECT, Number: 000, Revision: 07.12.2012 00:00:00 2012 Full Text Show Details

Title/Abstract Full Text Show Details

CHANCE

The Journal of pharmacology and experimental therapeutics, 1946 , vol. 87, p. 214 - 219 Title/Abstract Full Text View citing articles Show Details

SINNIGER

Schweizerische medizinische Wochenschrift, 1954 , vol. 84, # 12 p. 351 - 355 Title/Abstract Full Text View citing articles Show Details

ALLES; FAIRCHILD; JENSEN

Proceedings of the Western Pharmacology Society, 1961 , vol. 4, p. 23 - 26 Title/Abstract Full Text View citing articles Show Details

Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.

Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details

Švorc, Ľubomír; Vojs, Marian; Michniak, Pavol; Marton, Marián; Rievaj, Miroslav; Bustin, Dušan

Journal of Electroanalytical Chemistry, 2014 , vol. 717-718, p. 34 - 40 Title/Abstract Full Text View citing articles Show Details

Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.

Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details

6 of 172

Comment (Pharmacological Data)

Bioactivities present

Reference

Kousik, Sharanya M.; Napier, T. Celeste; Ross, Ryan D.; Sumner, D. Rick; Carvey, Paul M.

Journal of Pharmacology and Experimental Therapeutics, 2014 , vol. 351, # 2 p. 432 - 439 Title/Abstract Full Text View citing articles Show Details

Mata, Mariana M.; Napier, T. Celeste; Graves, Steven M.; Mahmood, Fareeha; Raeisi, Shohreh; Baum, Linda L.

European Journal of Pharmacology, 2015 , vol. 752, p. 26 - 33 Title/Abstract Full Text View citing articles Show Details

Jiang, Wenda; Li, Ji; Zhang, Zhuang; Wang, Hongxin; Wang, Zhejian

European Journal of Pharmacology, 2014 , vol. 745, p. 243 - 248 Title/Abstract Full Text View citing articles Show Details

Muramoto, Shin; Forbes, Thomas P.; Van Asten, Arian C.; Gillen, Greg

Analytical Chemistry, 2015 , vol. 87, # 10 p. 5444 - 5450 Title/Abstract Full Text View citing articles Show Details

Darvish, Mina; Qomi, Mahnaz; Akhgari, Maryam; Raoufi, Parviz

Biosciences Biotechnology Research Asia, 2015 , vol. 12, # 1 p. 587 - 597 Title/Abstract Full Text View citing articles Show Details

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

Sanchez, Ana B.; Varano, Giuseppe P.; De Rozieres, Cyrus M.; Maung, Ricky; Catalan, Irene C.; Dowling, Cari C.; Sejbuk, Natalia E.; Hoefer, Melanie M.; Kaul, Marcus

Antimicrobial Agents and Chemotherapy, 2016 , vol. 60, # 1 p. 168 - 179 Title/Abstract Full Text View citing articles Show Details

Rodríguez, José E.; Campbell, Kendall M.

Primary Care - Clinics in Office Practice, 2016 , vol. 43, # 1 p. 61 - 67 Title/Abstract Full Text View citing articles Show Details

Tao, Yijie; Zhang, Kai; Zhang, Zhaoyang; Cheng, Haifeng; Jiao, Chunlin; Zhao, Yulei

Chemical Engineering Journal, 2016 , vol. 293, p. 34 - 43 Title/Abstract Full Text View citing articles Show Details

Kitanaka, Junichi; Kitanaka, Nobue; Scott Hall; Uhl, George R.; Takemura, Motohiko

Drug Target Insights, 2016 , vol. 10, p. 1 - 7 Title/Abstract Full Text View citing articles Show Details

Collins, Karen C.; Schlosburg, Joel E.; Bremer, Paul T.; Janda, Kim D.

Journal of Medicinal Chemistry, 2016 , vol. 59, # 8 p. 3878 - 3885 Title/Abstract Full Text View citing articles Show Details

Mori, Tomohisa; Uzawa, Naoki; Iwase, Yoshiyuki; Masukawa, Daiki; Rahmadi, Mahardian; Hirayama, Shigeto; Hokazono, Mayuna; Higashiyama, Kimio; Shioda, Seiji; Suzuki, Tsutomu

Psychopharmacology, 2016 , vol. 233, # 12 p. 2343 - 2353 Title/Abstract Full Text View citing articles Show Details

Asadullin, Azat R.; Yuldashev, Vladimir L.; Galeeva, Elena Kh.; Achmetova, Elvina A.; Nikolaev, Ivan V.

International Journal of Environmental and Science Education, 2016 , vol. 11, # 8 p. 1913 - 1922 Title/Abstract Full Text View citing articles Show Details

Nožina, Miroslav; Kraus, Filip

Europe - Asia Studies, 2016 , vol. 68, # 3 p. 508 - 528 Title/Abstract Full Text View citing articles Show Details

De Jesús-Cortés, Héctor; Miller, Adam D.; Britt, Jeremiah K.; DeMarco, Anthony J.; De Jesús-Cortés, Mayralis; Stuebing, Emily; Naidoo, Jacinth; Vázquez-Rosa, Edwin; Morlock, Lorraine; Williams, Noelle S.; Ready, Joseph M.; Narayanan, Nandakumar S.; Pieper, Andrew A.

Parkinson's Disease, 2015 , vol. 1, art. no. 15010 Title/Abstract Full Text View citing articles Show Details

Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Rice, Kenner C.; Gannon, Brenda M.; Fantegrossi, William E.; Gonzalez, Carmen; Paule, Merle G.; Ali, Syed F.


Neuroscience Letters, 2016 , vol. 629, p. 125 - 130 Title/Abstract Full Text View citing articles Show Details

Tao, Yijie; Zhang, Kai; Zhang, Chaoyang; Cheng, Haifeng; Jiao, Chunlin; Zhao, Yulei

Materials Science in Semiconductor Processing, 2016 , vol. 56, p. 66 - 75 Title/Abstract Full Text View citing articles Show Details

Khorassani, Farah E.; Misher, Anne; Garris, Shauna

American Journal of Health-System Pharmacy, 2015 , vol. 72, # 9 p. 697 - 706 Title/Abstract Full Text View citing articles Show Details

Ramakrishna; Nagabhushana; Prasad, B. Daruka; Vidya; Sharma; Anantharaju; Prashantha; Choudhary, Nityanand

Journal of Luminescence, 2017 , vol. 181, p. 153 - 163 Title/Abstract Full Text Show Details

Donegani, Enrico; Paal, Peter; Küpper, Thomas; Hefti, Urs; Basnyat, Buddha; Carceller, Anna; Bouzat, Pierre; Van Der Spek, Rianne; Hillebrandt, David

High Altitude Medicine and Biology, 2016 , vol. 17, # 3 p. 157 - 184 Title/Abstract Full Text Show Details

7 of 172

Comment (Pharmacological Data)

Bioactivities present

Reference

Asadullin, Azat R.; Galeeva, Elena Kh.; Achmetova, Elvina A.; Nikolaev, Ivan V.

International Journal of Environmental and Science Education, 2016 , vol. 11, # 14 art. no. IJESE..001, p. 6697 - 6703 Title/Abstract Full Text Show Details

Goulding, David R.; White, Sally S.; McBride, Sandra J.; Fenton, Suzanne E.; Harry, G. Jean

NeuroToxicology, 2017 , vol. 58, p. 110 - 119 Title/Abstract Full Text Show Details

Hearne, Evelyn; Grund, Jean-Paul Cornelius; Van Hout, Marie Claire; McVeigh, Jim

Harm Reduction Journal, 2016 , vol. 13, # 1 art. no. 14 Title/Abstract Full Text Show Details

Weiß, Jennifer A.; Kadkhodaei, Kian; Schmid, Martin G.

Science and Justice, 2017 , vol. 57, # 1 p. 6 - 12 Title/Abstract Full Text Show Details

Florez, Diego Hernando Ângulo; dos Santos Moreira, Ana Maria; da Silva, Pedro Rafael; Brandão, Ricardo; Borges, Marcella Matos Cordeiro; de Santana, Fernando José Malagueño; Borges, Keyller Bastos

Drug and Alcohol Dependence, 2017 , vol. 173, p. 59 - 68 Title/Abstract Full Text Show Details

Brown, P.Leon; Shepard, Paul D.

Journal of Neurophysiology, 2016 , vol. 116, # 3 p. 1161 - 1174 Title/Abstract Full Text Show Details

CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.

Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details

8 of 172

9 of 172

10 of 172

11 of 172

12 of 172

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Sanchez, Ana B.; Varano, Giuseppe P.; De Rozieres, Cyrus M.; Maung, Ricky; Catalan, Irene C.; Dowling, Cari C.; Sejbuk, Natalia E.; Hoefer, Melanie M.; Kaul, Marcus

Antimicrobial Agents and Chemotherapy, 2016 , vol. 60, # 1 p. 168 - 179 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Mori, Tomohisa; Uzawa, Naoki; Iwase, Yoshiyuki; Masukawa, Daiki; Rahmadi, Mahardian; Hirayama, Shigeto; Hokazono, Mayuna; Higashiyama, Kimio; Shioda, Seiji; Suzuki, Tsutomu

Psychopharmacology, 2016 , vol. 233, # 12 p. 2343 - 2353 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Rice, Kenner C.; Gannon, Brenda M.; Fantegrossi, William E.; Gonzalez, Carmen; Paule, Merle G.; Ali, Syed F.

Neuroscience Letters, 2016 , vol. 629, p. 125 - 130 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Mata, Mariana M.; Napier, T. Celeste; Graves, Steven M.; Mahmood, Fareeha; Raeisi, Shohreh; Baum, Linda L.

European Journal of Pharmacology, 2015 , vol. 752, p. 26 - 33 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

physiological behaviour discussed


13 of 172

14 of 172

15 of 172

16 of 172

Reference

Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.

Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Kousik, Sharanya M.; Napier, T. Celeste; Ross, Ryan D.; Sumner, D. Rick; Carvey, Paul M.

Journal of Pharmacology and Experimental Therapeutics, 2014 , vol. 351, # 2 p. 432 - 439 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Jiang, Wenda; Li, Ji; Zhang, Zhuang; Wang, Hongxin; Wang, Zhejian

European Journal of Pharmacology, 2014 , vol. 745, p. 243 - 248 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

cytokine release; inhibition of

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

4 mg/kg

Kind of Dosing (Pharmacological Data)

dose administered 4 times; vehicle: saline

Method (Pharmacological Data)

mice treated with title comp.; 18 h later cytokine levels in plasma measured by mouse cytokine array kit

Results

title comp. reduced plasma interferon-γ level to 55percent of control and plasma interleukin-10 level to 50percent of control

Reference

Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka

Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

cytokine release; induction of

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

4 mg/kg

Kind of Dosing (Pharmacological Data)

dose administered 4 times; vehicle: saline

Method (Pharmacological Data)

mice treated with title comp.; 18 h later cytokine levels in plasma measured by mouse cytokine array kit

Further Details (Pharmacological Data)

MCP-1: monocyte chemotactic protein-1; TNF-α: tumor necrosis factor-α

Results

title comp. increased plasma interleukin-4, MCP-1, and TNF-α levels to 190percent, 130percent, and 120percent of control, resp.

Reference

Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka


Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details

17 of 172

18 of 172

19 of 172

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

3 mg/kg

Kind of Dosing (Pharmacological Data)

dose administered 3 or 4 times with 2-h intervals; vehicle: saline

Method (Pharmacological Data)

mice treated with title comp.; rectal temperature recorded 30 min before or after each title comp. injection

Further Details (Pharmacological Data)

control: vehicle; further investigations by administration of 20000 IU interferon-γ i.p. or 2000 IU interferon-γ i.c.v. 30 min prior to 1st and 3rd title comp. injection

Results

title comp. induced hyperthermia; effect was attenuated by peripheral, but not central interferon-γ pretreatment; fig.

Reference

Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka

Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

3 mg/kg

Kind of Dosing (Pharmacological Data)

dose administered 3 or 4 times with 2-h intervals; vehicle: saline

Method (Pharmacological Data)

mice treated with title comp.; 3 days after the last injection integrity of dopaminergic terminals in striatum assessed by dopamine transporter immunostaining

Further Details (Pharmacological Data)

control: vehicle; further investigations by administration of 20000 IU interferon-γ i.p. or 2000 IU interferon-γ i.c.v. 30 min prior to 1st and 3rd title comp. injection or 1 h after the last title comp. injection

Results

title comp. induced degeneration of striatal dopaminergic nerve terminals; effect was attenuated by both peripheral and central interferon-γ pretreatment and by central interferon-γ post-treatment, but not by periferal post-treatment; fig.

Reference

Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka

Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male


20 of 172

Show next 20

21 of 172

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

3 mg/kg

Kind of Dosing (Pharmacological Data)

dose administered 3 or 4 times with 2-h intervals; vehicle: saline

Method (Pharmacological Data)

mice treated with title comp.; 3 days after the last injection activated microglial cells and astrocytes were detected in striatum by CD11b and glial fibrillary acidic protein (GFAP) immunostaining, resp.

Further Details (Pharmacological Data)

control: vehicle; further investigations by administration of 20000 IU interferon-γ i.p. 30 min prior to 1st and 3rd title comp. injection

Results

title comp. induced accumulation of microglial cells and activated astrocytes; effect was not changed by peripheral interferon-γ pretreatment; fig.

Reference

Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka

Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Macaca mulatta, rhesus monkey

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.056 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d

Method (Pharmacological Data)

double-lumen catheter implanted into monkeys who trained to get reinforcer (0.032 mg/kg/injection of cocaine) by responding (16 responses) to central key resulted in cocaine delivery at 1-h sessions (4 sessions/d) performed during title comp. infusion

Further Details (Pharmacological Data)

control: saline (78.6 injections of cocaine/day during availability of 0.032 mg/kg/injection of cocaine; percent of cocaine-maintained responding; data obtained during last 3 days of treatment

Results

title comp. (at 0.056 mg/kg/h) sign. decreased 0.032 mg/kg/injection of cocaine self-administration to ca. 5percent of control (figure)

Reference

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details

Hide facts Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Macaca mulatta, rhesus monkey

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.056 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d

Method (Pharmacological

double-lumen catheter implanted into monkeys who trained to get reinforcer (25 food pellets/session) by responding (16 responses) to central key resulted in food delivery at 1-h sessions (4 sessions/day) performed during title comp. infusion


Data)

22 of 172

23 of 172

24 of 172

Further Details (Pharmacological Data)

control: saline (97.2 food pellets/d); percent of food-maintained responding; data obtained during last 3 days of treatment

Comment (Pharmacological Data)

No effect

Reference

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Macaca mulatta, rhesus monkey

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.056 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d

Method (Pharmacological Data)

double-lumen catheter implanted into monkeys who trained to get reinforcer (25 food pellets/session) by responding (16 responses) to central key; this resulted in food delivery at 1-h sessions (4 sessions/day) performed during title comp. infusion

Further Details (Pharmacological Data)

control: saline (95.3 food pellets/d); percent of food-maintained responding; data obtained during all 7 d of treatment to determine time course of title comp. effect

Results

title comp. at 0.056 mg/kg/h had slight effects on food-maintained responding during all 7 days of treatment (figure)

Reference

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Macaca mulatta, rhesus monkey

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.056 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d

Method (Pharmacological Data)

double-lumen catheter implanted into monkeys trained to get reinforcer (0.01 mg/kg/injection of cocaine) by responding (16 responses) to central key; this resulted in cocaine delivery at 1-h sessions (4 sessions/d) performed during title comp. infusion

Further Details (Pharmacological Data)

control: saline (79.2 injections of cocaine/day during availability of 0.01 mg/kg/injection of cocaine); percent of cocaine-maintained responding; data obtained during all 7 d of treatment to determine time course of title comp. effect

Results

during treatment with title comp. (0.056 mg/kg/h) maximal decreases in cocaine self-administration were achieved within 2 to 5 days, and decreases in cocaine self-administration generally sustained for duration of treatment (figure)

Reference

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details

Effect

behavioural symptoms


(Pharmacological Data)

25 of 172

26 of 172

Species or TestSystem (Pharmacological Data)

Macaca mulatta, rhesus monkey

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.01 - 0.056 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water; each dose of title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d

Method (Pharmacological Data)

double-lumen catheter implanted into monkeys who trained to get reinforcer (25 food pellets/session) by responding (16 responses) to central key; this resulted in food delivery at 1-h sessions (4 sessions/day) performed during title comp. infusion

Further Details (Pharmacological Data)

control: saline (95.3 food pellets/d); percent of food-maintained responding; data obtained during last 3 d of 7-d treatment

Type (Pharmacological Data)

ED50

Value of Type (Pharmacological Data)

> 0.073 mg/kg

Results

effect of title comp. on food-maintained responding varied; it either did not affect food-maintained responding or decreased it (figure, table)

Reference

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Macaca mulatta, rhesus monkey

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.01 - 0.056 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water; each dose of title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d

Method (Pharmacological Data)

double-lumen catheter implanted into monkeys who trained to get reinforcer (0.01 mg/kg/injection of cocaine) by responding (16 responses) to central key resulted in cocaine delivery at 1-h sessions (4 sessions/d) performed during title comp. infusion

Further Details (Pharmacological Data)

control: saline (79.2 injections of cocaine/day during availability of 0.01 mg/kg/injection of cocaine); percent of cocaine-maintained responding; data obtained during last 3 d of 7-d treatment

Type (Pharmacological Data)

ED50

Value of Type (Pharmacological Data)

0.024 mg/kg

Results

title comp. produced dose-dependent decreases in 0.01 mg/kg/injection cocaine self-administration (figure, table)

Reference

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details

Effect

behavioural symptoms


(Pharmacological Data)

27 of 172

28 of 172

Species or TestSystem (Pharmacological Data)

Macaca mulatta, rhesus monkey

Sex

male

Route of Application

intramuscular

Concentration (Pharmacological Data)

0.03 - 0.3 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water and was filter-sterilized using 0.22-μm Millipore filter

Method (Pharmacological Data)

monkeys trained to discriminate between saline and 0.4 mg/kg of cocaine i.m.; then increasing doses of title comp. administered cumulatively at beginning of time-out 15-min period; responding to title comp.-appropriate key assessed during 5 min

Further Details (Pharmacological Data)

control: saline (mean rate = 1.96 responses/s); percent of title comp.-appropriate responding for entire response period and response rate were determined

Type (Pharmacological Data)

ED50

Value of Type (Pharmacological Data)

0.10 mg/kg

Results

title comp. produced dose-dependent and complete substitution for cocaine training dose (0.4 mg/kg); dose that produced complete substitution either increased or decreased response rate (mean rate = 95.5percent of control) (figure, table)

Reference

Negus; Mello; Blough; Baumann; Rothman

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

agonist

Species or TestSystem (Pharmacological Data)

human embryonic kidney 293 cells

Concentration (Pharmacological Data)

Ca. 5E-09 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water

Method (Pharmacological Data)

effect of title comp. on rTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted

Further Details (Pharmacological Data)

data normalized to maximal level produced in response to PEA; cells expressing rTAAR1; rTAAR: rat trace amine-associated receptor; PEA: β-phenylethylamine

Type (Pharmacological Data)

EC50

Value of Type (Pharmacological Data)

0.89 μmol/l

Results

title comp. dose-dependently stimulated cAMP production and was full agonist (86.20percent PEAmax) (table, figure)

Reference

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

agonist

Species or TestSystem

human embryonic kidney 293 cells


(Pharmacological Data)

29 of 172

30 of 172

Concentration (Pharmacological Data)

Ca. 5E-09 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water

Method (Pharmacological Data)

effect of title comp. on mTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted

Further Details (Pharmacological Data)

data normalized to maximal level produced in response to PEA; cells expressing mTAAR1; mTAAR: mouse trace amine-associated receptor; PEA: β-phenylethylamine

Type (Pharmacological Data)

EC50

Value of Type (Pharmacological Data)

0.92 μmol/l

Results

title comp. dose-dependently stimulated cAMP production and was full agonist (91.76percent PEAmax) (table, figure)

Reference

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

agonist

Species or TestSystem (Pharmacological Data)

human embryonic kidney 293 cells

Concentration (Pharmacological Data)

Ca. 5E-09 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water

Method (Pharmacological Data)

effect of title comp. on h-rChTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted

Further Details (Pharmacological Data)

data normalized to maximal level produced in response to PEA; cells expressing h-rChTAAR1; h-rChTAAR: human-rat chimera trace amineassociated receptor; PEA: β-phenylethylamine

Type (Pharmacological Data)

EC50

Value of Type (Pharmacological Data)

4.44 μmol/l

Results

title comp. dose-dependently stimulated cAMP production (not saturated) and was full agonist (96.71percent PEAmax) (table, figure)

Reference

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Concentration (Pharmacological Data)

2 - 20 mg/kg

Kind of Dosing

title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight


(Pharmacological Data)

31 of 172

32 of 172

Method (Pharmacological Data)

mice were with title comp. alone or coadministered with morphine; stereotyped behavior, locomotion, sedation and ataxia observed just before and after administration at 30-480 min and at 24 and 48 h

Further Details (Pharmacological Data)

control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied

Results

title comp. + morphine induced hyperlocomotion, Straub tail reaction, miosis, ataxia after 60-180 min and behavioral disruption after 120 min; fullerene, cooling attenuated title comp. effect; mepacrine showed ataxia, self-injurious behavior; fig.

Reference

Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Concentration (Pharmacological Data)

2 - 20 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight

Method (Pharmacological Data)

mice were administered title comp. alone or coadministered with morphine; toxicity and percent mortality observed just before and after administration at 30-480 min and at 24 and 48 h

Further Details (Pharmacological Data)

control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied

Results

coadmin. of title comp. and morphine showed tremors before death after 60-180 min and more than 80percent mice died within 24 h; fullerene, mepacrine and cooling attenuated the lethal effect of title comp. coadministered with morphine; fig.

Reference

Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

colonic temperature; effect on

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Concentration (Pharmacological Data)

2 - 20 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight

Method (Pharmacological Data)

mice were administered with title comp. alone or coadministered with morphine; colonic temp. immediately measured before and after administration at 30 to 480 min and at 24 and 48 h

Further Details (Pharmacological Data)

control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied

Results

title comp.+ morphine induced signif. hyperthermia within 30 min and normalized within 60 min; after ca. 120 min colonic temp. decreased; fullerene decreased colonic temp. post-dose; cooling normalized colonic temp.; mepacrine had no effect; fig.

Reference

Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details


33 of 172

34 of 172

35 of 172

Effect (Pharmacological Data)

oxidant

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Concentration (Pharmacological Data)

20 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight

Method (Pharmacological Data)

mice were coadministered with title comp. and morphine; blood sampled from heart 60 min post-dose; centrifuged; oxidant effect determined by electron spin resonance analyzed using JEOL spin resonance apparatus

Further Details (Pharmacological Data)

control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied

Results

coadministered of title comp. and morphine increased hydroxyl radicals; title comp. effect was significantly and potently attenuated by fullerene and cooling while mepacrine slightly and nonsignificantly attenuated the effect; fig.

Reference

Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

cell morphology; effect on

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Concentration (Pharmacological Data)

20 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight

Method (Pharmacological Data)

mice were coadministered with title comp. and morphine; sacrificed after 4 h post-dose; kidney and liver collected; fixed; stained; effect of title comp. on cell morphology observed

Further Details (Pharmacological Data)

control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied

Results

coadministration of title comp. and morphine showed apparent rupture of hepatic cells and changes in form of kidney cells; these effects were abolished by fullerene, mepacrine and cooling; fig.

Reference

Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Concentration (Pharmacological Data)

20 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in saline containig 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight


36 of 172

37 of 172

38 of 172

Method (Pharmacological Data)

mice were coadministered with title comp. and morphine; sacrificed after 4 h post-dose; heart, kidney, liver and brain collected; fixed; stained; poly (ADP-ribose) polymerase positive cells determined by immunohistochemical analysis

Further Details (Pharmacological Data)

control: saline treated rats; further, effects of fullerene, mepacrine, benzamide and cooling on title comp. studied

Results

coadministration of title comp. and morphine signif. increased number of poly (ADP-ribose) polymerase cells in hepatic, cardiac and kidney cells and slightly in striatum; title comp. effect attenuated by fullerene, mepacrine, benzamide and cooling; fig.

Reference

Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neuroregulatoric

Species or TestSystem (Pharmacological Data)

limbic neuron/glia cells of newborn ICR mouse

Concentration (Pharmacological Data)

10 - 100 μmol/l

Method (Pharmacological Data)

co-cultures treated with title comp. for up to 3 days, then intensity of GFAP-like immunoreactivity measured with computer-assisted system

Further Details (Pharmacological Data)

control: normal medium; GFAP: glial fibrillary acidic protein

Results

title comp. caused robust activation of astrocytes even after 1 day of treatment and effect maintained 2 days after removal of title comp.; fig.

Reference

Suzuki, Tsutomu; Shindo, Keiko; Miyatake, Mayumi; Kurokawa, Kazuhiro; Higashiyama, Kimio; Suzuki, Masami; Narita, Minoru

European Journal of Pharmacology, 2007 , vol. 574, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

limbic neuron/glia cells of newborn ICR mouse

Concentration (Pharmacological Data)

10 - 1000 μmol/l

Method (Pharmacological Data)

co-cultures treated with title comp. for 3 days, then cells stained with antibody to cleaved caspase-3

Further Details (Pharmacological Data)

control: normal medium

Results

100-1000 μM title comp. caused dose-dependent expression of cleaved caspase-3; fig.

Reference

Suzuki, Tsutomu; Shindo, Keiko; Miyatake, Mayumi; Kurokawa, Kazuhiro; Higashiyama, Kimio; Suzuki, Masami; Narita, Minoru

European Journal of Pharmacology, 2007 , vol. 574, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

hyperthermic

Species or TestSystem (Pharmacological Data)

C57BL/6Jx129Sv/J mouse with wild type DAT, SERT genes copies

Sex

male and female

Route of Application

intraperitoneal

Concentration

45 mg/kg


(Pharmacological Data)

39 of 172

40 of 172

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe

Further Details (Pharmacological Data)

fluoxetine (FLU) and nisoxetine (NIS) used for reference; DAT, SERT: dopamine, serotonin transporters; genotypes: DAT+/+ SERT+/+, DAT+/+ SERT +/-, DAT+/- SERT+/-, DAT+/- SERT+/+

Results

title comp. sign. increased body temp. of DAT+/+ SERT +/+, DAT+/- SERT +/+ and DAT+/+ SERT+/-, DAT+/- SERT+/- mice 30-60 and 15-60 min after admin. by maximally ca. 1.5, 2 and 2.5, 1.7 degree, resp. (FLU was hyperthermic, NIS had no effect) (figures)

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

body temperature; effect on

Species or TestSystem (Pharmacological Data)

DAT single KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe

Further Details (Pharmacological Data)

nisoxetine (NIS) and fluoxetine (FLU) used for reference; DAT, SERT: dopamine, serotonin transporters; genotypes: DAT-/- SERT+/+, DAT-/- SERT +/-

Results

title comp. sign. increased body temp. of DAT-/- SERT +/+ mice 30-60 min after admin. and caused sign. hypothermia 15 min followed by sign. hyperthermia 45-60 min after admin. in DAT-/- SERT+/- mice (NIS, FLU were hypothermic) (figures)

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

hyperthermic

Species or TestSystem (Pharmacological Data)

SERT single KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe

Further Details (Pharmacological

nisoxetine (NIS) and fluoxetine (FLU) used for reference; DAT, SERT: dopamine, serotonin transporters; genotypes: DAT+/+ SERT-/-, DAT+/- SERT -/-


Data)

41 of 172

42 of 172

43 of 172

Results

title comp. sign. increased body temp. of SERT single KO mice 30-60 min after admin. by maximally ca. 2-2.5 degrees (NIS, FLU had no sign. effect) (figures)

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

hypothermic

Species or TestSystem (Pharmacological Data)

DAT/SERT double KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe

Further Details (Pharmacological Data)

nisoxetine (NIS) and fluoxetine (FLU) used for reference; DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-

Results

title comp. sign. decreased body temp. of DAT/SERT double KO mice 15-60 min after admin. by maximally ca. 2.2 degrees (NIS, FLU were hyperthermic) (figures)

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

gene expression; induction of

Species or TestSystem (Pharmacological Data)

DAT/SERT double KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. amount of IL-1β mRNA in hypothalamus, nucleus caudatus and accumbens, frontal cortex measured by RT-PCR; 1.2percent agarose gel electrophoresis; ethidium bromide staining

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-; IL-1β: interleukin-1β

Comment (Pharmacological Data)

No effect

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect

toxicity


(Pharmacological Data)

44 of 172

Species or TestSystem (Pharmacological Data)

DAT/SERT double KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 - 150 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

119.6 mg/kg

Results

90-150 mg/kg title comp. induced 10.0-100percent lethality in treated animals (table)

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

DAT single KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

15 - 150 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT+/-, DAT-/- SERT+/+

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

112.6 mg/kg

Results

45-150 mg/kg title comp. induced 9.1-100percent lethality in DAT-/- SERT+/+ mice, whereas in DAT-/- SERT+/- percent of lethality was substantially reduced (0 and 11.8percent at 45, 90 and 75 mg/kg, resp.) (table)

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details


45 of 172

46 of 172

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

SERT single KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 - 150 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/- SERT-/-

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

86.0 mg/kg

Results

45-150 mg/kg title comp. induced 4.3-94.7percent lethality in DAT+/- SERT-/- mice; table

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

SERT single KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 - 150 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/+ SERT-/-

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

76.5 mg/kg

Results

45-150 mg/kg title comp. induced 9.5-95.5percent lethality in DAT+/+ SERT-/- mice; table

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128


Title/Abstract Full Text View citing articles Show Details

47 of 172

48 of 172

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

15 - 110 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/+ SERT+/+

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

67.8 mg/kg

Results

15-110 mg/kg title comp. induced 5.0-100percent lethality in DAT+/+ SERT+/+ mice; table

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

15 - 150 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/- SERT+/+

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

73.3 mg/kg

Results

45-150 mg/kg title comp. induced 26.7-95.5percent lethality in DAT+/- SERT+/+ mice; table

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe,


Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

49 of 172

50 of 172

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 - 110 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/+ SERT+/-

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

80.5 mg/kg

Results

45-110 mg/kg title comp. induced 6.7-100percent lethality in DAT+/+ SERT+/- mice; table

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

15 - 150 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. percent of dead animals calculated

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/- SERT+/-

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

81.0 mg/kg

Results

45-150 mg/kg title comp. induced 13.3-100percent lethality in DAT+/- SERT+/- mice; table


51 of 172

52 of 172

53 of 172

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

gene expression; effect on

Species or TestSystem (Pharmacological Data)

DAT/SERT double KO C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. amount of IL-1β mRNA in hypothalamus, nucleus caudatus and accumbens, frontal cortex measured by RT-PCR; 1.2percent agarose gel electrophoresis; ethidium bromide staining

Further Details (Pharmacological Data)

DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-; IL-1β: interleukin-1β

Comment (Pharmacological Data)

No effect

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

gene expression; induction of

Species or TestSystem (Pharmacological Data)

C57BL/6Jx129Sv/J mouse

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

45 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9percent saline solution

Method (Pharmacological Data)

60 min after title comp. admin. amount of IL-1β mRNA in hypothalamus, nucleus caudatus and accumbens, frontal cortex measured by RT-PCR; 1.2percent agarose gel electrophoresis; ethidium bromide staining

Further Details (Pharmacological Data)

IL-1β: interleukin-1β

Results

title comp. sign. increased hypothalamic IL-1β gene expression by 5-fold; no effect in other brain tissues (figures)

Reference

Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro

European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem

BALB/c mouse


(Pharmacological Data)

54 of 172

55 of 172

56 of 172

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

20 mg/kg

Method (Pharmacological Data)

title comp. administered in combination with morphine (20 mg/kg); mice survival monitored

Further Details (Pharmacological Data)

control: saline

Results

more than 90percent of mice were dead within 24 h after dosing; fig.

Reference

Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

2 - 20 mg/kg

Method (Pharmacological Data)

mice treated with title comp.; mouse striatum conc. of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 3-methoxytyramine (3-MT) determined using HPLC

Results

title comp. at 20 mg/kg, but not at 2.0 mg/kg, decreased conc. of DA and DOPAC, but not HVA and 3MT; fig.

Reference

Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

oxidant

Species or TestSystem (Pharmacological Data)

BALB/c mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

20 mg/kg

Method (Pharmacological Data)

mice treated with title comp. alone or in combination with morphine (20 mg/kg); signal intensities of superoxide adducts (DMPO-AsA,OOH; DPPMPO-AsA,-OOH) in tissues (brain/heart/lung/liver/muscle) measured by ESP spin trap method

Further Details (Pharmacological Data)

DMPO: 5,5-dimethyl-1-pyrroline N-oxide; AsA: ascorbyl radical; DPPMPO: 5-diphenylphosphinoyl-5-methyl-4,5-dihydro-3H-pyrrole N-oxide; ESP: electron spin resonance; vehicle control

Results

title comp. induced high-intensity of free radical signal in brain (striatum) compared to title comp. plus morphine administration; in other tissues coadministration led to increased signal intensity compared to title comp.; fig.

Reference

Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko

Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details

Effect

drug interaction


(Pharmacological Data)

57 of 172

58 of 172

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

Ca. 0.5 - 10 μmol/kg

Method (Pharmacological Data)

rats trained to discriminate cocaine (29.4 μmol/kg, i.p.) from saline treated with title comp.; 5 or 15 min after rats tested in two-lever operant-conditioning chambers

Further Details (Pharmacological Data)

further studies: title comp. dosed with cocaine (ca. 3-30 μmol/kg)

Type (Pharmacological Data)

ED50

Value of Type (Pharmacological Data)

2.18 μmol/kg

Results

title comp. engendered dose-related increases in percent of responses on cocaine-appropriate lever; title comp. in combination with cocaine produced sign. greater effect

Reference

Li, Su-Min; Campbell, Bettye L.; Katz, Jonathan L.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 317, # 3 p. 1088 - 1096 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.3 - 1 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and administered as bolus injection

Method (Pharmacological Data)

rats administered with title comp.; blood collected every 15 min pre-dosing and at 15-min intervals for 90 min post-dosing; dialyzed; dialysates assayed for 5-hydroxytryptamine and 5-hydroxyindoleacetic acid using HPLC with electrochemical detection

Further Details (Pharmacological Data)

control: saline; ref.: fluoxetine

Results

title comp. elevated 5-hydroxytryptamine to 7- and 12-fold after 0.3 and 1.0 mg/kg, resp.; title comp. treatment did not affect plasma 5hydroxyindoleacetic acid levels; diagram

Reference

Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat blood

Sex

male

Concentration

0.3 - 33 μmol/l


(Pharmacological Data)

59 of 172

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline

Method (Pharmacological Data)

title comp. added to blood samples; microdialysis probes placed into blood samples; dialysate efflux collected for 15 min; assayed for 5hydroxytryptamine levels

Further Details (Pharmacological Data)

control: saline; ref.: fluoxetine

Results

title comp. increased plasma 5-hydroxytryptamine levels, producing 4- and 44-fold elevations when administered at concentrations of 3 and 33 μmol/l, resp.; diagram

Reference

Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.

Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

rearing activity; reduction of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Method (Pharmacological Data)

Example 2 Synergy Between an Allosteric Potentiator of AMPA Receptors and Clozapine in an Animal Model of Schizophrenia Amphetamine induction of stereotypic behavior is a well-known and widely used animal model of schizophrenia. The logic for this has been based primarily on two related sets of findings: 1) Amphetamine abuse in humans is known to provoke psychotic symptoms including paranoid ideation, delusions, hallucinations, and stereotyped compulsive behaviors; and,2) Antipsychotic drugs that are effective in the treatment of human schizophrenia are also known to attenuate stereotypic behaviors induced in rats by amphetamines. Finding no. (2) indicates that amphetamine-induced stereotypic behaviors in rats are a useful model for screening potential anti-schizophrenic drugs. Both findings have been instrumental in validating the hypothesis that psychotic symptoms are due, in part, to hyperactive dopaminergic transmission since amphetamines enhance dopamine release and typical neuroleptic drugs are potent dopamine receptor antagonists. The experiments described below used enhanced locomotor and stereotypic rearing activity induced by amphetamines in rats as a model. Published authority for the use and reliability of this model is found in: Janssen, et al., "Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine- or apomorphine-induced 'Cheroing' and 'agitation' in rats" Arzneimittel-Forschung 17:841-854 (1967); Bentall, A.C.C. et al., "Blockade of amphetamine-induced locomotor activity and stereotypy in rats by spiroperidol but not by an atypical neuroleptic, thioridazine," Neuropharmacology 19:699-703 (1980): Niemegeers. C.J.E., et al., "A systematic study of the pharmacological activities of dopamine antagonists," Life Science 24:2201-2216 (1979); and Hornykiewicz, O., "Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence," Neuroscience 3:773-783 (1978). In the present experiments, male Sprague-Dawley rats (250-300 g; Charles River Laboratories) were given ad libitum food and water and maintained on a 12:12 hr light:dark cycle with lights on at 6:00 AM. Behavioral studies utilized a computerized Photobeam Activity System (San Diego Instruments, San Diego, CA), in which each of ten test cages (standard polycarbonate animal cage; 26 cm x 48 cm x 20 cm; W x L x H) were surrounded by two photobeam arrays that were placed to detect locomotor behavior with a lower array and rearing behavior with an upper array. Locomotor and rearing activities were continuously monitored by computer for all ten test cages. Test cages (with photobeam arrays) were placed in a partially darkened room with room ventilation as background noise. On the test day, naive rats were initially placed in the test cages and baseline behavioral activity in the novel environment was monitored during a 30-minute acclimation period. The rats were then injected (i.p.) with vehicle or drug(s) dissolved in vehicle and immediately returned to the test cage and monitored undisturbed for 90 minutes. Experimental groups (n = 10-12, except vehicle, n = 6) were 1) vehicle (saline or 1percent lactic acid, pH 5.0); 2) S-(+)-methamphetamine HCl (METH: 2.0 mg/kg); 3) METH (2 mg/kg) + CX516 (10 mg/kg); 4) METH (2 mg/kg) + clozapine (1.0 mg/kg); and 5) METH (2 mg/kg) + CX516 (10 mg/kg) + clozapine (1.0 mg/kg). Behavioral experiments were repeated at least twice for each condition. Photobeam breaks were summed by the computer into ten-minute periods for analysis. Group means and standard errors are reported in the figures: means and standard deviations were used for statistical analysis by unpaired, two-tailed t test assuming unequal variance. Activity measurements presented in Figures 1 and 2 show that CX516 synergistically enhanced the antagonistic activity of c

Results

test compound administration has rearing activity (see fig. 1-4)

Location

Page/Page column 21-22

Reference

CORTEX PHARMACEUTICALS, INC.; The Regents of the University of California

Patent: EP1026950 B1, 2006 ; Title/Abstract Full Text Show Details

60 of 172

Effect (Pharmacological Data)

action potential; effect on

Species or TestSystem (Pharmacological Data)

sheep cardiac Purkinje fiber

Sex

male

Concentration

0.05 - 5 μmol/l


(Pharmacological Data)

61 of 172

62 of 172

Kind of Dosing (Pharmacological Data)

formulated in DMSO; added cumulatively

Method (Pharmacological Data)

after 30 min. treatment with title comp. fibers placed to two-channel recording chamber with two silver stimulation electrodes; 1 Hz; square-wave constant voltage pulses ca. 0.05 ms; cardiac action potentials (AP) monitored

Further Details (Pharmacological Data)

analysed parameters: AP duration at 50 percent or 90 percent repolarisation, maximum rate of rise in AP upstroke, upstroke amplitude, diastolic membrane potential; further investigation with dl-sotalol, human ether-a-go-go related gene/K(1+) current blocker

Comment (Pharmacological Data)

No effect

Reference

Sheridan, Robert D.; Turner, Simon R.; Cooper, Graham J.; Tattersall, John E.H.

European Journal of Pharmacology, 2005 , vol. 511, # 2-3 p. 99 - 107 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

title comp. administration; for up to 48 h after last injection prostaglandin E2 level in striatum determined by enzyme immunoassay

Further Details (Pharmacological Data)

control: vehicle

Comment (Pharmacological Data)

No effect

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

protein expression; induction of

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

title comp. administration; at 3 - 48 h after last injection COX-1 and COX-2 protein levels in striatum were determined by immunoblotting with specific antibodies

Further Details

COX: cyclooxygenase; control: vehicle


(Pharmacological Data)

63 of 172

64 of 172

65 of 172

Results

title comp. increased COX-2 level by 50 percent at 3 h after injection, and it remained high for up to 48 h with maximum of 390 percent of control at 24 h; title comp. had no effect on COX-1 level

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

protein expression; induction of

Species or TestSystem (Pharmacological Data)

B6;129P2-Ptgs1tm1Unc mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

wild-type mice and mice with null mutation of COX-1 were used; title comp. administration; at 24 h after last injection COX-2 protein level in striatum were determined by immunoblotting with specific antibodies

Further Details (Pharmacological Data)

COX: cyclooxygenase; control: vehicle

Results

title comp. increased COX-2 level by up to 320 percent of control in wild-type mice; in COX-1-null mice COX-2 level also was elevated by title comp.

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

protein expression; induction of

Species or TestSystem (Pharmacological Data)

B6;129P2-Ptgs2tm1Smi mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

wild-type mice and mice with null mutation of COX-2 were used; title comp. administration; at 24 h after last injection COX-1 and COX-2 protein levels in striatum were determined by immunoblotting with specific antibodies

Further Details (Pharmacological Data)

COX: cyclooxygenase; control: vehicle

Results

title comp. increased COX-2 level by up to 320 percent of control in wild-type mice; in COX-2-null mice COX-1 level also was not affected by title comp.

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

tm1Unc


66 of 172

67 of 172

Species or TestSystem (Pharmacological Data)

B6;129P2-Ptgs1

mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

wild-type mice and mice with null mutation of COX-1 were used; title comp. administration; at 48 h after last injection dopamine level in striatum were determined by high-performance liquid chromatography with electrochemical detection

Further Details (Pharmacological Data)

COX: cyclooxygenase; control: vehicle

Results

title comp. reduced dopamine level in striatum to ca. 30 percent of control both in wild-type and COX-1-null mice

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

B6;129P2-Ptgs2tm1Smi mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

wild-type mice and mice with null mutation of COX-2 were used; title comp. administration; at 48 h after last injection dopamine level in striatum were determined by high-performance liquid chromatography with electrochemical detection

Further Details (Pharmacological Data)

COX: cyclooxygenase; control: vehicle

Results

title comp. reduced dopamine level in striatum to ca. 30 percent of control in wild-type mice and to 81 percent of control in COX-2-null mice

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline


Data)

68 of 172

69 of 172

Method (Pharmacological Data)

title comp. administration; at 48 h after last injection dopamine level in striatum were determined by high-performance liquid chromatography with electrochemical detection

Further Details (Pharmacological Data)

control: vehicle; further investigations using inhibitors of cyclooxygenase 2 (rofecoxib, NS-398), cyclooxygenase 1 (SC-560), cyclooxygenases 1 and 2 (ketoprofen), and cyclooxygenase 3 (antipyrine)

Results

title comp. reduced dopamine level in striatum to ca. 30 percent of control; neither of cyclooxygenase inhibitors changed this effect

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

body temperature was monitored by telemetry from 1 h before title comp. first injection till 2 h after fourth injection; AUC value for this time period was calculated

Further Details (Pharmacological Data)

AUC: area under curve; control: vehicle; further investigations using inhibitors of cyclooxygenase 2 (rofecoxib, NS-398), cyclooxygenase 1 (SC-560), cyclooxygenases 1 and 2 (ketoprofen), and cyclooxygenase 3 (antipyrine)

Results

title comp. increased body temperature by ca. 1 deg C at time period of 1 - 6 h after first injection with AUC = 2514 vs AUC = 2160 in control; cyclooxygenase inhibitors had variable effects and did not show clear inhibition of title comp. effect

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

hypothermic

Species or TestSystem (Pharmacological Data)

B6;129P2-Ptgs1tm1Unc mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

mice were with null mutation of cyclooxygenase 1; body temperature was monitored by telemetry from 1 h before title comp. first injection till 2 h after fourth injection; AUC value for this time period was calculated

Further Details (Pharmacological Data)

AUC: area under curve; control: vehicle

Results

title comp. decreased body temperature by 1 - 2 deg C at time period of 1 - 3 h after first injection; later body temperature became slightly higher than in control; AUC = 2232 in title comp.-treated mice vs AUC = 2160 in control

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details


70 of 172

71 of 172

72 of 172

Effect (Pharmacological Data)

hypothermic

Species or TestSystem (Pharmacological Data)

B6;129P2-Ptgs2tm1Smi mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline

Method (Pharmacological Data)

mice were with null mutation of cyclooxygenase 2; body temperature was monitored by telemetry from 1 h before title comp. first injection till 2 h after fourth injection; AUC value for this time period was calculated

Further Details (Pharmacological Data)

AUC: area under curve; control: vehicle

Results

title comp. decreased body temperature by 1 - 2 deg C at time period of 1 - 3 h after first injection; later body temperature became slightly higher than in control; AUC = 2142 in title comp.-treated mice vs AUC = 2160 in control

Reference

Thomas, David M.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

mouse

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in 0.9 percent NaCl; title comp. in dose 1 mg/kg administered repeatedly on days 1, 3, 5, and again in dose 0.5 mg/kg on day 18 (challenge session)

Method (Pharmacological Data)

wild-type, heterozygous and nociceptin receptor knockout mice; sensitization and challenge with title comp.; locomotor activity monitored for 60 min after injection during sensitization and challenge sessions

Results

locomotor sensitization to title comp. and locomotion on challenge day occurred independently on null mutation of nociceptive receptor gene

Reference

Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.

European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

gene expression; induction of

Species or TestSystem (Pharmacological Data)

mouse

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in 0.9 percent NaCl; title comp. in dose 1 mg/kg administered repeatedly on 1, 3, and 5 day and again on day 18 in dose 0.5 mg/kg (challenge session)

Method (Pharmacological Data)

wild-type, heterozygous and nociceptin receptor knockout mice; sensitization and challenge with title comp.; 90 min after treatment immunohistochemical analysis of s-fos expression in 36 brain regions performed


73 of 172

74 of 172

75 of 172

Further Details (Pharmacological Data)

c-fos: marker of neural activation; NAC: nucleus accumbens core; VCP: ventromedial caudate putamen

Results

treatment with title comp. increased c-fos expression in a third of brain regions, challenge increased expression in almost half of brain regions (table); in NAC and VCP accentuated c-fos expression in nociceptin receptor knockout mice

Reference

Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.

European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

0.5 - 10 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline

Method (Pharmacological Data)

microdialysis probe implanted into substantia nigra; then rats were injected with title comp.; dialysis samples were collected every 30 min for 180 min after injection; conc. of neurotensin in samples was determined using solid-phase radioimmunoassay

Further Details (Pharmacological Data)

further investigations with D1 and D2 receptor antagonists SCH 23390 and eticlopride, resp.

Results

title comp. induced neurotensin release in the substantia nigra only at conc. 0.5 mg/kg with involvement of D1 and D2 dopamine receptors (figure)

Reference

Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.

European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

0.5 - 10 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline

Method (Pharmacological Data)

microdialysis probe implanted into globus pallidus; then rats were injected with title comp.; dialysis samples were collected every 30 min for 180 min after injection; conc. of neurotensin in samples was determined using solid-phase radioimmunoassay

Further Details (Pharmacological Data)

radioimmunoassay: protein G-neurotensin antiserum was incubated with samples, then washed and <125>I-neurotensin added; radioactivity counted after <125>I-neurotensin removal; data from treated rats were sorted to "responder" and "non-responder"

Results

title comp. at 0.5 mg/kg induced sign. neurotensin release only in distinct population of treated group ("responder"); 10 mg/kg had no effect in all treated rats (figure)

Reference

Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.

European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

uptake; inhibition of


76 of 172

77 of 172

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 90 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed

Further Details (Pharmacological Data)

control: saline

Results

title comp. caused 65 percent decrease in vesicular dopamine uptake

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

uptake; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 - 10 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 90 rat sacrificed 7 days after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed

Further Details (Pharmacological Data)

control: saline

Results

title comp. decreased vesicular dopamine uptake in dose dependent manner with approximately 75 percent decrease at 10 mg/kg (figure)

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

uptake; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg


78 of 172

79 of 172

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 40 rat sacrificed 7 days after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed

Further Details (Pharmacological Data)

control: saline

Comment (Pharmacological Data)

No effect

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 - 10 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 90 rat sacrificed 7 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle pellet prepared, sonicated; dopamine content in supernatant assayed using HPLC system with electrochemical detection

Further Details (Pharmacological Data)

control: saline; HPLC: high-performance liquid chromatography

Results

title comp. decreased dopamine tissue content in dose-dependent manner with about 40 percent decrease at 5 mg/kg (figure)

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 40 rat sacrificed 7 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle pellet prepared, sonicated; dopamine content in supernatant assayed using HPLC system with electrochemical detection

Further Details (Pharmacological Data)

control: saline; HPLC: high-performance liquid chromatography


80 of 172

81 of 172

82 of 172

Comment (Pharmacological Data)

No effect

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 90 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; deuterated title comp. added as internal standard; title comp. conc. detected by liquid chromatography/tandem mass spectrometry

Further Details (Pharmacological Data)

control: saline

Results

title comp. conc. found to be 4.3 ng/mg tissue

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 - 15 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 40 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; deuterated title comp. added as internal standard; title comp. conc. detected by liquid chromatography/tandem mass spectrometry

Further Details (Pharmacological Data)

control: saline

Results

title comp. conc. found to be 5.0 and 10.7 ng/mg tissue after administration of 10 and 15 mg/kg, resp.

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic


83 of 172

84 of 172

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

rectal temperatures of postnatal 90 day rat measured every 1 h beginning 30 min before first title comp. dose and containing until 30 min after last dose

Further Details (Pharmacological Data)

control: saline

Results

title comp. increased rectal temperature to approximately 40 deg C versus 37.5 deg C in control (figure)

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 - 15 mg/kg

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

rectal temperatures of postnatal 40 day rat measured every 1 h beginning 30 min before first title comp. dose and containing until 30 min after last dose

Further Details (Pharmacological Data)

control: saline

Results

title comp. increased rectal temperature to approximately 40 deg C versus 37.5 deg C in control (figure)

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

uptake; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 - 15 mg/kg


85 of 172

86 of 172

Kind of Dosing (Pharmacological Data)

dose for free base; four injections with 2-h intervals

Method (Pharmacological Data)

postnatal day 40 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed

Further Details (Pharmacological Data)

control: saline

Results

both doses of title comp. caused 45 percent decrease in vesicular dopamine uptake

Reference

Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.

Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Saimiri sciureus, squirrel monkey

Sex

male

Route of Application

intramuscular

Concentration (Pharmacological Data)

0.01 - 0.3 mg/kg

Kind of Dosing (Pharmacological Data)

training dose 0.3 mg/kg

Method (Pharmacological Data)

monkeys trained to discriminate injections of title comp. from saline were treated with title comp. in cumulative manner; title comp.associated lever responding and response rates calculated; substitution of title comp. evaluated

Further Details (Pharmacological Data)

monkeys trained under 10-response fixed ratio schedule of stimulus termination in chambers equipped with colored stimulus lights and two response levers (shock stimuli occurred every 10 s during illumination of stimulus lights); control: saline

Type (Pharmacological Data)

ED50

Value of Type (Pharmacological Data)

0.10 mg/kg

Results

title comp. at 0.3 mg/kg produced full substitution, whereas 0.1 mg/kg produced varying degrees of title comp.-lever responding (range 15-57 percent); ED50 range 0.05-0.15 mg/kg; response rates significantly increased by title comp. (0.1, 0.3 mg/kg) vs saline

Reference

Czoty, Paul W.; Ramanathan, Chinnasamy R.; Mutschler, Nicole H.; Makriyannis, Alexandros; Bergman, Jack

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 2 p. 720 - 727 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Fisher 344 rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.125 - 1 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline

Method (Pharmacological

rats trained to discriminate title comp. from saline after 2-week treatment with 2.0 mg/kg title comp.; training began under FR 1 reinforcement schedule, FR increased to 10; title comp. given 15 min before each session; 6 months withdrawal


Data)

87 of 172

88 of 172

89 of 172

Further Details (Pharmacological Data)

FR: fixed-ratio; 15-min sessions conducted once a day; saline as a control; generalization test with 1.25-10 mg/kg cocaine

Results

title comp. produced a dose-related increase in title comp.-appropriated responses (figure); it founded cross-sensitization with cocaine in title comp.-sensitized rats; sensitization lasted for at least 6 months

Reference

Suzuki, Tsutomu; Fukuoka, Yoshie; Mori, Tomohisa; Miyatake, Mayumi; Narita, Minoru

European Journal of Pharmacology, 2004 , vol. 498, # 1-3 p. 157 - 161 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 - 10 mg/kg

Kind of Dosing (Pharmacological Data)

four injections with 2-h interval between

Method (Pharmacological Data)

20-25 g mice; 48 h after last dose decapitated, slices from striatum and substantia nigra labeled with HRP-conjugated ILB4; microglial activity quantified by stereological analysis under light microscope; DA amount in striatal slices determd. by HPLC

Further Details (Pharmacological Data)

HRP: horseradish peroxidase; ILB4: isolectin B4 from Griffonia simplicifolia; DA: dopamine; further investigations on mechanism of action using hyperthermia, D1/D2 receptor agonists and DA transporter antagonists

Results

title comp. activates striatal microglia in dose-dependent manner, coincident with DA nerve ending damage (graph); neither microglial activation nor DA cell body damage in substantia nigra; microglial activation suggested as early step in neurotoxicity

Reference

Thomas, David M.; Walker, Paul D.; Benjamins, Joyce A.; Geddes, Timothy J.; Kuhn, Donald M.

Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 1 p. 1 - 7 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

embryotoxic

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in 0.9 percent saline; administered from day 0 to day 21 of pregnancy

Method (Pharmacological Data)

pregnant rats treated with title comp.; neonates sacrificed on postnatal day 0, 2, 5, 9, 14 or 56; heart removed; upper side of ventricle fixed, cut and stained with hematoxylin-eosin; junction between ventricular and intraventricular septum observed

Results

title comp. treatment induced eosinophilic changes with large and picnotic nuclei, hypertrophy and disarray at postnatal day 0, by postnatal day 14 these lesions disappeared and normal cardiomyocytes formed myocardium (figure)

Reference

Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji

Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

hormone release; inhibition of


90 of 172

91 of 172

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in 0.9 percent saline

Method (Pharmacological Data)

pregnant rats treated with title comp. during 16 days; blood collected; plasma conc. of T3, T4, testosterone and progesterone determined

Further Details (Pharmacological Data)

control: saline

Results

title comp. treatment significantly decreased T4 and progesterone plasma levels and had no effect on T3 and testosterone plasma levels (figure)

Reference

Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji

Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

mRNA expression; effect on

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in 0.9 percent saline; administered from day 0 to day 21 of pregnancy

Method (Pharmacological Data)

pregnant rats treated with title comp.; neonates sacrificed on postnatal day 0, 2, 5, 9, 14 or 56; heart removed; mRNA expression of αand β-myosin heavy chain (MHC) observed in ventricular muscles by quantitative reverse transcription-PCR

Further Details (Pharmacological Data)

PCR: polymerase chain reaction

Results

title comp. increased α-MHC mRNA expression at postnatal day 0 and 5; title comp. had no significant effect on rapid decrease of β-MHC mRNA expression after birth (figure)

Reference

Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji

Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

embryotoxic

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg


92 of 172

93 of 172

94 of 172

Kind of Dosing (Pharmacological Data)

title comp. dissolved in 0.9 percent saline; administered from day 0 to day 21

Method (Pharmacological Data)

pregnant rats treated with title comp.; neonates sacrificed on postnatal day 0, 2, 5, 9, or 14; neonate body weight, heart weight and heart weight/body weight ratio evaluated

Results

title comp. treatment increased heart weight (significant effect at postnatal day 0) (table)

Reference

Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji

Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

mRNA expression; effect on

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Method (Pharmacological Data)

title comp. administered once daily for 5 d followed by 21-d abstinence period; after abstinence period total RNA isolated from tissues; OCTs mRNA expression determined by RT-PCR

Further Details (Pharmacological Data)

RT-PCR: reverse transcriptase-polymerase chain reaction; OCT: organic cation transporter

Results

in title comp.-treated rats expression of OCT3 mRNA was decreased in kidney, brain, and lung compared to untreated control; expression of other OCT mRNAs was not affected

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Endpoint of Effect (Pharmacological Data)

locomotor activity

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.8 mg/kg

Method (Pharmacological Data)

sensitized and control rats were treated with title comp.; locomotor activity evaluated using photosensor for 2 h every 10 min

Further Details (Pharmacological Data)

behavioral sensitization: treatment with 5 mg/kg of title comp. once a day i.p. for 5 d followed by 21-d abstinence period

Results

significant enhance of locomotor activity in sensitized rats vs. control at 0 - 1 h, but not 1 - 2 h after title comp. administration

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect

pharmacokinetics


(Pharmacological Data)

95 of 172

96 of 172

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

5 mg/kg

Method (Pharmacological Data)

sensitized and control rats were treated with bolus injection of title comp.; plasma samples collected for up to 3 h; concentration of title comp. evaluated by high performance liquid chromatography

Further Details (Pharmacological Data)

sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period; AUC: area under plasma conc.-time curve; Vd: steady-state volume of distribution

Results

significant increase in plasma title comp. conc. in sensitized rats vs control at all time points except 3 h after administration; increase in AUC, decrease in systemic clearance and Vd, and prolongation of t1/2 (57.1 vs 47.4 min) in sensitized rats

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

5 mg/kg

Method (Pharmacological Data)

sensitized and control rats were treated with bolus injection of title comp.; brain dialysate samples collected for up to 3 h; concentration of title comp. evaluated by high-performance liquid chromatography

Further Details (Pharmacological Data)

sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period

Results

concentration of title comp. in brain dialysate was significantly increased in sensitized rats vs control at all time points

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

0.8 mg/kg

Method (Pharmacological Data)

sensitized and control rats were treated with injection of title comp.; penetration through blood-brain barrier estimated as AUCbrain/AUCplasma; conc.-time curve for title comp. in each rat analyzed individually by noncompartmental method

Further Details

sensitization: treatment with 5 mg/kg of title comp. i.p. for 5 d followed by 21-d abstinence period; AUC: area under the curve;


97 of 172

98 of 172

99 of 172

(Pharmacological Data)

AUCbrain/AUCplasma: ratio of AUC of unbound title comp. in plasma to AUC in brain extracellular area

Results

significant increase in AUCbrain and AUCbrain/AUCplasma in sensitized rats at 0 - 1 h, but not at 1 - 2 h after administration; increase in AUCplasma at 0 - 2 h

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

5 mg/kg

Method (Pharmacological Data)

sensitized and control rats were treated with bolus injection of title comp.; 2 h later plasma and tissue samples collected; title comp. conc. determined by high-performance liquid chromatography

Further Details (Pharmacological Data)

sensitization: by treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period

Results

relative magnitude of accumulation, compared to plasma: kidney (43 times) > lung > liver > brain > heart > muscle (7 times) in control rats; tissue/plasma ratios in sensitized rats were significantly decreased in lung and heart

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intravenous

Kind of Dosing (Pharmacological Data)

bolus injection of 1.09 mg/kg followed by constant-rate infusion of 834 μg/h/kg at a flow rate 2 ml/h

Method (Pharmacological Data)

sensitized and control rats treated with title comp. for 60 min; plasma title comp. conc. determined by high performance liquid chromatography

Further Details (Pharmacological Data)

sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period; further invest. using tetraethylammonium, cimetidine, π-aminohippuric acid, and carnitine; Css: conc. of title comp. at steady-state

Results

Css in sensitized rats was significantly higher than in control (200.1 vs 148 ng/ml, resp.); in both groups Css was increased by tetraethylammonium and cimetidine, but not carnitine and p-aminohippuric acid

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Wistar rat


100 of 172

101 of 172

Sex

male

Route of Application

intravenous

Kind of Dosing (Pharmacological Data)

loading dose of 1.09 mg/kg followed by constant-rate infusion of 834 μg/h/kg at a flow rate 2 ml/h

Method (Pharmacological Data)

sensitized and control rats treated with title comp. for 60 min; plasma and urine samples collected; title comp. conc. determined by highperformance chromatography; renal clearance determined (CLR)

Further Details (Pharmacological Data)

sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period; further investigations with tetraethylammonium, cimetidine, π-aminohippuric acid, and carnitine or with urine alkalization (pH 8)

Results

CLR in sensitized rats was lower than in control (10.3 vs 12.2 μl/min, resp.); in both groups CLR was decreased by tetraethylammonium and cimetidine, but not carnitine, p-aminohippuric acid and urine alkalization

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

protein binding

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

5 mg/kg

Method (Pharmacological Data)

sensitized and control rats were treated with bolus injection of title comp.; title comp. plasma protein binding determined by ultrafiltration

Further Details (Pharmacological Data)

behavioral sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period

Results

no significant difference in plasma protein binding between sensitized rats vs control observed (unbound fraction 0.48 and 0.46, resp.)

Reference

Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki

European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

ICR mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

once daily; dissolved in saline; administered in volume of 0.1 ml/10 g of body weight

Method (Pharmacological Data)

title comp. administered for 5 consecutive days (test d 2-6) and on test d 11; after injections, locomotor activity counted for 30 min (within 5-min intervals) and then for 23 h 30 min (within 30-min intervals)

Further Details (Pharmacological Data)

control: saline


102 of 172

103 of 172

104 of 172

Results

title comp. significantly increased locomotor activity for about 12 h (figure); effect increased at every 5-min interval up to 30 min (figure); effect reached maximal on test d 4 and plateaued thereafter, indicating behavioral sensetization (figures)

Reference

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

ICR mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

once daily; dissolved in saline; administered in volume of 0.1 ml/10 g of body weight

Method (Pharmacological Data)

title comp. injected daily on d 2-6 and d 11 (RA) or only on d 11 (SA); 30 min after last injection, animals decapitated; striata and regions of thalami and hypothalami isolated; contents of L-DOPA, DOPAC, 5-HT and 5-hydroxytryptophan determined by HPLC

Further Details (Pharmacological Data)

RA, SA: single, repeated administration, resp.; control: saline; HPLC: high-performance liquid chromatography; L-DOPA: Ldihydroxyphenylalanine; DOPAC: 3,4-dihydroxyphenylacetic acid; 5-HT: 5-hydroxytryptamine

Results

title comp. reduced L-DOPA and 5-HT level in striatum+accumbens (both SA and RA) but not in thalamus+hypothalamus, reduced DOPAC level (RA only) in striatum+accumbens and thalamus+hypothalamus, had no effect on 5-hydroxytryptophan content (table)

Reference

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

ICR mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in saline; administered in volume of 0.1 ml/10 g of body weight

Method (Pharmacological Data)

title comp. injected daily on test 2-6 and 11 or only on d 11; 30 min after last injection animals decapitated; striata and regions of thalami and hypothalami isolated; homogenized; contents of 5-HIAA, norepinephrine and MHPG determined by HPLC

Further Details (Pharmacological Data)

control: saline; HPLC: high-performance liquid chromatography; 5-HIAA: 5-hydroxyindolacetic acid; MHPG: 3-methoxy-4hydroxyphenylglycol

Results

both single and repeated treatment with title comp. reduced 5-HIAA acid content in thalamus+hypothalamus but not in striatum+accumbens, had no effect on content of norepinephrine and its metabolite MHPG (table)

Reference

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological

ICR mouse


Data)

105 of 172

106 of 172

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in saline; administered in volume of 0.1 ml/10 g of body weight

Method (Pharmacological Data)

title comp. injected daily on test d 2-6 and d 11 or only on d 11; 30 min after last injection animals decapitated; striata and regions of thalami and hypothalami isolated; homogenized; centrifuged; washed; content of dopamine determined by HPLC

Further Details (Pharmacological Data)

control: saline; HPLC: high-performance liquid chromatography

Results

title comp. did not change dopamine content in thalamus+hypothalamus (at both single and repeated treatment) but increased content of dopamine in striatum+accumbens after single administration but not after repeated treatment (table)

Reference

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

ICR mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in saline; administered in volume of 0.1 ml/10 g of body weight

Method (Pharmacological Data)

title comp. injected daily on test d 2-6 and d 11 or only on d 11; 30 min after last injection animals decapitated; striata and regions of thalami and hypothalami isolated; homogenized; contents of 3-MT and HVA determined by HPLC

Further Details (Pharmacological Data)

control: saline; HPLC: high-performance liquid chromatography; 3-MT: 3-methoxytyramine; HVA: homovanilic acid

Comment (Pharmacological Data)

No effect

Reference

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

ICR mouse

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in saline; administered in volume of 0.1 ml/10 g of body weight


107 of 172

108 of 172

109 of 172

Method (Pharmacological Data)

title comp. injected daily on 1-6 and 11 days; body weight measured

Further Details (Pharmacological Data)

control: saline

Comment (Pharmacological Data)

No effect

Reference

Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko

European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

dopamine uptake; inhibition of

Species or TestSystem (Pharmacological Data)

CF-1 mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in 0.9 percent saline; administered as four injections with 2-h intervals

Method (Pharmacological Data)

title comp. administered; 1-24 h later striatal synaptic vesicles obtained; vesicular <3H>dopamine uptake measured by incubation of vesicles (ca. 2.5 μg protein) with 30 nmol/l <3H>dopamine at 30 deg C, 3 min, pH 7.5; radioactivity on filters counted

Further Details (Pharmacological Data)

further investigation with SCH23390 and eticlopride (dopamine D1 and D2 receptor antagonists, resp.); furtherinvestigation in 28.5 or 4 deg C environment

Results

title comp. rapidly decreased vesicular <3H>dopamine uptake; effect was sign. attenuated by eticlopride at 23 deg C and less at 28.5 deg C; SCH23390 had no effect; at 28.5 deg C 80 percent decrease, at 4 deg C 35 percent decrease of <3H>dopamine uptake, resp.

Reference

Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

hyperthermic

Species or TestSystem (Pharmacological Data)

CF-1 mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in 0.9 percent saline; administered as four injections with 2-h intervals

Method (Pharmacological Data)

title comp. administered in 6 or 28.5 deg C environment; body temperature measured

Results

title comp. caused hyperthermia (38.5 - 40.5 deg C) in mice at 28.5 deg C environment but failed to induce hyperthermia at 6 deg C

Reference

Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological

binding; inhibition of


Data)

110 of 172

111 of 172

Species or TestSystem (Pharmacological Data)

CF-1 mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in 0.9 percent saline; administered as four injections with 2-h intervals

Method (Pharmacological Data)

title comp. administered; 1 or 24 h later striatal synaptic vesicles obtained; <3H>DTB binding measured by incubation of vesicles (ca. 6 μg protein) with 2 nmol/l <3H>DTB at 25 deg C for 10 min; radioactivity bound to filters counted

Further Details (Pharmacological Data)

<H3>DTB: <3H>dihydrotetrabenazine, ligand of vesicular monoamine transporter-2 (VMAT-2)

Results

title comp. rapidly decreased vesicular <3H>DTB binding

Reference

Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

protein expression; effect on

Species or TestSystem (Pharmacological Data)

CF-1 mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in 0.9 percent saline; administered as four injections with 2-h intervals

Method (Pharmacological Data)

title comp. administered; 1 h later striatal subcellular fractions obtained; VMAT-2 immunoreactivity assayed in separate fractions (S3, P3) by Western blotting using specific antibodies

Further Details (Pharmacological Data)

VMAT-2: vesicular monoamine transporter-2; S3: vesicular fraction; P3: membrane-associated fraction

Results

title comp. caused subcellular redistribution of VMAT-2 immunoreactivity (decrease in S3 and increase in P3 fractions)

Reference

Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

4 times 10 mg/kg title comp. inj. at 2-h intervals

Method

rats (14/10 h light/dark cycle; 24 deg C) without/with pretreatment with 15 mg/kg s.c. title comp. on two consecutive days weekly for six


112 of 172

113 of 172

114 of 172

(Pharmacological Data)

consecutive weeks; 1 week later, at postnatal day 90 challenged with 'binge' treatment

Further Details (Pharmacological Data)

striatal <3H>dopamine (DA) uptake determined; title comp. effect without/with pretreatment on DA uptake sstudied

Results

long-term DA deficits without pretreatment; response blocked by pretreatment; title comp.-induced hyperthermia also attenuated by pretreatment (graph)

Reference

Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

receptor; binding activity

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

4 times 10 mg/kg title comp. inj. at 2-h intervals

Method (Pharmacological Data)

rats (14/10 h light/dark cycle; 24 deg C) without/with pretreatment with 15 mg/kg s.c. title comp. on two consecutive days weekly for six consecutive weeks; 1 week later, at postnatal day 90 challenged with 'binge' treatment

Further Details (Pharmacological Data)

striatal <3H>WIN35428 (WIN) binding determined; title comp. effect without/with pretreatment on WIN binding sstudied

Results

long-term decrease of transporter ligand binding without pretreatment; response blocked by pretreatment (graph)

Reference

Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.

European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.1 - 3 mg/kg

Kind of Dosing (Pharmacological Data)

daily dose; each dose was separated by at least 2 days of saline treatment; injected in volume of 1 ml/kg

Method (Pharmacological Data)

title comp. was administered; locomotor activity was tested; distance traveled was measured

Further Details (Pharmacological Data)

control: saline

Results

title comp. increased locomotor activity in dose-dependent manner; females were more sensitive to this effect than were males

Reference

Schindler, Charles W.; Bross, Joshua G.; Thorndike, Eric B.

European Journal of Pharmacology, 2002 , vol. 442, # 3 p. 231 - 235 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem

Sprague-Dawley rat


(Pharmacological Data)

115 of 172

116 of 172

Sex

male and female

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

<= 3 mg/kg

Kind of Dosing (Pharmacological Data)

single dose; each dose was separated by at least 2 days of saline treatment; injected in volume of 1 ml/kg

Method (Pharmacological Data)

title comp. was administered; rat was placed on one side of chamber; place preference (time spent on title comp. paired side) was monitored

Further Details (Pharmacological Data)

control: saline

Results

preference for title comp. paired side was dose-dependent; no differences between males and females were found

Reference

Schindler, Charles W.; Bross, Joshua G.; Thorndike, Eric B.

European Journal of Pharmacology, 2002 , vol. 442, # 3 p. 231 - 235 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

secretion stimulant

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

7.5 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in 0.9 percent NaCl

Method (Pharmacological Data)

adult rats (aged ca. 55 days, 240-300 g) housed at constant temperature, food and water provided ad libitum; extracellular glutamate and 5-HT levels in the ventral hippocampus determined by in vivo microdialysis

Results

title comp. markedly increased extracellular 5-HT (ca. 250 percent) and glutamate levels (77 percent over control values)

Reference

Rocher; Gardier

Naunyn-Schmiedeberg's Archives of Pharmacology, 2001 , vol. 363, # 4 p. 422 - 428 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

female

Route of Application

subcutaneous

Concentration (Pharmacological Data)

40 mg/kg

Kind of Dosing (Pharmacological Data)

administered twice daily

Method (Pharmacological Data)

pregnant mice were treated with title comp. from gestation day 7 through 18; 21 days postparturition striatal monoamine and metabolite levels were determined to assess neurotoxic effectiveness; high-performance liquid chromatography

Further Details

saline control; determined monoamines and metabolites: dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA),


117 of 172

118 of 172

119 of 172

(Pharmacological Data)

5-hydroxytryptamine (5-HT), 3-methoxytyramine (3-MT), 5-hydroxyindoleacetic acid (5-HIAA)

Results

title comp. produced long-lasting depletion of striatal dopaminergic markers, but did not affect 3-MT, 5-HT, or 5-HIAA levels (table)

Reference

Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa

Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

male and female

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 - 20 mg/kg

Method (Pharmacological Data)

3-month old offsprings, exposed in utero to saline or title comp. were challenged twice (spaced 2 h apart) with title comp.; 7 days later brain monoamine and metabolite levels were determined to assess neurotoxic effectiveness; HPLC

Further Details (Pharmacological Data)

saline control; determined monoamines and metabolites: dopamine (DA), dihydroxyphenyacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5-HT), 3-methoxytyramine (3-MT), 5-hydroxyindoleacetic acid (5-HIAA)

Results

title comp. depleted dopaminergic markers in striatum, brainstem, cortex and cerebellum, but did not affect serotonergic markers; effect of title comp. was greater in males and was enhanced by prenatal exposure to title comp. (table, figure)

Reference

Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa

Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

male and female

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 - 20 mg/kg

Method (Pharmacological Data)

3-month old offsprings, exposed in utero to saline or title comp. were challenged twice (spaced 2 h apart) with title comp.; rectal temperature was measured during administration of title comp. and over 5 - 6 h following last injection

Further Details (Pharmacological Data)

saline control; pregnant females received title comp. (40 mg/kg s.c.) from gestational day 7 through 18 twice a day

Results

title comp. caused hyperthermic responses in males regardless of prenatal treatment; title comp. had no effect in females (table)

Reference

Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa

Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

C57BL/6 mouse

Sex

male

Route of Application

subcutaneous


120 of 172

121 of 172

122 of 172

Concentration (Pharmacological Data)

10 mg/kg

Method (Pharmacological Data)

15-week-old mice were given 2 injections of title comp. (2 h apart); 1 week later striatal level of DA and DAT binding site density and affinity were determined to assess neurotoxic effectiveness

Further Details (Pharmacological Data)

saline control; DA level was determined by HPLC; DAT binding was assessed in saturation studies using 125I-RTI-121; DA: dopamine; DAT: dopamine transporter

Results

title comp. reduced DA level and DAT without change in affininty of transporter (table)

Reference

Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa

Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals

Method (Pharmacological Data)

start: 8 weeks old; DRL 72-s schedule training for 12 weeks before title comp. treatment; 1-REG or 3-REG group; data (response, reinforcement rates, PkA, PkL measures) collected at 26-28, 33-35, 40-42, 62 weeks

Further Details (Pharmacological Data)

baseline data: 19-21 weeks, saline control; DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens; PkA: peak area; PkL: peak location

Results

title comp. decreased PkA at 26-28 weeks (1-REG), 40-42 weeks (1-REG, 3-REG), increased responses rate at 26-28 weeks (1-REG) (figure)

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter synthesis; effect on

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals

Method (Pharmacological Data)

start: 8 weeks old; DRL 72-s schedule training for 12 weeks before title comp. treatment; 1-REG or 3-REG group; at 70 weeks old 10 brain regions assayed for tissue conc. of dopamine and serotonin by reversed phase HPLC

Further Details (Pharmacological Data)

DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: 3 regimens; PkA/PkL: peak area/location

Results

title comp. decreased serotonin in somatosensory cortex, occipital cortex and hippocampus (1-REG, 3-REG), increased serotonin and dopamine in septum (3-REG) (figure)

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological

behavioural symptoms


Data)

123 of 172

124 of 172

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals

Method (Pharmacological Data)

title comp. treatment at 23 weeks old, 1-REG or 3-REG group; first DRL 72-s schedule training at 60 weeks for 10 weeks; data (response, reinforcement rates, PkA, PkL measures) collected across 3-week periods

Further Details (Pharmacological Data)

saline control; DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens; PkA: peak area; PkL: peak location

Comment (Pharmacological Data)

No effect

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter synthesis; effect on

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals

Method (Pharmacological Data)

title comp. treatment at 23 weeks old, 1-REG or 3-REG group; first DRL 72-s schedule training at 60 weeks for 10 weeks; at 70 weeks old 10 brain regions assayed for dopamine and serotonin by reversed phase HPLC

Further Details (Pharmacological Data)

saline control; DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens

Results

title comp. decreased serotonin conc. in somatosensory cortex, occipital cortex and hippocampus (1-REG, 3-REG) and increased it in striatum (3-REG) (figure)

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals

Method (Pharmacological Data)

at 23 weeks old title comp. injected (1-REG/3-REG); at 70 weeks frontal, somatosensory, occipital cortex, hippocampus, amygdala, n. accumbens+olfactory tuberie, striatum, septum, hypothalamus, ventral midbrain: dopamine, serotonin by reversed phase HPLC


125 of 172

126 of 172

127 of 172

Further Details (Pharmacological Data)

saline control; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens

Results

title comp. decreased serotonin conc. in somatosensory cortex, occipital cortex and hippocampus (1-REG, 3-REG) (figure)

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time at 2-h intervals

Method (Pharmacological Data)

dopamine and serotonin tissue conc. determined 2 weeks after title comp. injection in 10 brain regions by reversed phase HPLC

Results

title comp. decreased dopamine in striatum and serotonin in striatum, nucleus accumbens+olfactory tubercle, somatosensory cortex and hippocampus (figure)

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pyrogenic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological Data)

15 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals

Method (Pharmacological Data)

at 22 weeks old temperature-sensitive transmitter implanted into abdominal region; 1 week later title comp. injected (1-REG/2-REG/3REG); average core temperature analysed across treatment period (1000 min)

Further Details (Pharmacological Data)

saline control; 1-REG: group received of one regimen of title comp.; 2-REG/3-REG: group received 2/3 regimens

Results

individual injection of title comp. increased core body temperature; this pattern was apparent throughout individual regimens and in all cases of multiple regimens (figure, table)

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter release; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Concentration (Pharmacological

15 mg/kg


Data)

128 of 172

129 of 172

130 of 172

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals

Method (Pharmacological Data)

at 23 weeks old title comp. injected (1-REG/2-REG/3-REG); 6 weeks later last treatment dopamine and serotonin analysed in 10 brain regions by reversed phase HPLC

Further Details (Pharmacological Data)

saline control; 1-REG: group received of one regimen of title comp. (15 mg/kg/injection*4, at 2-h intervals); 2-REG/3-REG: group received 2/3 regimens separated by 7 weeks

Results

title comp. (1-REG, 2-REG, 3-REG) decreased serotonin in frontal cortex, somatosensory cortex, occipital cortex, hippocampus, amygdala and striatum; it also decreased dopamine in striatum and septum (figure)

Reference

Sabol; Richards; Yung

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

synaptosomes preexposed to title comp. for 10-80 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting

Further Details (Pharmacological Data)

control: vehicle; DA: dopamine

Results

title comp. time-dependently reduced <3H>DA uptake (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

1E-07 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting

Further Details (Pharmacological Data)

control: vehicle; DA: dopamine

Results

title comp. concentration-dependently reduced <3H>DA uptake (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect

transport; inhibition of


(Pharmacological Data)

131 of 172

132 of 172

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting; Eadie-Hofstee plot constructed

Further Details (Pharmacological Data)

control: vehicle; DA: dopamine

Results

title comp. reduced <3H>DA uptake by reducing maximum number of <3H>DA transporters, without significantly altering transporter affinity (noncompetitive inhibition) (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

loaded with unlabeled DA, synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in absence or presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting

Further Details (Pharmacological Data)

control: vehicle; DA: dopamine

Results

title comp. reduced <3H>DA uptake by 57.4percent in absence of external DA, and smaller reduction, 16.7percent in presence of external DA (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

synaptosomes preexposed to title comp. for 60 min at 34, 37, and 40 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting


133 of 172

134 of 172

135 of 172

Further Details (Pharmacological Data)

control: vehicle; DA: dopamine

Results

title comp. temperature-dependently decreased <3H>DA uptake; at 34, 37, and 40 deg C uptakes of <3H>DA were 81.1, 63.8, and 32.4percent of control values, respectively (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting

Further Details (Pharmacological Data)

control: vehicle; in presence of DA transporter blockers (bupropion, methylphenidate, and cocaine, all at 10 μmol/l) and protein kinase C inhibitors (chelerythrine and bisindolylmaleimide, at 0.1-1 μmol/l); DA: dopamine

Results

title comp. significantly reduced <3H>DA uptake; effect blocked in presence of all DA transporter inhibitors tested, but not protein kinase C inhibitors (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

40 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

animals treated with title comp. 1 h before decapitation; striatal synaptosomes prepared and exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting

Further Details (Pharmacological Data)

control: vehicle; DA: dopamine

Results

title comp. significantly reduced <3H>DA uptake by 58.3percent (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

receptor; binding activity

Species or TestSystem

Sprague-Dawley rat striatal synaptosomes


(Pharmacological Data)

136 of 172

137 of 172

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>WIN35,428 in presence of unlabeled WIN35,428 for 5 min; changes in specific binding of radioligand determined by scintillation counting

Further Details (Pharmacological Data)

control: vehicle; reference comp.: 1-methyl-4-phenyl-pyridinium (MPP(1+)), at 10 μmol/l

Comment (Pharmacological Data)

No effect

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

receptor; binding activity

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

40 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

animals treated with title comp. 1 h before decapitation; striatal synaptosomes prepared and exposed to 30 nmol/l <3H>WIN35,428 in presence of unlabeled WIN35,428 for 5 min; changes in specific binding of radioligand determined

Further Details (Pharmacological Data)

control: vehicle

Comment (Pharmacological Data)

No effect

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological

synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>glutamate in presence of unlabeled glutamate for 5 min; changes in <3H>glutamate uptake assayed by scintillation counting


Data)

138 of 172

139 of 172

140 of 172

Further Details (Pharmacological Data)

control: vehicle

Comment (Pharmacological Data)

No effect

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

10 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting

Further Details (Pharmacological Data)

control: vehicle; reference comp.: amphetamine (AMPH), fenfluramine, 6-hydroxydopamine (6-OHDA), and 1-methyl-4-phenyl-pyridinium (MPP(1+)), all at 10 μmol/l; DA: dopamine

Results

similar to DA neurotoxins AMPH, MPP(1+) and 6-OHDA, but not fenfluramine (selective serotonin neurotoxin), title comp. reduced <3H>DA uptake (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transport; inhibition of

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat striatal synaptosomes

Sex

male

Concentration (Pharmacological Data)

0.1 μmol/l

Kind of Dosing (Pharmacological Data)

dissolved in saline

Method (Pharmacological Data)

after pretreatment with title comp. for 1 h and washing, synaptosomes exposed to <3H>DA in presence of title comp. and unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting; Eadie-Hofstee plot constructed

Further Details (Pharmacological Data)

control: vehicle; DA: dopamine

Results

title comp. reduced <3H>DA uptake by reducing affinity of <3H>DA transporter, without significantly altering maximum number of <3H>DA transporters (competitive inhibition) (figure)

Reference

Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.

Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

releasing hormones

Species or TestSystem

Sprague-Dawley rats


(Pharmacological Data)

141 of 172

142 of 172

143 of 172

144 of 172

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

1 - 2.5 mg/kg

Method (Pharmacological Data)

dialysis probe was inserted into caudate-putamen via previously implanted cannula and was perfused, after stable baseline levels were obtained for DA, DOPAC, HVA, 5-HIAA, title comp. was administered and dialysate samples were collected for 90 min

Further Details (Pharmacological Data)

dialysate samples were analyzed by HPLC with electrochemical detector; dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA)

Results

extracellular conc. of DA and its metabolites were increased; areas under microdialysate DA conc. versus time curve (AUC 0-60 min) of 9.586 and 25.939 nM/l*min at 1.0 and 2.5 mg/kg doses, resp.; diagrams are given

Reference

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rats

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2.5 mg/kg

Method (Pharmacological Data)

animals were sacrified by decapitation at 10-60 min after title comp. administration, caudate-putamen, cortex, and cerebellum were rapidly dissected, fozen in liquid nitrogen, and stored at -70 deg C until analyzed

Further Details (Pharmacological Data)

tissue sample was homogenized and centrifuged, supernatant was alkalinized (Na2CO3) and extracted with isopropanol-dichloromethane mixture and processed for GC/MS analysis

Results

area under tissue conc. versus time curve (AUC) of title comp. from 0 to 60 min after administration was 760 nmol/g*min

Reference

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

treatment of male Sprague-Dawley rat with 0.5 mg/kg, significantly, but transiently increased dopamine release to ca. 250 and 180percent in nucleus accumbens and corpus striatum, resp. after 2 h effects disappeared

Reference

Fukuchi, Isao; Asahi, Toshio; Kawashima, Kazutaka; Kawashima, Yumiko; Yamamura, Michio; Matsuoka, Yuzo; Kinoshita, Kiyoshi

Arzneimittel-Forschung/Drug Research, 1998 , vol. 48, # 4 p. 353 - 359 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

treatment of male Sprague-Dawley rat with 0.5 mg/kg, decreased 3,4-dihydroxyphenylacetic acid, homovanillic acid in nucleus accumbens, did not influence in corpus striatum; no effect on 5-hydroxy-3-indoleacetic acid, increased 3-methoxytyramine levels

Reference

Fukuchi, Isao; Asahi, Toshio; Kawashima, Kazutaka; Kawashima, Yumiko; Yamamura, Michio; Matsuoka, Yuzo; Kinoshita, Kiyoshi

Arzneimittel-Forschung/Drug Research, 1998 , vol. 48, # 4 p. 353 - 359 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

mice

Route of

intraperitoneal


Application

145 of 172

146 of 172

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. added 3 times, every 3 h

Method (Pharmacological Data)

nNOS(-/-), nNOS(+/-), B6/SV129, C57BL/6 and SV129 strains of mice divided into 2 subgroups, one treated with title comp., animals sacrified 72 h after the last injection, brain removed, dopamine and its metabolites determined by HPLC

Further Details (Pharmacological Data)

nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice; DOPAC: 3,4-dihydroxyphenylacetic acid, HVA: homovanillic acid, DA: dopamine

Results

no signif. change in tissue content of DA, DOPAC and HVA in nNOS(-/-) mice; in nNOS(+/-) mice 35 percent decrease in DA concn. obsd.; decreases in DA/DOPAC/HVA concn. in B6/SV129, C57BL/6 and SV129 mices 45/37/35 percent, 68/61/45 percent and 37/35/39 percent, resp.

Reference

Itzhak; Gandia; Huang; Ali

The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

mice

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. added 3 times, every 3 h

Method (Pharmacological Data)

nNOS(-/-), nNOS(+/-), B6/SV129, C57BL/6 and SV129 strains of mice treated with title comp., animals sacrified 72 h after the last injection, brain removed, striatal tissue homogenized, centrifuged, <3H>mazindol binding measured

Further Details (Pharmacological Data)

nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice

Results

admin. of title comp. to B6/SV129, C57BL/6 and SV129 mice resulted in 60, 66 and 49 percent decreases, resp., to nNOS(-/-) and nNOS(+/-) only 12 and 32 percent decreases, resp. in <3H>mazindol binding sites

Reference

Itzhak; Gandia; Huang; Ali

The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

mice

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. added 3 times, every 3 h

Method (Pharmacological Data)

nNOS(-/-), nNOS(+/-), B6/SV129, C57BL/6 and SV129 strains of mice treated with title comp., body temp. measured before the first injection of title comp. and every 30 min therafter, for a total periosd of 120 min

Further Details (Pharmacological Data)

nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice


147 of 172

148 of 172

149 of 172

Results

30 and 60 min after the admin. of the first dose of title comp. to nNOS(+/-), B6/SV129, C57BL/6 and SV129 mice, a marked increase in body temp. obsd., no signif. effect obsd. on nNOS(-/-) mice

Reference

Itzhak; Gandia; Huang; Ali

The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

mice

Route of Application

intraperitoneal

Kind of Dosing (Pharmacological Data)

title comp. added in a following way: 1 mg/kg, 3 times 5 mg/kg in 3-h intervals

Method (Pharmacological Data)

nNOS(-/-), B6/SV129 and C57BL/6 strains of mice treated with title comp. in a programmed way, locomotor activity measured 68-72 h after the last injection

Further Details (Pharmacological Data)

nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice

Results

on d 1, admin. of 1 mg/kg title comp. caused a marked increase in locomotor activity in all the 3 groups tested, on d 4 the loc. activity of nNOS(-/-) mice was similar in intensity to that on d 1; for the 2 others a signif. sensitized response obsd.

Reference

Itzhak; Gandia; Huang; Ali

The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

enzyme; inhib. of

Species or TestSystem (Pharmacological Data)

human liver microsomes

Method (Pharmacological Data)

effect on activity of enzyme CYP2D6 studied; 0.5 to 5.0 μmol/l dextromethorphan incubated in 0.2 mol/l phosphate buffer with (μmol/l): 0.1 NADP, 1 glucose-6-phosphate, 0.5 MgCl2 and 0.2 U glucose-6-phosphate dehydrogenase with/without title compound

Further Details (Pharmacological Data)

reaction started by adding microsomal protein; incubation at 37 deg C for 30 min; stopped with 70 percent perchloric acid; centrifuged; supernatant assayed for dextrorphan by HPLC

Results

competitive inhibitory effect; apparent inhibition constant (Ki) = 25 μmol/l

Reference

Wu, Dafang; Victoria Otton, S.; Inaba, Tadanobu; Kalow, Werner; Sellers, Edward M.

Biochemical Pharmacology, 1997 , vol. 53, # 11 p. 1605 - 1612 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

Fischer-344 rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 mg/kg

Kind of Dosing (Pharmacological Data)

dissolved in saline, administered four times 1 day at 2-hr intervals

Method (Pharmacological Data)

rats (210-280 g) used; in vivo electrochemistry and microdialysis used to examine potassium- and amphetamine-evoked release of DA in the striatum (S) and nucleus accumbens (NAc); animals killed, S and NAc dissected, monoamine content analyzed by HPLC

Further Details

DA = dopamine


(Pharmacological Data)

150 of 172

151 of 172

152 of 172

Results

title comp. treatment resulted in dramatic decreases in DA basal levels, in potassium- and amphetamine-evoked DA release and overflow in S, NAc not significantly affected; post-mortem levels of tissue DA decreased by 41 to 67 percent in S and 25 to 31 percent in NAc

Reference

Cass, Wayne A.

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 280, # 1 p. 105 - 113 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

inotropic pos.

Species or TestSystem (Pharmacological Data)

ferret right ventricle papillary muscle

Sex

male

Concentration (Pharmacological Data)

1E-08 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. dissolved in deionized water

Method (Pharmacological Data)

papillary muscles bathed in physiological soln.; aequorin loaded; title comp. added; intracellular calcium <Ca(2+)>i and developed tension measured by multichannel analyzer

Further Details (Pharmacological Data)

aequorin: bioluminescent calcium indicators; PIE: positive ionotropic effect; control: without title comp.; MTR: maximal tension response; effect of propranolol, atropine in the presence of title comp. also studied

Results

title comp. showed PIE in dose-dependent manner with increased <Ca(2+)>i with threshold of 1E-7 mol/l and a MTR and <Ca(2+)>i at 1E-5 mol/l; signif. decrease in developed tension with further decrease in <Ca(2+)>i at 1E-3 mol/l observed; diagram

Reference

Ishiguro, Yoshiki; Morgan, James P.

Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

inotropic neg.

Species or TestSystem (Pharmacological Data)

ferret right ventricle papillary muscle

Sex

male

Concentration (Pharmacological Data)

1E-08 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. dissolved in deionized water

Method (Pharmacological Data)

reserpine pretreated test system bathed in physiological soln.; title comp. added; intracellular calcium <Ca(2+)>i and developed tension measured using multichannel analyzer

Further Details (Pharmacological Data)

NIE: negative inotropic effect; PIE: positive ionotropic effect; control: without title comp.; ferrets injected with reserpine (1 mg/kg, i.m.) for the depletion of catecholamines

Results

title comp. at higher conc. (>1E-5 mol/l) manifested NIE with decreased calcium signal; title comp. failed to show signif. PIE; diagram

Reference

Ishiguro, Yoshiki; Morgan, James P.

Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

inotropic neg.

Species or TestSystem (Pharmacological Data)

ferret papillary right ventricle muscle

Sex

male


153 of 172

154 of 172

Concentration (Pharmacological Data)

0.0002 mol/l

Kind of Dosing (Pharmacological Data)

title comp. dissolved in deionized water

Method (Pharmacological Data)

test system bathed in physiological soln.; treated with calcium/histamine/isoproterenol with/without title comp.; tension response measured; dose-response curve to histamine, calcium, isoproterenol with/without title comp. plotted

Further Details (Pharmacological Data)

NIE: negative inotropic effect; inotropic agents: isoproterenol (1E-9 - 1E-5 mmol/l); histamine (1E-8 - 1E-4 mmol/l); calcium (0.7 - 8 mmol/l); MEC: minimally effective concentration

Results

title comp. did not shift dose-response curves to calcium or histamine signif., but signif. altered isoproterenol by shifting MEC without affecting the conc. at which maximal effect was obtained; diagram

Reference

Ishiguro, Yoshiki; Morgan, James P.

Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

ddY mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 mg/kg

Method (Pharmacological Data)

title compd. dissolved in isotonic saline; behavioural symptoms (linear locomotion, circling, rearing and grooming) measured in Animex II apparatus, evaluated by PC

Results

marked behavioural sensitization

Reference

Toyoshi, Tohru; Ukai, Makoto; Kameyama, Tsutomu

Biological and Pharmaceutical Bulletin, 1996 , vol. 19, # 3 p. 369 - 374 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

HSD Wistar rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

0.1 - 1 mg/kg

Kind of Dosing (Pharmacological Data)

30 min before measurement

Method (Pharmacological Data)

rats treated with title comp.; killed; release of biogenic amines from brain samples <striatum, substantia nigra, tuberculum olfactorium (dopamine), lobus coeruleus (noradrenaline) and raphe (serotonin)> measured

Further Details (Pharmacological Data)

compared with the activity of desmethylimipramine (DMI, 0.25 - 5.0 mg/kg), (-)- and (+)deprenyl (0.01 - 0.25 mg/kg) ()methamphetamine (0.1 - 1.0 mg/kg)

Comment (Pharmacological Data)

No effect

Reference

Knoll; Miklya; Marko; Kelemen

Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details


155 of 172

156 of 172

157 of 172

Effect (Pharmacological Data)

drug interaction

Species or TestSystem (Pharmacological Data)

dd mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10.8 μmol/kg

Method (Pharmacological Data)

6 week-old mice; ambulation activity generated by slight tilt of cage; effect of title comp. on ambulation activity after pretreatment (5 times at 3 d intervals) with 1.4-47.2 μmol/kg s.c. CMMA

Further Details (Pharmacological Data)

CMMA (= N-cyanomethylmethamphetamine HCl) accelerated ambulation activity

Results

cross-sensitization between title comp. and MAP (activity counts were significantly higher in 14.2-47.2 μmol/kg-pretreated mice, 1.4 and 4.7 μmol/kg pretreatment had no effect); graphical representations

Reference

Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji

Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

dd mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10.8 μmol/kg

Kind of Dosing (Pharmacological Data)

5 repeated admin. at 3 d intervals

Method (Pharmacological Data)

6-week-old mice; ambulation activity generated by slight tilt of cage and measured for 3 h after administration

Results

accelerated ambulation (ca. 2.0 times higher activity counts in 5th admin. than in 1st, respectively); graphical representations

Reference

Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji

Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

dd mouse

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2 mg/kg

Kind of Dosing (Pharmacological Data)

single dose repeated three times at 3, 6, 12, 24 or 48 h, then 2 times at intervals of 3 days

Method

25-28 g, 6-week-old mice (T=23 deg C; R.H.=55 percent; 12 h light/dark cycle); after treatment ambulatory activity (AA) of mice


158 of 172

159 of 172

160 of 172

(Pharmacological Data)

measured with an ambulometer for 3 h

Further Details (Pharmacological Data)

effect of interdose interval on ambulatory sensitization (increase of AA on repeated doses) studied

Results

interdose interval of 24 h or longer is required for induction of ambulatory sensitization (graph)

Reference

Kuribara, Hisashi

European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 6 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

drug dependence

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

1 - 4 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline

Method (Pharmacological Data)

IM induced in rat paw by formalin (2.5 percent, 50 μl), λ-carrageenan (1 percent, 100 μl) or vehicle (100 μl); title comp. admin.; conditioned in SB at first, fifth, or fourteenth day after IM induction; after conditioning TS in each compartment measured by IBS

Further Details (Pharmacological Data)

control: vehicle (saline, 1 ml/kg, i.p.); conditioning sessions conducted once daily for 50 min; IM: inflammation; SB: shuttlebox; IBS: infrared beam sensor; TS: time spent

Results

title comp. produced a dose-related place preference; it showed significant conditioning at 1, 2 and 4 mg/kg; no effect in presence of induced inflammation; diagram

Reference

Suzuki, Tsutomu; Kishimoto, Yayoi; Misawa, Miwa

Life Sciences, 1996 , vol. 59, # 19 p. 1667 - 1674 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

effect on cocaine self-administration

Species or TestSystem (Pharmacological Data)

Fischer F-344 rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

3.2 mg/kg

Kind of Dosing (Pharmacological Data)

chronic adm. 0.32, 1.0 and 3.2 mg/kg/12 hr for 7 days; dissolved in 0.9 percent saline

Method (Pharmacological Data)

Fischer F-344 rats (270 g) were implanted with indwelling jugular catheters and were trained to self-adm. cocaine under a progressiveratio (PR) schedule of reinforcement; 0.028-0.25 mg/inj. of cocaine

Further Details (Pharmacological Data)

the number of reinforcers obtained was measured

Results

chronic treatment shifted the dose-response curve for breaking points significantly to the right

Reference

Peltier; Li; Lytle; Taylor; Emmett-Oglesby

Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological

effect on cocaine self-administration


Data)

161 of 172

162 of 172

Species or TestSystem (Pharmacological Data)

Fischer F-344 rat

Sex

male

Concentration (Pharmacological Data)

0.32 - 3.2 mg/kg

Kind of Dosing (Pharmacological Data)

chronic adm. 0.32, 1.0 and 3.2 mg/kg/12 hr for 7 days; dissolved in 0.9 percent saline

Method (Pharmacological Data)

Fischer F-344 rats (270 g) were implanted with an indwelling catheter inserted into the right external jugular; after 5 days were given opportunity to FR2 self-administer cocaine (0.125-0.5 mg/infusion)

Further Details (Pharmacological Data)

interreinforcer time (min) measured; FR2 = fixed-ratio 2 schedule of reinforcement

Results

chronic treatment shifted the cocaine self-administration curve to the right (diagram, table given)

Reference

Peltier; Li; Lytle; Taylor; Emmett-Oglesby

Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

effect on the discrimination of cocaine

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

0.32 - 3.2 mg/kg

Kind of Dosing (Pharmacological Data)

chronic adm. 0.32, 1.0 and 3.2 mg/kg/12 hr for 7 days; dissolved in 0.9 percent saline

Method (Pharmacological Data)

Sprague-Dawley rats (330 g) trained to discriminate 10 mg/kg (i.p.) of cocaine from saline with food as a reinforcer, using a cumulative dose testing procedure (1.0-17.8 mg/kg of cocaine)

Further Details (Pharmacological Data)

cocain-lever responding ( percent) determined

Type (Pharmacological Data)

EC50

Value of Type (Pharmacological Data)

16.67 mg/kg

Results

chronic adm. of title comp. resulted in cross-tolerance to the discriminative stimulus effects in cocaine; ED50 = 3.84 mg/kg (base-line) (table, diagram given)

Reference

Peltier; Li; Lytle; Taylor; Emmett-Oglesby

Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

human

Sex

male and female

Route of Application

intravenous


163 of 172

164 of 172

Concentration (Pharmacological Data)

30 mg

Kind of Dosing (Pharmacological Data)

ethanol (or placebo) in 6 drinks of fruit juice over 30 min; title comp. (or placebo) 60 min after the first drink in 0.9 percent NaCl

Exposure Period (Pharmacological Data)

48 h

Method (Pharmacological Data)

8 users (7 men and 1 woman) of title comp. and ethanol, 24-38 year; double-blind, double-placebo, Latin-square design; subjective and neuropsychological effects of drug combination with ethanol

Further Details (Pharmacological Data)

title comp. and amphetamine in plasma and urine by GC for 48 h; urine collected 48 h; data analyzed by repeated-measures ANOVA

Results

pharmacokinetics not altered by concurrent adm. of etahanol with the exception of lowering the apperent volume of distribution for the title comp. at steady state

Reference

Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton

Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

sympathomimetic

Species or TestSystem (Pharmacological Data)

human

Sex

male and female

Route of Application

intravenous

Concentration (Pharmacological Data)

30 mg

Kind of Dosing (Pharmacological Data)

ethanol (or placebo) in 6 drinks of fruit juice over 30 min; title comp. (or placebo) 60 min after the first drink in 0.9 percent NaCl

Exposure Period (Pharmacological Data)

48 h

Method (Pharmacological Data)

8 users (7 men and 1 woman) of title comp. and ethanol 24-38 year; double-blind, double-placebo, Latin-square design; subjective and neuropsychological effects of drug combination with ethanol

Further Details (Pharmacological Data)

title comp. and amphetamine in plasma and urine by GC for 48 h; urine collected 48 h; data analyzed by repeated-measures ANOVA

Results

title comp. alone increased alertness, relaxation, stimulation, euphoria, sensory awareness; no change in these subjective effects on concurrent adm. of ethanol

Reference

Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton

Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

cardiovascular

Species or TestSystem (Pharmacological Data)

human

Sex

male and female

Route of Application

intravenous

Concentration (Pharmacological Data)

30 mg

Kind of Dosing (Pharmacological

ethanol (or placebo) in 6 drinks of friut juice over 30 min; title comp. (or placebo) 60 min after the first drink in 0.9 percent NaCl


Data)

165 of 172

166 of 172

167 of 172

Exposure Period (Pharmacological Data)

420 min

Method (Pharmacological Data)

8 users (7 men and 1 woman) of title comp. and ethanol, 24-38 year; double-blind, double-placebo, Latin-square design; systolic and diastolic blood pressure, heart rate, rate pressure product; breath ethanol concn. by IR

Results

increased systolic blood-pressure; minimal change in heart rate; concurrent adm. of ethanol increased heart rate, decreased systolic blood pressure; increase in rate pressure product, cardiac work index and myocardial oxygen consumption

Reference

Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton

Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Wistar-King rat

Sex

male

Route of Application

subcutaneous

Kind of Dosing (Pharmacological Data)

1 mg/kg for 10 days, then 7-8 day withdrawal, then single 0.5 mg/kg

Method (Pharmacological Data)

animals weighing 200-250 g housed individually, 12 h dark/light cycle, 24 deg C, 50 percent humidity, free access to standard diet and water

Results

significantly enhanced motor activity

Reference

Ohmori, T.; Abekawa, T.; Koyama, T.

Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1230 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

agonist

Species or TestSystem (Pharmacological Data)

Fischer-344 rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

10 mg/kg

Method (Pharmacological Data)

effect of title comp. on rectal temperature measured by YSI tele-thermometer

Results

title comp. caused significant increase in body temperature at 2.5 h after inj. which was gradually declined and returned to basal level at ca. 5 h

Reference

Bronstein; Hong

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

toxicity

Endpoint of Effect (Pharmacological Data)

death

Species or TestSystem (Pharmacological Data)

rat

Sex

male


168 of 172

169 of 172

Route of Application

subcutaneous

Concentration (Pharmacological Data)

5 - 40 mg/kg

Method (Pharmacological Data)

Fischer-344 and Sprague-Dawley rats; number of deaths determined in the 48 h following administration

Further Details (Pharmacological Data)

LD50 refers to Srague-Dawley rats

Type (Pharmacological Data)

LD50

Value of Type (Pharmacological Data)

10.4 mg/kg

Results

title comp. produced dose-dependent lethality in both strains of rats (no lethality at 5 mg/kg, 100 percent lethality at 20 mg/kg or greater); majority of death occurred within 3-4 h

Reference

Bronstein; Hong

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

sensitization

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.5 - 5 mg/kg

Kind of Dosing (Pharmacological Data)

daily inj. at 14:00 for 6, 13 or 20 consecutive days

Method (Pharmacological Data)

rats weighing 200 to 250 g; housed individually; 12 h light-dark cycle; T: 23 deg C; food and water ad libitum; title comp. inj. withdrawn on day 7, 14 or 21; locomotor activity measured from 14:00 to 17:00 on the withdrawal day

Further Details (Pharmacological Data)

DA, dopamine; NMDA, N-methyl-D-aspartate

Results

daily inj. of title comp. for 6 consec. days was sufficient to produce an increase of anticipatory activity in a dose-dependent manner (0.5 to 2 mg/kg, but moderate at 5 mg/kg); DA, NMDA and sigma receptor mechanisms are involved in the effect

Reference

Shibata; Ono; Fukuhara; Watanabe

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 688 - 694 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

1 - 5 mg/kg

Kind of Dosing (Pharmacological Data)

in 0.9 percent saline


170 of 172

171 of 172

Method (Pharmacological Data)

femoral vein of rats (300-325g) was cannulated; dialysate samples were collected for 90 min postdrug injection; blood samples were collected before sacrifice 5,10,20,30,40 and 60 min; HPLC; brain tissues were analysis with GC/MS

Further Details (Pharmacological Data)

determination of plasma or striatum content of title comp. vs. time; determination of striatum/plasma content ratio vs. time; determination of drug-induced dopamine efflux profiles

Results

title comp. and D-amphetamine on the strital dopamine system were equipotent and pharmacokinetic (and pharmacodynamic) profiles of each drug were similar

Metabolite (Pharmacological Data)

3,4-dihydroxyphenylacetate [Reaxys RN: 2211017] ; 5-Hydroxyindole-3-acetic acid [Reaxys RN: 168797] ; Homovanillic acid [Reaxys RN: 2213447]

Reference

Melega; Williams; Schmitz; DiStefano; Cho

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 1 p. 90 - 96 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

Swiss Webster mice

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

5 - 10 mg/kg

Kind of Dosing (Pharmacological Data)

10, 10, 5 and 5 mg/kg (four injection i.p.) at 2-hr intervals

Method (Pharmacological Data)

mice received four injections of title comp. at 2-h intervals, other groups injected with saline (control); colonic temp. recorded 30 min before the first injection of title comp. and 1 h after each title comp. injection

Further Details (Pharmacological Data)

mice sacrificed 7 days later, both neostriata removed and assayed for dopamine (DA) and for its metabolites by HPLC-electrochemical detection; neostriatal tyrosine hydroxylase (TH) activity measured by a radioenzymatic technique

Results

striatal TH activity and DA content were decreased by 57 and 68 percent seven days, after treatment with title comp. (TH activity 43 percent title comp.; 100 percent saline treatment)

Reference

Albers; Sonsalla

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 275, # 3 p. 1104 - 1114 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neurotoxicity

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

4 doses spaced 1 h apart

Method (Pharmacological Data)

in vivo; effect on brain 5-HT, 5-HIAA and DA level assayed; rats weighed 225-250 g; kept in individual cages at 20-22 deg C under 12 h light/dark cycle with free access to food and water; rats killed 72 h after treatment; brain removed

Further Details (Pharmacological Data)

striatum and hippocampus dissected; 5-HT, 5-HIAA and DA levels in striatum and hippocampus measured by HPLC; 5-HT: serotonin; 5HIAA: 5-hydroxyindole acetic acid; DA: dopamine

Results

in hippocampus title comp. decreased 5-HT/5-HIAA levels to 42/59 percent of control; title comp. decreased also striatal DA level

Reference

Farfel; Seiden


Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details

172 of 172

Effect (Pharmacological Data)

hyperthermic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

10 mg/kg

Kind of Dosing (Pharmacological Data)

4 doses given with 1 h intervals

Method (Pharmacological Data)

in vivo; effect on body temp. assayed; rats weighed 225-250 g; kept in individual cages at 20-22 deg C under 12 h light/dark cycle with free access to food and water; rats implanted with temp.-sensitive radiotransmitter into intraperitoneal cavity

Further Details (Pharmacological Data)

body temp. measured for at least 4 h after treatment

Results

title comp. increased core body temp. to 3.6 deg C above base-line at 300 min after the first dose of title cmop. and body temp. returned to base-line level by the next day; graphical representation

Reference

Farfel; Seiden

Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details

Ecotoxicology (1) 1 of 1

Effect (Ecotoxicology)

toxicity to invertebrates

Species or TestSystem (Ecotoxicology)

Daphnia pulex Leydig

Concentration (Ecotoxicology)

1 - 1000 mg/l

Method (Ecotoxicology)

Daphnia incub. with title comp. in freshwater (17-21 deg C; 24 h; in a darkbox); number of Daphnia immobile counted; mean mortalities calculated; EC50 determined using regression analysis

Type (Ecotoxicology)

EC50

Value of Type (Ecotoxicology)

109.5 mg/l

Reference

Morrow; Corrigan; Waldren

Planta Medica, 2001 , vol. 67, # 9 p. 843 - 846 Title/Abstract Full Text View citing articles Show Details

Other Data Use (5) Use Pattern

Location

Reference

Pharmaceuticals

Page/Page column title page; 26

CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.

Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details

attention deficit hyperactive disorder (ADHD)

Page/Page column title page; 26

CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.

Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details

treatment of attention deficit disorder (ADD)

Page/Page column title page; 26

CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.

Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details


Drug

HISAMITSU PHARMACEUTICAL CO., INC.

Patent: EP1541177 A1, 2005 ;

Title/Abstract Full Text Show Details

a stimulan-antihypnotic agent

HISAMITSU PHARMACEUTICAL CO., INC.

Patent: EP1541177 A1, 2005 ;

Title/Abstract Full Text Show Details

Chemical Name: (R)-2-N-methylamino-1-phenylpropane hydrochloride Reaxys Registry Number: 5617071

CAS Registry Number: 826-10-8 Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697

InChI Key: TWXDDNPPQUTEOV-SBSPUUFOSA-N

42

1 prep out of 3 reactions.

Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-2-N-methylamino-1-phenylpropane hydrochloride, (R)-N-methyl-1-phenylpropan-2-amine hydrochloride, (R)-(-)-methamphetamine hydrochloride, (-)-methamphetamine hydrochloride, methamphetamine hydrochloride, Methamphtamine hydrochloride, (R)-(-)-methamphetamine HCl Identification Substance Label (6) Label

Reference

ent-4

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

I

Colucid Pharmaceuticals, Inc.

Patent: US2010/256229 A1, 2010 ; Title/Abstract Full Text Show Details

R-(-)-METH; - METH

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Merck Index 6015

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

MERCK 6015

Knoll, Joseph; Miklya, Ildiko

Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text View citing articles Show Details

(R)-4a*HCl

Takashashi; Chida; Higashiyama; Onishi

Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (3) Melting Point

Solvent (Melting Point)

Reference

165 - 166 °C

ethanol diethyl ether

Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall

Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details

Identification Physical Data (6) Bioactivity (12)

15


171 - 173 °C

Takashashi; Chida; Higashiyama; Onishi

Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details

170 - 171 °C

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Optical Rotatory Power (3) Type (Optical Rotatory Power)

Concentration (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

Temperature (Optical Rotatory Power)

[alpha]

1g/100ml

water

17.51 deg

589 nm

[alpha]

0.52 g/100ml

H2O

-16.3 deg

[alpha]

-14.8 deg

Location

Reference

25 °C

supporting information

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

589 nm

Takashashi; Chida; Higashiyama; Onishi

Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details

589 nm

22 °C

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Bioactivity Pharmacological Data (12) 1 of 12

Comment (Pharmacological Data)

Bioactivities present

Reference

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Takashashi; Chida; Higashiyama; Onishi

Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details

Nomura; Yotsumoto; Oki

Journal of Pharmacy and Pharmacology, 1981 , vol. 33, # 4 p. 264 - 266 Title/Abstract Full Text View citing articles Show Details

Chafetz; Desai; Sukonik

Journal of Pharmaceutical Sciences, 1994 , vol. 83, # 9 p. 1250 - 1252 Title/Abstract Full Text View citing articles Show Details

Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall

Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details

Knoll, Joseph; Miklya, Ildiko

Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text View citing articles Show Details

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

Knoll; Miklya; Marko; Kelemen

Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Colucid Pharmaceuticals, Inc.

Patent: US2010/256229 A1, 2010 ; Title/Abstract Full Text Show Details

Knoll; Miklya; Marko; Kelemen

Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text Show Details

Knoll, Joseph; Miklya, Ildiko

Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text Show Details


Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.

Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details

Lalwani, Komal G.; Sudalai, Arumugam

Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details

Cheong, Jae Hoon; Choi, Mee Jung; Jang, Choon-Gon; Lee, Yong Sup; Lee, Sooyeun; Kim, Hee Jin; Seo, Joung-Wook; Yoon, Seong Shoon

Psychopharmacology, 2017 , vol. 234, # 5 p. 857 - 867 Title/Abstract Full Text Show Details

2 of 12

3 of 12

4 of 12

5 of 12

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Cheong, Jae Hoon; Choi, Mee Jung; Jang, Choon-Gon; Lee, Yong Sup; Lee, Sooyeun; Kim, Hee Jin; Seo, Joung-Wook; Yoon, Seong Shoon

Psychopharmacology, 2017 , vol. 234, # 5 p. 857 - 867 Title/Abstract Full Text Show Details

Comment (Pharmacological Data)

physiological behaviour discussed

Reference

Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.

Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

agonist

Species or TestSystem (Pharmacological Data)

human embryonic kidney 293 cells

Concentration (Pharmacological Data)

Ca. 5E-09 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water

Method (Pharmacological Data)

effect of title comp. on rTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted

Further Details (Pharmacological Data)

data normalized to maximal level produced in response to PEA; cells expressing rTAAR1; rTAAR: rat trace amine-associated receptor; PEA: β-phenylethylamine

Type (Pharmacological Data)

EC50

Value of Type (Pharmacological Data)

1.19 μmol/l

Results

title comp. dose-dependently stimulated cAMP production and was partial agonist (75.05percent PEAmax) (table, figure)

Reference

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

agonist

Species or TestSystem (Pharmacological Data)

human embryonic kidney 293 cells

Concentration (Pharmacological Data)

Ca. 5E-09 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water

Method (Pharmacological

effect of title comp. on mTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted


Data)

6 of 12

7 of 12

Further Details (Pharmacological Data)

data normalized to maximal level produced in response to PEA; cells expressing mTAAR1; mTAAR: mouse trace amine-associated receptor; PEA: β-phenylethylamine

Type (Pharmacological Data)

EC50

Value of Type (Pharmacological Data)

2.44 μmol/l

Results

title comp. dose-dependently stimulated cAMP production and was full agonist (91.33percent PEAmax) (table, figure)

Reference

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

agonist

Species or TestSystem (Pharmacological Data)

human embryonic kidney 293 cells

Concentration (Pharmacological Data)

Ca. 5E-09 - 0.001 mol/l

Kind of Dosing (Pharmacological Data)

title comp. was dissolved in water

Method (Pharmacological Data)

effect of title comp. on h-rChTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted

Further Details (Pharmacological Data)

data normalized to maximal level produced in response to PEA; cells expressing h-rChTAAR1; h-rChTAAR: human-rat chimera trace amineassociated receptor; PEA: β-phenylethylamine

Type (Pharmacological Data)

EC50

Value of Type (Pharmacological Data)

9.83 μmol/l

Results

title comp. dose-dependently stimulated cAMP production and was full agonist (91.55percent PEAmax) (table, figure)

Reference

Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.

Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

pharmacokinetics

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rats

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

2.5 - 20 mg/kg

Method (Pharmacological Data)

animals were sacrified by decapitation at 10-60 min after title comp. administration, caudate-putamen, cortex, and cerebellum were dissected, fozen in liquid N2, and stored at -70 deg C; plasma samples were obtained from trunk blood

Further Details (Pharmacological Data)

tissue sample was homogenized, centrifuged, alkalinized (Na2CO3) and extracted with i-PrOH-CH2Cl2 mixture and processed for GC/MS analysis; plasma sample was alkalinized and extracted similarly, derivatized with (CF3CO)2O in MeCN and analyzed by GC/MS

Results

area under tissue conc. versus time curve (AUC) of title comp. in caudate putamen from 0 to 60 min after dose of 2.5 and 20 mg/g were 795 and 4875 nmol/g*min, resp.; diagram is given

Reference

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.


Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

8 of 12

9 of 12

10 of 12

Effect (Pharmacological Data)

biotransformation

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rats

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

20 mg/kg

Method (Pharmacological Data)

animals were sacrified by decapitation at 5-50 min after title comp. administration, caudate-putamen, cortex, and cerebellum were rapidly dissected, fozen in liquid nitrogen, and stored at -70 deg C until analyzed

Further Details (Pharmacological Data)

tissue sample was homogenized and centrifuged, supernatant was alkalinized (Na2CO3) and extracted with isopropanol-dichloromethane mixture and processed for GC/MS analysis

Results

relative to striatal levels of title comp., l-amphetamine caudate-putamen levels ranged from 5 to 10 percent, whereas p-hydroxy-lmethamphetamine levels were less than 0.25 percent; diagrams are given

Metabolite (Pharmacological Data)

l-amphetamine [Reaxys RN: 2432739] ; (-)-p-Hydroxymethamphetamine [Reaxys RN: 3197900]

Reference

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

releasing hormones

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rats

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

20 mg/kg

Method (Pharmacological Data)

dialysis probe was inserted into caudate-putamen via previously implanted cannula and was perfused, after stable baseline levels were obtained for DA, DOPAC, HVA, 5-HIAA, title comp. was administered and dialysate samples were collected for 90 min

Further Details (Pharmacological Data)

dialysate samples were analyzed by HPLC with electrochemical detector; dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA)

Results

extracellular conc. of DA and its metabolites were increased; area under microdialysate DA conc. versus time curve (AUC 0-60 min) of 21.120 nM*l/min; diagrams are given

Reference

Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.

Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

transmitter releasing

Species or TestSystem (Pharmacological Data)

HSD Wistar rat

Sex

male

Route of Application

subcutaneous

Concentration

0.1 - 1 mg/kg


(Pharmacological Data)

11 of 12

12 of 12

Kind of Dosing (Pharmacological Data)

30 min before measurement

Method (Pharmacological Data)

rats treated with title comp.; killed; release of biogenic amines from brain samples <striatum, substantia nigra, tuberculum olfactorium (dopamine), lobus coeruleus (noradrenaline) and raphe (serotonin)> measured

Further Details (Pharmacological Data)

compared with the activity of desmethylimipramine (DMI, 0.25 - 5.0 mg/kg), (-)- and (+)deprenyl (0.01 - 0.25 mg/kg) (+)methamphetamine (0.1 - 1.0 mg/kg)

Results

title comp. enhanced activity of noradrenergic and dopaminergic neurons (table III)

Reference

Knoll; Miklya; Marko; Kelemen

Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

neuroregulatoric

Species or TestSystem (Pharmacological Data)

Wistar rat

Sex

male

Route of Application

subcutaneous

Concentration (Pharmacological Data)

0.05 mg/kg

Exposure Period (Pharmacological Data)

21 d

Method (Pharmacological Data)

after treatment, sexualy highly active rats decapitated, brain samples removed, held in Krebs solution (37 deg C, 5 percent CO2); 2x20 min incubation in Krebs-solution

Further Details (Pharmacological Data)

dopamine (D) released from striatum (ST), substantia nigra (SN), tuberculum olfactorum (TO); noradrenaline (NA) from locus coeruleus (LC), serotonin (5-HT) from raphe (R) determined by HPLC

Results

significant enhancement of resting release of catecholamines (D, NA); decrease of S

Reference

Knoll, Joseph; Miklya, Ildiko

Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

locomotor stimulating action (rat)

Reference

Nomura; Yotsumoto; Oki

Journal of Pharmacy and Pharmacology, 1981 , vol. 33, # 4 p. 264 - 266 Title/Abstract Full Text View citing articles Show Details

Chemical Name: (+)-methamphetamine hydrochloride Reaxys Registry Number: 6489321

Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697

InChI Key: TWXDDNPPQUTEOV-UHFFFAOYSA-N

43

Synthesize | Hide Details Find similar

no reactions.

Identification Spectra (2) Bioactivity (9)

5


Chemical Names and Synonyms (+)-methamphetamine hydrochloride, (+)-Metamfetamin Hydrochlorid, methamphetamine hydrochloride Identification Substance Label (2) Label

Reference

METH

Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details

1-HCl

Neugebauer

Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details

Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)

Nucleus (NMR Spectroscopy)

Solvents (NMR Spectroscopy)

Chemical shifts

1H

dimethylsulfoxide-d6

Reviriego, Felipe; Navarro, Pilar; Domenech, Antonio; Garcia-Espana, Enrique

Journal of the Chemical Society, Perkin Transactions 2, 2002 , # 9 p. 1634 1638 Title/Abstract Full Text View citing articles Show Details

Chemical shifts

13C

dimethylsulfoxide-d6

Reviriego, Felipe; Navarro, Pilar; Domenech, Antonio; Garcia-Espana, Enrique

Journal of the Chemical Society, Perkin Transactions 2, 2002 , # 9 p. 1634 1638 Title/Abstract Full Text View citing articles Show Details

Reference

Bioactivity Pharmacological Data (9) 1 of 9

2 of 9

Comment (Pharmacological Data)

Bioactivities present

Reference

Ueno; Kitagawa; Kohei; Furukawa; Kushiku

Arzneimittel-Forschung/Drug Research, 1986 , vol. 36, # 3 A p. 560 - 567 Title/Abstract Full Text View citing articles Show Details

Neugebauer

Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details

Kim; Kang; Rheu; Cho; Oh

Planta Medica, 1995 , vol. 61, # 1 p. 22 - 25 Title/Abstract Full Text View citing articles Show Details

Reviriego, Felipe; Navarro, Pilar; Domenech, Antonio; Garcia-Espana, Enrique

Journal of the Chemical Society, Perkin Transactions 2, 2002 , # 9 p. 1634 - 1638 Title/Abstract Full Text View citing articles Show Details

Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

cardiovascular

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

3 mg/kg

Kind of Dosing

title comp. was administered over 10 to 15 s in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10


3 of 9

4 of 9

(Pharmacological Data)

days

Method (Pharmacological Data)

rats were administered with title comp.; mean arterial blood pressure and heart rate (HR) recorded for 1 h after each dosing

Further Details (Pharmacological Data)

control: normal saline

Results

pressor response elicited by first three doses of title comp. in second/third binges were signif. larger than those elicited by corresponding doses in first binge; HR responses elicited by title comp. were similar within and among three binges; table

Reference

Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

cardiovascular

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

3 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. was administered in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10 days

Method (Pharmacological Data)

rats were administered with title comp.; acetylcholine, sodium nitroprusside (SN) and isoproterenol admin. i.v. before each binge and 10 days after last binge; mean arterial blood pressure and heart rate (HR) recorded

Further Details (Pharmacological Data)

control: normal saline

Results

10 days after last title comp. binge, depressor responses elicited by SN, isoproterenol, acetylcholine were signif. smaller than those elicited before each binge; no signif. differences in magnitude of HR elicited by SN/isoproterenol/acetylcholine; fig.

Reference

Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

cardiovascular

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

3 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. administered over 10 to 15 s in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10 days

Method (Pharmacological Data)

rats were administered with title comp.; 5-hydroxytryptamine (5-HT) or phenylephrine administered i.v. before each binge and 10 days after last binge; mean arterial blood pressure and heart rate (HR) recorded

Further Details (Pharmacological Data)

control: normal saline

Results

title comp. treatment did not affect HR responses elicited by 5-HT although they were markedly reduced 10 days after last binge; no signif. differences in either mean arterial blood pressure or heart rate responses elicited by phenylephrine; diagram

Reference

Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne


Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details

5 of 9

6 of 9

7 of 9

8 of 9

9 of 9

Effect (Pharmacological Data)

cardiovascular

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intravenous

Concentration (Pharmacological Data)

3 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. administered over 10 to 15 s in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10 days

Method (Pharmacological Data)

rats were administered with title comp.; 1 day after each binge, 4 rats were sacrificed; hearts removed; histological studies performed

Further Details (Pharmacological Data)

control: saline

Results

hearts from title comp.-treated rats showed focal inflammatory infiltrates with abundant monocytes and occasional necrotic foci; no pathologic fibrosis observed; photo, table

Reference

Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne

Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

application to albumen of embryonated hen's eggs: application on first day of incubation: LD 50: 12.7 mg at 12. day and 10.4 mg at 17. day of incubation; application on sixth day of incubation: LD 50: 7.0 mg at 12. and 6.4 mg at 17. day of incubation

Reference

Neugebauer

Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

in vivo ambulation-accelerating activity in male mice

Reference

Kim; Kang; Rheu; Cho; Oh

Planta Medica, 1995 , vol. 61, # 1 p. 22 - 25 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

metabolism after application to the albumen of embryonated hen's eggs: application of 4 to 16 mg at the first or sixth day of incubation; analysis between the 8. and 18. day of incubation

Reference

Neugebauer

Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details

Comment (Pharmacological Data)

influence on locomotor activity (5 mg/kg s.c.) and chewing behaviour in rats (16 mg/kg i.v.)

Reference

Ueno; Kitagawa; Kohei; Furukawa; Kushiku

Arzneimittel-Forschung/Drug Research, 1986 , vol. 36, # 3 A p. 560 - 567 Title/Abstract Full Text View citing articles Show Details

Chemical Name: d-methamphetamine hydrochloride

44

Reaxys Registry Number: 8159451

Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*ClH Molecular Weight: 185.697

InChI Key: TWXDDNPPQUTEOV-UHFFFAOYSA-N

no reactions.

Identification Bioactivity (6)

2


Synthesize | Hide Details Find similar Chemical Names and Synonyms d-methamphetamine hydrochloride, d-metamphetamine hydrochloride Identification Substance Label (1) Label

Reference

d-MP hydrochloride

Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi

Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (6) 1 of 6

2 of 6

Comment (Pharmacological Data)

Bioactivities present

Reference

Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi

Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details

Ohno; Watanabe

European Journal of Pharmacology, 1995 , vol. 275, # 1 p. 39 - 44 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

metabolic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat CYP2C13 isozymes

Sex

male

Concentration (Pharmacological Data)

1 mmol/l

Exposure Period (Pharmacological Data)

10 min

Method (Pharmacological Data)

in vitro; rats 340-350 g; title comp. incubated 37 deg C, pH 7.4 with 0.1 nmol test subst., 0.8 unit NADPH-P450 reductase, 15 μg dilauroylphosphatidylcholine

Further Details (Pharmacological Data)

substrate specificity, P450 enzyme activity of deamination

Results

10.3 nmol P450/mg protein; metabolic product, nmol/min/nmol P450: formaldehyde 4.52

Reference

Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi

Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72


Title/Abstract Full Text View citing articles Show Details

3 of 6

4 of 6

5 of 6

Effect (Pharmacological Data)

metabolic

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat CYP2C11 isozymes

Sex

male

Concentration (Pharmacological Data)

1 mmol/l

Exposure Period (Pharmacological Data)

10 min

Method (Pharmacological Data)

in vitro; rats 340-350 g; title comp. incubated 37 deg C, pH 7.4 with 0.1 nmol test subst., 0.8 unit NADPH-P450 reductase, 15 μg dilauroylphosphatidylcholine

Further Details (Pharmacological Data)

substrate specificity, P450 enzyme activity of deamination

Results

12.3 nmol P450/mg protein; metabolic products, nmol/min/nmol P450: formaldehyde 6.46, phenylacetone 0.42

Reference

Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi

Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

metabolic

Species or TestSystem (Pharmacological Data)

New Zealand White rabbit CYP2C3 isozymes

Sex

male

Concentration (Pharmacological Data)

1 mmol/l

Exposure Period (Pharmacological Data)

10 min

Method (Pharmacological Data)

in vitro; rabbits ca. 3 kg; title comp. incubated 37 deg C, pH 7.4 with 0.1 nmol test subst., 0.8 unit NADPH-P450 reductase, 15 μg dilauroylphosphatidylcholine

Further Details (Pharmacological Data)

substrate specificity, P450 enzyme activity of deamination

Results

15.3 nmol P450/mg protein; metabolic products, nmol/min/mg P450: formaldehyde 11.68, phenylacetone 2.14

Reference

Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi

Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

metabolic

Species or TestSystem (Pharmacological Data)

New Zealand White rabbit liver microsomes

Sex

male

Exposure Period (Pharmacological Data)

10 min

Method (Pharmacological

in vitro; rabbits ca. 3 kg; varying conc. title comp. incubated 37 deg C, pH 7.4 with 0.5-1.0 protein of microsomes, NADP; colorimetric and HPLC analysis


Data)

6 of 6

Further Details (Pharmacological Data)

substrate specificity, kinetic parameters of deamination

Results

metabolic products: formaldehyde: Km = 0.148 mM, Vmax = 10.6 nmol/min/mg protein; phenylacetone: Km = 0.045 mM, Vmax = 1.06 nmol/min/mg protein

Reference

Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi

Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

sensitization

Species or TestSystem (Pharmacological Data)

ddY strain mice

Sex

male

Route of Application

intraperitoneal

Kind of Dosing (Pharmacological Data)

chronic: 7 consecutive days 1/d title comp. 1.0 mg/kg, preceded or not by L-NA (10-30), L-NAME (30-100), D-NAME (100), MK-801 (0.2) (all i.p.mg/kg), on day 10: challenge, then test

Exposure Period (Pharmacological Data)

10 d

Method (Pharmacological Data)

25-30 g mice; open-field activity tested 20 min after title comp. challenge (a) acute: 1.0 mg/kg with/without L-NA or L-NAME or D-NAME or MK-801 i.p.; (b) chronic: challenge dose 0.5 mg/kg on day 10 after pretreatment, see kind of dosing

Further Details (Pharmacological Data)

locomotor activation by title comp. and effect of NO-synthase inhibitors NG-nitro-L-arginine (L-NA), its methyl ester (L-NAME), or of NMDA receptor antagonist MK-801; D-NAME = NG-nitro-D-arginine methyl ester

Results

significant increase of locomotor activity by title comp., almost completely blocked by 30 mg/kg L-NA or 100 mg/kg L-NAME both in acute and chronic regimen, by 0.2 mg/kg MK-801 only in chronic regimen; D-NAME had no antagonizing effect

Reference

Ohno; Watanabe

European Journal of Pharmacology, 1995 , vol. 275, # 1 p. 39 - 44 Title/Abstract Full Text View citing articles Show Details

Reaxys Registry Number: 20232066

Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H14(2)HN*ClH

1 prep out of 1 reactions.

1

Chemical Name: acetonitrile ice

no reactions.

1

Molecular Weight: 186.689

InChI Key: TWXDDNPPQUTEOV-XUBZWTSNSA-N

45

Synthesize Find similar

46

Reaxys Registry Number: 30265482

Molecular Formula: C2H3N*C10H15N Linear Structure Formula: C2H3N*C10H15N Molecular Weight: 190.288

InChI Key: XGNXOMUXFOZOSD-FVGYRXGTSA-N


Synthesize | Hide Details Find similar Chemical Names and Synonyms acetonitrile ice Chemical Name: DL-[13C6]-methamphetamine hydrochloride

2 prep out of 2 reactions.

Reaxys Registry Number: 26969006

CAS Registry Number: 1419916-80-5 Molecular Formula: C10H15N*ClH Linear Structure Formula: C4(13)C6H15N*ClH

Identification Physical Data (1) Spectra (4)

2

Molecular Weight: 191.631

InChI Key: TWXDDNPPQUTEOV-XLGVMALESA-N

47

Synthesize | Hide Details Find similar Chemical Names and Synonyms DL-[13C6]-methamphetamine hydrochloride, DL-[13C6]-methamphetamine hydrochloride Identification Substance Label (1) Label

Reference

1b

Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge

Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (1) Melting Point

Reference

133.5 - 134.1 °C

Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge

Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details

Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)

Nucleus (NMR Spectroscopy)

Coupling Nuclei

Solvents (NMR Spectroscopy)

Frequency (NMR Spectroscopy)

Chemical shifts

1H

1H

water-d2

400 MHz

Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge

Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details

Chemical shifts

13C

water-d2

100 MHz

Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge

Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details

Mass Spectrometry (2)

Reference


Description (Mass Spectrometry)

Reference

electron impact (EI) spectrum

Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge

Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details

high resolution mass spectrometry (HRMS) spectrum

Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge

Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details

Chemical Name: formamide ice

no reactions.

1

no reactions.

1

no reactions.

3

Reaxys Registry Number: 30250298

Molecular Formula: CH3NO*C10H15N Linear Structure Formula: CH3NO*C10H15N Molecular Weight: 194.277

InChI Key: XVHFCTKZOSOGDK-FVGYRXGTSA-N

48

Synthesize | Hide Details Find similar Chemical Names and Synonyms formamide ice Chemical Name: methamphetamine ethanol Reaxys Registry Number: 29844919

Molecular Formula: C2H6O*C10H15N Linear Structure Formula: C2H6O*C10H15N Molecular Weight: 195.305

InChI Key: MMYWFWOYXAXTQT-UHFFFAOYSA-N

49

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine ethanol Chemical Name: ice ethyl alcohol Reaxys Registry Number: 29867953

Molecular Formula: C2H6O*C10H15N Linear Structure Formula: C2H6O*C10H15N Molecular Weight: 195.305

InChI Key: MMYWFWOYXAXTQT-FVGYRXGTSA-N

50

Synthesize | Hide Details Find similar Chemical Names and Synonyms


ice ethyl alcohol, ethanol ice, ice ethanol Chemical Name: water methanol ice

no reactions.

1

no reactions.

1

no reactions.

1

no reactions.

1

Reaxys Registry Number: 30655327

Molecular Formula: CH4O*C10H15N*H2O Linear Structure Formula: CH4O*C10H15N*H2O Molecular Weight: 199.293

InChI Key: ZNSBDMQCKXEGEI-WWPIYYJJSA-N

51

Synthesize | Hide Details Find similar Chemical Names and Synonyms water methanol ice Chemical Name: acrylonitrile ice Reaxys Registry Number: 30639273

Molecular Formula: C3H3N*C10H15N Linear Structure Formula: C3H3N*C10H15N Molecular Weight: 202.299

InChI Key: GWXHFJDEYQWKPF-FVGYRXGTSA-N

52

Synthesize | Hide Details Find similar Chemical Names and Synonyms acrylonitrile ice Chemical Name: methamphetamine hydrochloride water Reaxys Registry Number: 30656215

Molecular Formula: C10H15N*ClH*H2O Linear Structure Formula: C10H15N*ClH*H2O Molecular Weight: 203.712

InChI Key: ISNOBPWHINYYAZ-UHFFFAOYSA-N

53

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine hydrochloride water Chemical Name: acrolein ice Reaxys Registry Number: 30671867

Molecular Formula: C3H4O*C10H15N


Linear Structure Formula: C3H4O*C10H15N Molecular Weight: 205.3

InChI Key: ITQWMQLXSRJPKZ-FVGYRXGTSA-N

54

Synthesize | Hide Details Find similar Chemical Names and Synonyms acrolein ice Chemical Name: dry ice acetone

no reactions.

2

no reactions.

1

no reactions.

Spectra (2)

2

Reaxys Registry Number: 30426731

Molecular Formula: C3H6O*C10H15N Linear Structure Formula: C3H6O*C10H15N Molecular Weight: 207.316

InChI Key: HJNNWPJYYQQRKA-FVGYRXGTSA-N

55

Synthesize | Hide Details Find similar Chemical Names and Synonyms dry ice acetone, acetone ice Chemical Name: Sodium chloride ice Reaxys Registry Number: 30432865

Molecular Formula: C10H15N*Cl*Na Linear Structure Formula: C10H15N*Cl(1-)*Na(1+)

Molecular Weight: 207.679

InChI Key: GHYPUHAATGFZBQ-WWPIYYJJSA-M

56

Synthesize | Hide Details Find similar Chemical Names and Synonyms Sodium chloride ice Chemical Name: ice acetic acid Reaxys Registry Number: 22269336

CAS Registry Number: 1246496-41-2 Molecular Formula: C2H4O2*C10H15N Linear Structure Formula: C2H4O2*C10H15N Molecular Weight: 209.288


InChI Key: CLVYMGAXECNXBV-FVGYRXGTSA-N

57

Synthesize | Hide Details Find similar Chemical Names and Synonyms ice acetic acid Spectra Mass Spectrometry (2) Description (Mass Spectrometry)

Reference

CID (collision-induced dissociation) Tandem mass spectrometry Spectrum

Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao

International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details

DESI (desorption electrospray ionization) IT (ion trap) LCMS (Liquid chromatography mass spectrometry) Spectrum

Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao

International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details

Chemical Name: urea ice

no reactions.

1

no reactions.

1

Reaxys Registry Number: 29844013

Molecular Formula: CH4N2O*C10H15N Linear Structure Formula: CH4N2O*C10H15N Molecular Weight: 209.291

InChI Key: GYKPPPOGKMGVKS-FVGYRXGTSA-N

58

Synthesize | Hide Details Find similar Chemical Names and Synonyms urea ice Chemical Name: dry ice propanol

59

Reaxys Registry Number: 30705902

Molecular Formula: C3H8O*C10H15N Linear Structure Formula: C3H8O*C10H15N Molecular Weight: 209.332

InChI Key: XUIIOIDMDMXGNO-FVGYRXGTSA-N


Synthesize | Hide Details Find similar Chemical Names and Synonyms dry ice propanol Chemical Name: ethanethiol ice

no reactions.

1

no reactions.

Physical Data (1)

1

no reactions.

1

Reaxys Registry Number: 30676805

Molecular Formula: C2H6S*C10H15N Linear Structure Formula: C2H6S*C10H15N Molecular Weight: 211.371

InChI Key: JRAWJVFUPHBRAF-FVGYRXGTSA-N

60

Synthesize | Hide Details Find similar Chemical Names and Synonyms ethanethiol ice Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; nitrate Reaxys Registry Number: 6099506

Type of Substance: isocyclic Molecular Formula: C10H15N*HNO3

Linear Structure Formula: C10H15N*HNO3

Molecular Weight: 212.249

InChI Key: YZCCVMSXIRFRPB-SBSPUUFOSA-N

61

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; nitrate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Nitrat Physical Data Melting Point (1) Melting Point

Reference

73 - 74 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: ice nitrate

62

Reaxys Registry Number: 30784604

Molecular Formula: C10H15N*HNO3

Linear Structure Formula: C10H15N*HNO3

Molecular Weight: 212.249

InChI Key: YZCCVMSXIRFRPB-FVGYRXGTSA-N


Synthesize | Hide Details Find similar Chemical Names and Synonyms ice nitrate Chemical Name: Meth methanol

no reactions.

1

no reactions.

2

no reactions.

1

Reaxys Registry Number: 30212679

Molecular Formula: CH4O*C10H15N*ClH Linear Structure Formula: CH4O*C10H15N*ClH Molecular Weight: 217.739

InChI Key: YIVHWUCCLFAUKP-WWPIYYJJSA-N

63

Synthesize | Hide Details Find similar Chemical Names and Synonyms Meth methanol Chemical Name: ice ether Reaxys Registry Number: 30264149

Molecular Formula: C4H10O*C10H15N Linear Structure Formula: C4H10O*C10H15N Molecular Weight: 223.359

InChI Key: BJYJORMDDZABNX-FVGYRXGTSA-N

64

Synthesize | Hide Details Find similar Chemical Names and Synonyms ice ether Chemical Name: silicate ice Reaxys Registry Number: 30053862

Molecular Formula: C10H15N*H2O3Si Linear Structure Formula: C10H15N*H2O3Si Molecular Weight: 227.335

InChI Key: QGFYPZNTXZCRCF-FVGYRXGTSA-N


65

Synthesize | Hide Details Find similar Chemical Names and Synonyms silicate ice Chemical Name: pyrimidine ice

no reactions.

1

no reactions.

Physical Data (1)

1

Reaxys Registry Number: 30839666

Molecular Formula: C4H4N2*C10H15N Linear Structure Formula: C4H4N2*C10H15N Molecular Weight: 229.325

InChI Key: XROJWYNTLKGLPF-FVGYRXGTSA-N

66

Synthesize | Hide Details Find similar Chemical Names and Synonyms pyrimidine ice Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide Reaxys Registry Number: 6118175

Type of Substance: isocyclic Molecular Formula: BrH*C10H15N Linear Structure Formula: C10H15N*BrH Molecular Weight: 230.148

InChI Key: GPMZKGCPEDRJPV-FVGYRXGTSA-N

67

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Hydrobromid Physical Data Melting Point (1) Melting Point

Reference

151 - 153 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161


Full Text Show Details

Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide

no reactions.

Physical Data (1)

1

no reactions.

2

1 prep out of 1 reactions.

Physical Data (2) Spectra (2)

1

Reaxys Registry Number: 6118176

Type of Substance: isocyclic Molecular Formula: BrH*C10H15N Linear Structure Formula: C10H15N*BrH Molecular Weight: 230.148

InChI Key: GPMZKGCPEDRJPV-SBSPUUFOSA-N

68

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Hydrobromid Physical Data Melting Point (1) Melting Point

Reference

151 - 153 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: hexane dry ice Reaxys Registry Number: 30235479

Molecular Formula: C6H14*C10H15N Linear Structure Formula: C6H14*C10H15N Molecular Weight: 235.413

InChI Key: SYLZFKYURFEYGI-FVGYRXGTSA-N

69

Synthesize | Hide Details Find similar Chemical Names and Synonyms hexane dry ice, hexane ice Chemical Name: methamphetamine oxalate Reaxys Registry Number: 20382304

CAS Registry Number: 175166-06-0 Molecular Formula: C2H2O4*C10H15N Linear Structure Formula: C2H2O4*C10H15N Molecular Weight: 239.271

InChI Key: QBHXOBRIGUCDQX-UHFFFAOYSA-N

70

Synthesize | Hide Details


Find similar Chemical Names and Synonyms methamphetamine oxalate, N,α-dimethyl-2-phenylethylamine oxalate Physical Data Melting Point (1) Melting Point

Reference

149 - 151 °C

Schulze, Matthias

Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details

Crystal Property Description (1) Colour & Other Properties

Reference

white

Schulze, Matthias

Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details

Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)

Nucleus (NMR Spectroscopy)

Solvents (NMR Spectroscopy)

Frequency (NMR Spectroscopy)

Chemical shifts

1H

dimethylsulfoxide-d6

300 MHz

Schulze, Matthias

Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details

Chemical shifts

13C

dimethylsulfoxide-d6

75 MHz

Schulze, Matthias

Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details

Chemical Name: phenol ice

Reference

no reactions.

1

no reactions.

Physical Data (1)

1

Reaxys Registry Number: 30418382

Molecular Formula: C6H6O*C10H15N Linear Structure Formula: C6H6O*C10H15N Molecular Weight: 243.349

InChI Key: NPDCNQZQKBYOOQ-FVGYRXGTSA-N

71

Synthesize | Hide Details Find similar Chemical Names and Synonyms phenol ice Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phosphate

Reaxys Registry Number: 6099766

CAS Registry Number: 942068-47-5 Type of Substance: isocyclic Molecular Formula: C10H15N*H3O4P Linear Structure Formula: C10H15N*H3O4P Molecular Weight: 247.231


InChI Key: LERYZJIMAXSLFC-FVGYRXGTSA-N

72

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phosphate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Phosphat Physical Data Melting Point (1) Melting Point

Solvent (Melting Point)

Reference

197 °C

methanol

Temmler-Werke

Patent: DE871155 , 1938 ; Full Text Show Details

Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; sulfate

no reactions.

Physical Data (1)

1

no reactions.

Identification Bioactivity (7)

1

Reaxys Registry Number: 6099911

CAS Registry Number: 17086-30-5, 20189-61-1, 28297-73-6, 2829774-7, 58670-90-9 Type of Substance: isocyclic Molecular Formula: C10H15N*H2O4S Linear Structure Formula: C10H15N*H2O4S Molecular Weight: 247.315

InChI Key: SOBAVQRLBCJNQT-SBSPUUFOSA-N

73

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; sulfate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Sulfat Physical Data Melting Point (1) Melting Point

Reference

122 - 124 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: methamphetamine sulfate

Reaxys Registry Number: 10472660

Type of Substance: isocyclic Molecular Formula: C10H15N*H2O4S Linear Structure Formula: C10H15N*H2O4S Molecular Weight: 247.315

InChI Key: SOBAVQRLBCJNQT-FVGYRXGTSA-N


74

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine sulfate Identification Substance Label (1) Label

Reference

MAP

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details

Bioactivity Pharmacological Data (7) 1 of 7

2 of 7

Comment (Pharmacological Data)

Bioactivities present

Reference

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.3 - 3 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and admin. in a volume of 1 ml/kg

Method (Pharmacological Data)

rats trained under the temporal response differentiation (TRD) 1-1.3 sec schedule; title comp. admin.; after 10 min, effect on number of responses emitted and interresponse times (IRTs) collected as performance indicators during every session

Further Details (Pharmacological Data)

control: saline; illumination of house light in the ceiling, stimulus light above the right lever, signaled the beginning of the sessions; RF: relative frequency; RD: response durations; RDI: response distribution; UW: upward; LW: leftward; CU: curve

Results

title comp. at 0.3 mg/kg, RF of RD increased, as dose increased, RF of RD that were too short, too long to produce the reinforcer increased (progressive flattening of RDI) and CU shifted UW, LW; at higher doses CU did not reach asymptote; diagram

Reference

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details


3 of 7

4 of 7

5 of 7

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.3 - 3 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and admin. in a volume of 1 ml/kg

Method (Pharmacological Data)

rats trained under the temporal response differentiation (TRD) 4-5.2 sec schedule; title comp. admin.; after 10 min, effect on number of responses emitted and interresponse times (IRTs) collected as performance indicators during every session

Further Details (Pharmacological Data)

control: saline; illumination of house light in the ceiling, stimulus light above the right lever, signaled the beginning of the sessions; UW: upward; CU: curve; CFC: cumulative frequency curves; FQ: frequency; SD: short duration; RES: response

Results

title comp. shifted CFC to UW, left without any change in asymptote; at 1.0 mg/kg, increased in FQ of RES of SD; at 1.7 mg/kg, large increased in short RES occurred; at higher doses, more than 50 percent of RES are short causing CU to shifted UW, left; diagram

Reference

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.3 - 3 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and admin. in a volume of 1 ml/kg

Method (Pharmacological Data)

rats trained under the temporal response differentiation (TRD) 10-13 sec schedule; title comp. admin.; after 10 min, effect on number of responses (RES) emitted and interresponse times (IRTs) collected as performance indicators during every session

Further Details (Pharmacological Data)

control: saline; illumination of house light in ceiling, stimulus light above the right lever, signaled the beginning of sessions; UW: upward; LW: leftward; CFD: cumulative frequency distributions; SRD: short RES duration; AS: asymptotic

Results

title comp. at lower doses shifted CFD to UW, LW (little change in AS portion); increased in relative frequency of SRD, CF shifted LW, more pronounced at higher doses; at 1.7 mg/kg, >50 percent of RES occurred; at 3.0 mg/kg, 67 percent of all RES <1 sec; diagram

Reference

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration

0.3 - 5.6 mg/kg


(Pharmacological Data)

6 of 7

7 of 7

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and admin. in a volume of 1 ml/kg

Method (Pharmacological Data)

rats trained under the temporal response differentiation (TRD) 1-1.3 sec schedule; title comp. admin.; after 10 min, effect on accuracy, mean interresponse time and response rate studied

Further Details (Pharmacological Data)

control: saline; MRD: mean response duration; AC: accuracy

Results

title comp. at 1.0 and 3.0 caused dose-dependent decreased in AC with increasing time duration; had no effect on MRD; had no effect on response rates until dose levels reached that eliminated responding (but at 5.60 mg/kg signif. decreased); table

Reference

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.3 - 5.6 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and admin. in a volume of 1 ml/kg

Method (Pharmacological Data)

rats trained under the temporal response differentiation (TRD) 4-5.2 sec schedule; title comp. admin.; after 10 min, effect on accuracy, mean interresponse time and response rate studied

Further Details (Pharmacological Data)

control: saline; MRD: mean response duration; AC: accuracy

Results

title comp. at 1.0 and 3.0 caused dose-dependent decreased in AC with increasing time duration; large decreased occurred in MRD (5fold); no signif. effect on response rate up to 3 mg/kg (but signif. decrease at 5.6 mg/kg); table

Reference

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details

Effect (Pharmacological Data)

behavioural symptoms

Species or TestSystem (Pharmacological Data)

Sprague-Dawley rat

Sex

male

Route of Application

intraperitoneal

Concentration (Pharmacological Data)

0.3 - 5.6 mg/kg

Kind of Dosing (Pharmacological Data)

title comp. dissolved in saline and admin. in a volume of 1 ml/kg

Method (Pharmacological Data)

rats trained under the temporal response differentiation (TRD) 10-13 sec schedule; title comp. admin.; after 10 min, effect on accuracy, mean interresponse time and response rate studied

Further Details (Pharmacological Data)

control: saline; MRD: mean response duration; AC: accuracy


Results

title comp. at all doses caused dose-dependent decreased in AC with increasing time duration; large decreased occurred in MRD (10-fold); no signif. effect on response rate up to 4.20 mg/kg (but signif. decrease at 5.6 mg/kg); table

Reference

Mcclure; Wenger; Mcmillan

Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details

Chemical Name: ice water, ethyl acetate Reaxys Registry Number: 19666566

Molecular Formula: C4H8O2*C10H15N*H2O Linear Structure Formula: C4H8O2*C10H15N*H2O Molecular Weight: 255.357

InChI Key: OWYKDZCKPRLYNA-WWPIYYJJSA-N

75

0 prep out of 1 reactions.

1

no reactions.

Identification

1

no reactions.

5

Synthesize | Hide Details Find similar Chemical Names and Synonyms ice water, ethyl acetate Chemical Name: meth acrylamide Reaxys Registry Number: 15408256

Molecular Formula: C3H5NO*C10H15N*ClH Linear Structure Formula: C3H5NO*C10H15N*ClH Molecular Weight: 256.776

InChI Key: UOBXUAKQDYKZMZ-WWPIYYJJSA-N

76

Synthesize | Hide Details Find similar Chemical Names and Synonyms meth acrylamide Identification Patent-Specific Data (1) Location in Patent

Reference

Claim

GelTex Pharmaceuticals, Inc.

Patent: US6271264 B1, 2001 ; Title/Abstract Full Text Show Details

Chemical Name: meth acrylic acid

77

Reaxys Registry Number: 30173792

Molecular Formula: C3H4O2*C10H15N*ClH Linear Structure Formula: C3H4O2*C10H15N*ClH Molecular Weight: 257.76

InChI Key: GKLKPLBCJLADSQ-WWPIYYJJSA-N


Synthesize | Hide Details Find similar Chemical Names and Synonyms meth acrylic acid, meth acrylate Chemical Name: SMA ice

no reactions.

1

no reactions.

1

no reactions.

Physical Data (1)

1

Reaxys Registry Number: 30655984

Molecular Formula: C2H2ClO2*C10H15N*Na Linear Structure Formula: C2H2ClO2(1-)*C10H15N*Na(1+)

Molecular Weight: 265.715

InChI Key: MOMAUAKHRDBPQK-WWPIYYJJSA-M

78

Synthesize | Hide Details Find similar Chemical Names and Synonyms SMA ice Chemical Name: ICE V Reaxys Registry Number: 30311961

Molecular Formula: C5H11NO2*C10H15N Linear Structure Formula: C5H11NO2*C10H15N Molecular Weight: 266.384

InChI Key: SMCCTKZYRJBKFZ-AGAVTAENSA-N

79

Synthesize | Hide Details Find similar Chemical Names and Synonyms ICE V Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; benzoate Reaxys Registry Number: 6101798

Type of Substance: isocyclic Molecular Formula: C7H6O2*C10H15N Linear Structure Formula: C10H15N*C7H6O2

Molecular Weight: 271.359

InChI Key: NGCJUVZJTGXSGE-SBSPUUFOSA-N

80

Synthesize | Hide Details Find similar Chemical Names and Synonyms


methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; benzoate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Benzoat Physical Data Melting Point (1) Melting Point

Reference

85 - 87 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate

no reactions.

Physical Data (1)

1

no reactions.

Physical Data (1)

1

Reaxys Registry Number: 6121025

Type of Substance: isocyclic Molecular Formula: C2H2Cl2O2*C10H15N Linear Structure Formula: C10H15N*C2H2Cl2O2

Molecular Weight: 278.178

InChI Key: BVGQWEAQESJUOG-FVGYRXGTSA-N

81

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Dichloracetat Physical Data Melting Point (1) Melting Point

Reference

77 - 79 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate Reaxys Registry Number: 6121026

Type of Substance: isocyclic Molecular Formula: C2H2Cl2O2*C10H15N Linear Structure Formula: C10H15N*C2H2Cl2O2

Molecular Weight: 278.178

InChI Key: BVGQWEAQESJUOG-SBSPUUFOSA-N

82

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Dichloracetat Physical Data Melting Point (1) Melting Point

Reference

76 - 77 °C

Chiang; Li


Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: caprine ice

no reactions.

1

no reactions.

31

no reactions.

1

no reactions.

Physical Data (1)

1

Reaxys Registry Number: 30710813

Molecular Formula: C6H13NO2*C10H15N Linear Structure Formula: C6H13NO2*C10H15N Molecular Weight: 280.411

InChI Key: YCOHMYYFNVQFGV-LMECJBHSSA-N

83

Synthesize | Hide Details Find similar Chemical Names and Synonyms caprine ice Chemical Name: IDA ICE Reaxys Registry Number: 29628165

Molecular Formula: C4H7NO4*C10H15N Linear Structure Formula: C4H7NO4*C10H15N Molecular Weight: 282.34

InChI Key: VJOFJHXTHDLKJN-FVGYRXGTSA-N

84

Synthesize | Hide Details Find similar Chemical Names and Synonyms IDA ICE Chemical Name: methamphetamine amphetamine Reaxys Registry Number: 29844906

Molecular Formula: C9H13N*C10H15N Linear Structure Formula: C9H13N*C10H15N Molecular Weight: 284.445

InChI Key: GEIDWHRAKJQHQQ-UHFFFAOYSA-N

85

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine amphetamine Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 2-methyl benzoate Reaxys Registry Number: 6102388


Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2

Molecular Weight: 285.386

InChI Key: QVGKMZIGUIAKJJ-SBSPUUFOSA-N

86

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 2-methyl benzoate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; 2-Methyl-benzoat Physical Data Melting Point (1) Melting Point

Reference

70 - 71 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate

no reactions.

Reaxys Registry Number: 6121353

Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2

Molecular Weight: 285.386

InChI Key: GBTLMZBLFVVCKS-FVGYRXGTSA-N

87

Physical Data (1)

1

Physical Data (1)

1

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; 4-Methyl-benzoat Physical Data Melting Point (1) Melting Point

Reference

85 - 87 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate

88

Reaxys Registry Number: 6121354

Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2

Molecular Weight: 285.386

InChI Key: GBTLMZBLFVVCKS-SBSPUUFOSA-N

no reactions.


Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; 4-Methyl-benzoat Physical Data Melting Point (1) Melting Point

Reference

85 - 86 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate

no reactions.

Physical Data (1)

1

no reactions.

Physical Data (1)

1

Reaxys Registry Number: 6121427

Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2

Molecular Weight: 285.386

InChI Key: XFAAKZRQUDXEEI-FVGYRXGTSA-N

89

Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Phenylacetat Physical Data Melting Point (1) Melting Point

Reference

81 - 82 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate

90

Reaxys Registry Number: 6121428

Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2

Molecular Weight: 285.386

InChI Key: XFAAKZRQUDXEEI-SBSPUUFOSA-N


Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Phenylacetat Physical Data Melting Point (1) Melting Point

Reference

80 - 81 °C

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

Chemical Name: ethyl meth acrylate

no reactions.

1

no reactions.

1

Reaxys Registry Number: 30297758

Molecular Formula: C5H8O2*C10H15N*ClH Linear Structure Formula: C5H8O2*C10H15N*ClH Molecular Weight: 285.814

InChI Key: SREKFPXANIMQBH-WWPIYYJJSA-N

91

Synthesize | Hide Details Find similar Chemical Names and Synonyms ethyl meth acrylate Chemical Name: isophorone ice Reaxys Registry Number: 30616718

Molecular Formula: C9H14O*C10H15N Linear Structure Formula: C9H14O*C10H15N Molecular Weight: 287.445

InChI Key: JSKWQGNPDQRXPR-FVGYRXGTSA-N

92

Synthesize | Hide Details Find similar Chemical Names and Synonyms


isophorone ice Chemical Name: methamphetamine depen

no reactions.

1

no reactions.

Identification Physical Data (7)

3

Reaxys Registry Number: 30138018

Molecular Formula: C5H11NO2S*C10H15N Linear Structure Formula: C5H11NO2S*C10H15N Molecular Weight: 298.45

InChI Key: AMIDPTMDMUWREW-SCKZZFMESA-N

93

Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine depen Chemical Name: (S)-methamphetamine (2R,3R)-tartrate Reaxys Registry Number: 5488465

CAS Registry Number: 7487-70-9, 32359-31-2, 62265-33-2, 6544027-9, 90027-30-8, 93777-08-3, 140166-94-5 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6

Molecular Weight: 299.324

InChI Key: SOSGXQJCXKXQCB-FVGYRXGTSA-N

94

Synthesize | Hide Details Find similar Chemical Names and Synonyms (S)-methamphetamine (2R,3R)-tartrate, methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; Dg-hydrogentartrate, Methyl-((S)-1-methyl-2-phenyl-aethyl)amin; Dg-Hydrogentartrat, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Lg-Hydrogentartrat Identification Substance Label (1) Label

Reference

(S)-4*(2R,3R)-8

Kozma, David; Pokol, Gyoergy; Acs, Maria

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (4) Melting Point

Solvent (Melting Point)

Reference

113.85 °C

Kozma, David; Pokol, Gyoergy; Acs, Maria

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details

115 - 117 °C

ethanol

Walton

Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details

164 - 165 °C

H2O

Walton

Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details


118 - 119 °C

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Enthalpy of Fusion (1) Enthalpy of Fusion

Reference

35900 Jmol-1

Kozma, David; Pokol, Gyoergy; Acs, Maria

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details

Optical Rotatory Power (2) Type (Optical Rotatory Power)

Concentration (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

Temperature (Optical Rotatory Power)

[alpha]

c=3

H2O

24.7 deg

589 nm

16 °C

Walton

Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details

[alpha]

c=0.8

H2O

-3.2 deg

589 nm

16 °C

Walton

Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details

Chemical Name: (R)-methamphetamine (2R,3R)-tartrate

Reference

no reactions.

Reaxys Registry Number: 5488466

CAS Registry Number: 7487-70-9, 32359-31-2, 62265-33-2, 6544027-9, 90027-30-8, 93777-08-3, 140166-94-5 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6

Molecular Weight: 299.324

InChI Key: SOSGXQJCXKXQCB-SBSPUUFOSA-N

95

Identification Physical Data (5)

Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-methamphetamine (2R,3R)-tartrate, methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; Lg-hydrogentartrate, Methyl-((R)-1-methyl-2-phenyl-aethyl)amin; Lg-Hydrogentartrat Identification Substance Label (1) Label

Reference

(R)-4*(2R,3R)-8

Kozma, David; Pokol, Gyoergy; Acs, Maria

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (3) Melting Point

Solvent (Melting Point)

Reference

163.85 °C

Kozma, David; Pokol, Gyoergy; Acs, Maria

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details

3


164 - 166 °C

ethanol

Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

165 - 166 °C

Ogata

Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details

Enthalpy of Fusion (1) Enthalpy of Fusion

Reference

50000 Jmol-1

Kozma, David; Pokol, Gyoergy; Acs, Maria

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details

Optical Rotatory Power (1) Type (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

[alpha]

H2O

5.15 deg

589 nm

Chemical Name: (S)-(+)-N-methylamphetamine (RR)-tartrate Reaxys Registry Number: 6081392

CAS Registry Number: 179805-09-5 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6

Molecular Weight: 299.324

InChI Key: SOSGXQJCXKXQCB-WGTXBUCSSA-N

96

Reference Chiang; Li

Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details

1 prep out of 1 reactions.

Identification Physical Data (9)

Synthesize | Hide Details Find similar Chemical Names and Synonyms (S)-(+)-N-methylamphetamine (RR)-tartrate Identification Substance Label (1) Label

Reference

SMERTA

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Related Structure (1) Related Structure

Reference

The author investigated the configuration

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (1)

1


Melting Point

Solvent (Melting Point)

Comment (Melting Point)

114 - 115 °C

ethanol

Decomposition

Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Density (1) Density

Type (Density)

Reference

1.292 g·cm-3

crystallographic

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Crystal Phase (1) Description (Crystal Phase) Crystal structure determination

Comment (Crystal Phase)

Reference

β=93.9 grad, a=14.38 Angstroem, b=6.85 Angstroem, c=7.83 Angstroem, n=2. Temperature: 30 C. Method of determination: X-ray Diffraction

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (19721999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Crystal System (1) Crystal System

Reference

monoclinic

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Enthalpy of Fusion (1) Enthalpy of Fusion

Reference

70000 Jmol-1

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Interatomic Distances and Angles (1) Description

Reference

Interatomic distances and angles

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Optical Rotatory Power (1) Type (Optical Rotatory Power)

Concentration (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

Temperature (Optical Rotatory Power)

[alpha]

5 g/100ml

H2O

22.1 deg

589 nm

20 °C

Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Solubility (MCS) (1) Saturation in pure solvent

Temperature (Solubility (MCS))

Solvent (Solubility (MCS))

Comment (Solubility (MCS))

20 °C

ethanol

Solubility: 4.10 p(g/100g solution)

Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886


Title/Abstract Full Text View citing articles Show Details

Space Group (1) Space Group

Reference

4

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Chemical Name: (R)-(-)-N-methylamphetamine (RR)-tartrate Reaxys Registry Number: 6081393

CAS Registry Number: 170591-59-0 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6

Molecular Weight: 299.324

InChI Key: SOSGXQJCXKXQCB-VXLLBCKSSA-N

97

1 prep out of 1 reactions.

Identification Physical Data (9)

Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-(-)-N-methylamphetamine (RR)-tartrate Identification Substance Label (1) Label

Reference

RMERTA

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Related Structure (1) Related Structure

Reference

The author investigated the configuration

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (1) Melting Point

Solvent (Melting Point)

Reference

163 - 164 °C

ethanol

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Density (1) Density

Type (Density)

Reference

1.331 g·cm-3

crystallographic

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Crystal Phase (1) Description (Crystal

Comment (Crystal Phase)

Reference

1


Phase) Crystal structure determination

β=91.4 grad, a=14.04 Angstroem, b=6.9 Angstroem, c=7.72 Angstroem, n=2. Temperature: 30 C. Method of determination: X-ray Diffraction

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (19721999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Crystal System (1) Crystal System

Reference

monoclinic

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Enthalpy of Fusion (1) Enthalpy of Fusion

Reference

48800 Jmol-1

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Interatomic Distances and Angles (1) Description

Reference

Interatomic distances and angles

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Optical Rotatory Power (1) Type (Optical Rotatory Power)

Concentration (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

Temperature (Optical Rotatory Power)

[alpha]

5 g/100ml

H2O

4.77 deg

589 nm

20 °C

Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Solubility (MCS) (1) Saturation in pure solvent

Temperature (Solubility (MCS))

Solvent (Solubility (MCS))

Comment (Solubility (MCS))

20 °C

ethanol

Solubility: 0.16 p(g/100g solution)

Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Space Group (1) Space Group

Reference

4

Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan

Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details

Reaxys Registry Number: 6835793

Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6

Molecular Weight: 299.324

InChI Key: SOSGXQJCXKXQCB-LREBCSMRSA-N

no reactions.

Identification Physical Data (4)

1


98

Synthesize | Hide Details Find similar

Identification Substance Label (1) Label

Reference

III-R,R-XIII

Kozma, David; Acs, Maria; Fogassy, Elemer

Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (2) Melting Point

Reference

113.85 °C

Kozma, David; Acs, Maria; Fogassy, Elemer

Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details

163.85 °C

Kozma, David; Acs, Maria; Fogassy, Elemer

Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details

Enthalpy of Fusion (2) Enthalpy of Fusion

Reference

35880 Jmol-1

Kozma, David; Acs, Maria; Fogassy, Elemer

Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details

49040 Jmol-1

Kozma, David; Acs, Maria; Fogassy, Elemer

Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details

Reaxys Registry Number: 7454315

Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6

Molecular Weight: 299.324

InChI Key: SOSGXQJCXKXQCB-KZKMUFAMSA-N

99

Synthesize | Hide Details Find similar

1 prep out of 1 reactions.

Identification Physical Data (2)

1


Identification Substance Label (1) Label

Reference

(R)-4 salt

Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.

Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details

Physical Data Melting Point (1) Melting Point

Solvent (Melting Point)

Reference

162 - 164 °C

H2O

Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.

Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details

Optical Rotatory Power (1) Type (Optical Rotatory Power)

Concentration (Optical Rotatory Power)

Solvent (Optical Rotatory Power)

Optical Rotatory Power

Wavelength (Optical Rotatory Power)

Temperature (Optical Rotatory Power)

[alpha]

0.8 g/100ml

H2O

4.4 deg

589 nm

20 °C

Reference Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.

Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.